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Abstract
Central white matter and peripheral nerves function by conducting action potentials, 
which rely on the presence of transmembrane potentials generated by ion gradients. 
The maintenance of these transmembrane potentials is the main energy-dependent 
process in the nervous system. In this thesis I investigated the ability of endogenous 
glycogen to support the energy requirements of nervous tissue and the role of lactate 
in this process. Glycogen in the CNS is located in astrocytes but is capable of 
supporting axonal conduction, implying axon-glial metabolic interactions. These 
interactions were investigated in both the mouse optic nerve (MON),  a central white 
matter tract, and the mouse sciatic nerve (MSN), a mixed peripheral nerve. 
Electrophysiological techniques were used to record action potential conduction in the 
nerves as an index of nerve function. Parallel experiments to quantify glycogen 
content using biochemical assay, or simultaneous real-time measurement of lactate 
release from the nerves using enzyme-based lactate biosensors, correlated action 
potential conduction with glycogen content, or lactate release, respectively. Depletion 
of glycogen leaves the MON vulnerable to irreversible injury to a greater extent than 
exposure to moderate hyperthermia during aglycemia. Glycogen also greatly 
enhanced the neuroprotective effects of mild hypothermia during aglycemia. Under 
resting conditions lactate in the immediate vicinity of the MON was stable at ~0.5 
mM, a concentration that increased with axonal activity,  dependent upon stimulus 
intensity. Raising extracellular K+ evoked lactate release, suggesting that increased 
neuronal activity promotes lactate release. Inhibition of glycogen metabolism, partly 
reduced lactate release from the MON, implying that glycogen metabolism is 
important under normal physiological conditions. The relative contribution of 
glycogen to lactate release increased with axonal activity, consistent with activity-
induced glycogenolysis.  These studies were then extended to the peripheral nervous 
system as the role of glycogen in this tissue has not previously been considered. 
Glycogen, which was present in Schwann cells, supported myelinated, but not un-
myelinated axons during aglycemia, suggesting a more complex and selective 
neuroprotective role than that in central white matter. 
These results advance our understanding of white matter energy metabolism in 
relation to both the contributions of glycogen and lactate. The novel functional role of 
glycogen in supporting peripheral nerve function has also been described. 
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1.1 Energy Metabolism in the Nervous System
The mammalian nervous system is responsible for performing a vast number 
of tasks critical for survival. Performing these functions requires energy which 
is obtained from food. The focus of this thesis is the energy requirements of 
the parts of the nervous system that conduct action potentials between cells, 
namely central white matter and peripheral nerves. This introductory chapter 
provides a general overview of energy metabolism and the idiosyncrasies of 
the nervous system. 
The energy used to drive biochemical process in cells and keep them alive is 
obtained from energy stored in the chemical bonds of food molecules. Food 
molecules that are potential sources of energy come from three main 
categories: polysaccharides, fats and proteins (See Fig. 1.1). The reactions of 
energy metabolism ultimately generate ATP (adenosine 5Õ-triphosphate) 
which is used to store energy, and as a cellular energy currency to power the 
myriad reactions that occur inside every cell. 
The brain is particularly reliant on the metabolism of glucose to generate the 
vast majority of its ATP. The traditional view maintains that the brain requires 
a constant supply of glucose from the blood (Greutter et al., 1992; Chih and 
Roberts, 2003). This is based on the following evidence: (1) hormonal 
mechanisms which maintain a stable blood glucose concentration; (2) 
gluconeogenesis converts non-glucose substrates into glucose; (3) the brain 
contains glucose sensing neurons; (4) the arterial-venous difference of blood 
glucose is positive; (5) labelled glucose metabolites are detected by magnetic 
resonance studies in the brain; (6) during insulin overdose there is no 
alternative blood-borne energy substrate that supports brain function;.. 
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Figure 1.1 SimpliÞed diagram of the routes of energy production from food 
showing conservation of metabolic pathways. 1. The Þrst stage is the breakdown of 
macromolecules into their constituent sub-units. 2. Stage 2 occurs mainly in the 
cytosol and is the breakdown of the simple sub-units to acetyl CoA. This stage yields 
limited amounts of ATP and NADH. 3. The Þnal stage is the complete oxidation of 
acetyl CoA to CO2 and H2O, which yields large amounts of ATP and NADH in the 
mitochondrion.
1.1.1 Glucose Metabolism
Glucose is the most biologically important carbohydrate molecule. The 
glucose molecule is the starting point of cellular energy metabolism and it is 
the only fuel that can be used by all cells in the body. 
1.1.1.1 Glycolysis 
The metabolism of glucose begins with the glycolytic pathway. Glycolysis (the 
Embden-Meyerhof pathway) is the term given to the set of reactions that split 
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glucose and form two molecules of pyruvate and a small amount of energy. 
The reactions of glycolysis are shown in Fig. 1.2 below. The Þrst reaction is the 
phosphorylation of glucose to form glucose-6-phosphate by the enzyme 
hexokinase. This reaction, which occurs intracellularly, is the rate-limiting step 
for glucose metabolism in the brain (Whitesell et al., 1995). Phosphorylation 
traps glucose inside the cell, but consumes one molecule of ATP per glucose 
molecule. A further molecule of ATP is used in the reaction catalysed by 
phosphofructokinase. Following this step the 6 carbon molecule is cleaved to 
produce two 3 carbon molecules which means that for each glucose molecule 
the steps after this reaction occur two times. From glyceraldehyde-3-
phosphate a series of enzymes produce pyruvate, yielding 1 molecule of 
NADH and 2 of ATP. Pyruvate can then enter the TCA cycle where it is 
oxidatively metabolised to yield ATP. Alternatively pyruvate can be converted 
to lactate (see below). Glycolysis produces relatively little ATP in comparison 
to oxidative metabolism, but does not require molecular oxygen and is 
therefore how cells that lack mitochondria generate their ATP (e.g. red blood 
cells). 
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Figure 1.2 An outline of glycolysis. Key enzymes are shown in blue (HK = 
hexokinase). Iodoacetate, a known glycolytic inhibitor was used in Chapter 4, its site 
of action is shown. Glycolysis can either proceed to pyruvate, which then enters the 
TCA cycle, or to produce lactate. 
Chapter 1
5
1.1.1.2 Oxidative Metabolism
As the reactions of glycolysis only yield a small amount of ATP, the vast 
majority of ATP is generated by reactions which occur in the mitochondria 
and require oxygen (Fernie et al., 2004). Pyruvate generated from the 
breakdown of glucose in the reactions of glycolysis forms the starting point for 
oxidative metabolism. Pyruvate is converted into acetyl CoA which is then fed 
into the series of reactions collectively known as the tricarboxylic acid (TCA) 
cycle (Fig. 1.3.A). The reactions of the TCA cycle catalyse the reduction of 
NAD+ to NADH and FAD to FADH2, which then act as electron donors for the 
electron transport chain. Electrons are donated to a series of enzyme 
complexes located in the mitochondrial inner membrane (Fig. 1.3.B). Electrons 
that pass through this system are left in an increasingly lower energy state, 
and the free energy derived from this process is used to pump hydrogen ions 
into the space between the mitochondrial membranes. The proton gradient is 
then used by ATP synthase to produce ATP.
The reactions of the TCA cycle and electron transport chain require molecular 
oxygen in order to proceed. No oxygen is directly consumed in the TCA cycle 
but it is required  for the recycling of electron accepting molecules e.g. NAD+. 
When oxygen is not available the supply of NAD+ is exhausted and the 
reactions of the TCA cycle cannot proceed. 
The purpose of the TCA cycle is not restricted to the production of energy, it 
also plays a crucial role in the biosynthesis of many important molecules in 
the cell. Non-essential amino acids are among the products which can be 
made from TCA cycle intermediaries and the synthesis of molecules such as 
these will depend upon the energy state of the cell as well as demand. 
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Figure 1.3 An overview of oxidative phosphorylation. A. TCA cycle B. The electron 
transport chain. The inner mitochondrial membrane is shown with the chain of 
electron donors / acceptors (Complex I - IV, ubiquitin (UQ), and cytochrome c (cyt 
c)). The H+ ion gradient created by the passage of electrons along the chain is used to 
drive ATP Synthase (S) which forms ATP. C. Fluoroacetate (FA) is an inhibitor of the 
TCA cycle. FA is converted to ßuorocitrate which inhibits the enzyme aconitase. Key 
enzymes are shown in blue. 
In the brain, as with almost all tissues, oxidative metabolism is the largest 
contributor to ATP synthesis. Not all glucose consumed by the brain is fully 
oxidised. The brain uses 31 mmol of glucose per 100g of tissue per minute, a 
value greater than the 26.6 mmol/100g.min that can be accounted for by the 
brainÕs oxygen consumption, which leaves 4.4 mmol/100g.min for other 
pathways (Magistretti et al., 2000). 
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1.1.1.3 Lactate
Lactate is an alternate end product of glycolysis which is typically described 
as only being produced under anaerobic conditions. Lactate is formed from 
pyruvate by the enzyme lactate dehydrogenase (LDH), a reaction that also 
results in the production of NAD+ from NADH. LDH is also capable of 
catalysing the reverse reaction, i.e. the formation of pyruvate from lactate. The 
direction with which the reaction proceeds depends upon the relative 
concentrations of lactate and pyruvate and also the LDH isoenzyme in 
question. LDH is a tetramer composed of a combination of two subunits: the 
heart (H) and muscle (M) subunits. A homo-tetramer of the H subunit forms 
the LDH-1 isoenzyme and LDH composed of four M subunits forms the 
LDH-5 isoenzyme. For this reason the H subunit has been referred to as the 
LDH-1 subunit and the M subunit as the LDH-5 subunit (Bittar et al 1996). The 
LDH-1  isoform is more suited to the oxidation of lactate to form pyruvate. 
LDH-5 favours the conversion of pyruvate to lactate and is found in tissues 
that produce lactate (Cahn et al., 1962). The cellular expression pattern of these 
subunits in the brain is of importance when determining the role in this organ 
(see below). 
Under anaerobic conditions and in red blood cells, which do not possess 
mitochondria, the formation of lactate is a method of regenerating the NAD+, 
which is required for the continuation of glycolysis. Lactate is then released 
from the cell as a waste product. This view has led to the presence of lactate in 
tissue being viewed as potentially harmful and an indication of disrupted 
energy metabolism. On the contrary, healthy tissue does produce lactate. In 
muscle and the brain, lactate is produced under aerobic conditions. The term 
aerobic glycolysis is given to this formation of lactate as the end product of 
glycolysis in fully oxygenated tissue. Lactate is also no longer viewed as a 
metabolic dead-end: rather than being a waste product lactate can enter the 
pathway of oxidative metabolism and yield more ATP. A single lactate 
molecule, after conversion to pyruvate by lactate dehydrogenase, can enter the 
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pathway of oxidative phosphorlyation to produce 18 molecules of ATP 
(Magistretti and Pellerin, 1999). Further references to the oxidation of lactate 
refer to this process. Despite changing attitudes towards the possible 
metabolic fate of lactate, there still is no exact consensus as to the importance 
of lactate oxidation. This is particularly relevant to brain energy metabolism 
and is discussed later in this thesis. 
Lactate transport into and out of cells is performed by members of a family of 
membrane proteins called monocarboxylate transporters (MCTs). The most 
important members of this family with regards to lactate transport are MCT1-
MCT4 as these have been shown to transport lactate and other 
monocarboxylates such as pyruvate and ketone bodies (Halestrap and 
Meredith, 2004). Generally, MCT1 and 2 are associated with lactate uptake in 
the liver, heart, kidney and red skeletal muscle. MCT4 is expressed by cells 
that exhibit a high rate of glycolysis and is associated with lactate efßux (Juel 
and Halestrap, 1999). MCT1, 2 and 4 are widely expressed in the brain, with 
MCT3 restricted to the choroid plexus and pigment cells in the retina 
(Simpson et al, 2007). Because of the limited expression of MCT3 in the brain a 
focus will be placed on MCT1, 2 and 4. The association of MCT subtypes with 
lactate uptake or release is central to the role of lactate in the brain which will 
be discussed below (1.2.4). Each of the MCTs has a different afÞnity for lactate 
and inhibitors (Halestrap and Price, 1999). Table 1.1 summarises some of the 
characteristics of the three MCTs expressed in the brain. 
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Expression Lactate Km 
(mM)
Suggested 
Function
Inhibitors*
MCT1 Blood vessels, 
astrocytes, 
neurons
3.5
Ketone body 
transport (1)
MCT2
Neurons 0.7
Lactate 
uptake
4-CIN (2 & 3)
pCMBS (3)
MCT4
Astrocytes 35
Lactate 
release
Quercetin 
(4)
Table 1.1 A summary of the three main MCTs of importance in the brain. The 
predominant cell type expressing the transporter is listed along with the Km for 
lactate transport, the simpliÞed suggested function and some inhibitors of note. * 
SpeciÞc MCT inhibitors are not currently in widespread use. Most inhibitors will 
affect all three MCTs but those listed are examples which have been used a 
concentration designed to target the speciÞc subtype. This table summarises the text 
of Pellerin et al. (2005). Other sources used are: (1) Simpson et al., 2007; (2) 
Erlichman et al. (2008); (3) Wender et al (2000); (4) McKenna et al. (1998). 
The data in Table 1.1 shows that MCT2 has the highest afÞnity for lactate, 
MCT1 is intermediate and MCT4 the lowest afÞnity. The signiÞcance of the 
brain expression is discussed later (1.2.4.1) but it is worth noting that the 
location of expression listed is the predominant one. Some studies have shown 
that MCT expression can vary depending upon the conditions, particularly in 
cell culture (Pellerin et al., 2005). It is thought that MCT1 is particularly 
important in the transport of ketone bodies during suckling as its expression 
declines during development (Simpson et al., 2007). The inhibitors listed are 
those which have been used in attempts to selectively block speciÞc MCTs. 
Most MCT inhibitors will affect all MCTs but differences in afÞnity enable a 
careful choice of concentration to achieve a selective block. For example, 4-
CIN at a concentration of 100 !M has been used to block the neuronal uptake 
of lactate via MCT2 (Wender et al., 2000; Erlichman et al., 2008). 
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1.1.1.4 Carbohydrate Storage
Carbohydrates can be stored as polymers of glucose, and glycogen is the 
primary storage carbohydrate in the mammalian body. Glycogen is a 
branched polymer of glucose that can readily be stored or broken down 
depending upon the availability of glucose. Storing glucose in the form of 
glycogen provides an energy reserve that does not affect the osmotic balance 
of cells due to the insolubility of glycogen. The main locations of glycogen 
storage are the liver and skeletal muscles where it accounts for 6-8% and 1-2% 
of the masses of these tissues, respectively. The function of glycogen in the 
liver is to act as a buffer for plasma glucose ensuring that the concentration of 
glucose in the blood remains steady (between 4 and 7.2 mM is considered 
normal in humans). When blood glucose drops glycogen in the liver is 
mobilised to buffer the glucose concentration. Glycogen stored in the liver can 
be replenished when blood glucose is raised due to intake of nutrients after 
feeding.
The function of glycogen in other tissues is different to that in the liver, 
glycogen acts as a local energy reserve. The best known and characterised 
example of glycogen acting as a local energy reserve is skeletal muscle. This is 
perhaps not surprising due to this tissue having the next highest concentration 
of glycogen after liver (Hargreaves, 2004).
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Figure 1.4 An outline of glycogen synthesis and breakdown. Key enzymes are 
shown in blue. DAB is an inhibitor of glycogen phosphorylase.
The reactions involved in glycogen metabolism are summarised in Fig. 1.4, 
where glycogen acts as a storage depot for phosphorylated glucose molecules. 
Glycogen phosphorylase (GP) is the key enzyme involved in glycogenolysis 
which liberates the glucose stored in the glycogen molecule. GP acts on the 
linear chains of glucose residues contained within the glycogen molecule, a 
de-branching enzyme is required to completely digest glycogen. GP is in its 
active state when it is phosphorylated and this is governed by phosphorylase 
kinase (Brown, 2004). The transition of GP from its inactive to active form is 
very rapid which allows glycogen to be quickly mobilised when needed 
(Schulman and Rothman, 2001). Allosteric interactions with molecules such as 
glucose and AMP allow the activity of GP to be responsive to the energy state 
of the cell (Johnson, 1992). It exists in tissue-speciÞc isoenzymes: muscle 
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(GPMM), liver (GPLL) and brain (GPBB), although expression is not restricted 
to these speciÞc tissues (Newgard et al., 1989). Glycogen breakdown and 
therefore access to the stored glucose can be inhibited by compounds that bind 
to GP, an example of an inhibitor of GP is the compound DAB (Walls et al., 
2008). 
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1.2 Energy Metabolism in the Healthy Brain
1.2.1 Energy Demands of the Brain
The Central Nervous System (CNS) is a very demanding tissue in terms of its 
requirements of both glucose and oxygen supply. Despite only accounting for 
2 % of body mass, the brain consumes 20 % of the oxygen and 25 % of plasma 
glucose (Raichle and Gusnard, 2002). The Þrst measurements of whole brain 
blood ßow were determined by measuring the cerebral arterial and venous 
concentrations of nitrous oxide after inhaling a small amount of the gas (Kety 
and Schmidt, 1948). This technique was used to show that total cerebral blood 
ßow and oxygen consumption remains relatively constant irrespective of the 
degree of brain activity. Both variables were found to be unaltered by mental 
exertion in the form of mental arithmetic (Sokoloff et al., 1955). Cerebral 
oxygen consumption is also unchanged during natural sleep (Mangold et al., 
1955). The dependence of the brain on a steady supply of glucose and oxygen 
from the blood was vividly demonstrated by a study carried out during World 
War II.  Blood supply to the brain was temporarily interrupted in healthy 
volunteers by applying pressure to the neck with an inßatable device; 
consciousness in all 141 subjects was lost in 4 to 10 seconds (Rossen et al., 
1943).
The energy-dependence of the brain largely arises from the amount of energy 
required to maintain the ion distribution that is responsible for generating 
resting membrane potential. The electrochemical ion gradient across the cell 
membrane underlies many cellular functions such as action potential 
conduction, neurotransmitter signalling and nutrient transport. These 
processes cause Na+ to enter the cell, and for function to continue as normal 
the Na+ must be actively pumped back into the extracellular space (i.e. 
homeostasis must be maintained). The extrusion of Na+ is performed by the 
Na+/K+ ATPase which has been estimated to consume around 40 - 50 % of the 
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energy required by the brain (Whittam, 1962; Astrup et al., 1981; Attwell and 
Laughlin, 2001). The other major functions of the brain which consume the 
majority of energy are estimated as follows: vegetative metabolism (5 -15 %), 
Ca2+ ßux (3 - 7 %), processing of neurotransmitters (10 - 20 %), intracellular 
signalling (20 - 30 %) and axonal transport (20 - 30%) (Ames, 2000). 
The observed lack of a response in total cerebral blood ßow during mental 
activity led early researchers to speculate that neural activity was not 
accompanied by an increase in energy demand (Sokoloff et al., 1955). 
However, neural activity involves an increase in the energy-consuming 
processes described above and does require more energy to support it. It was 
only when regional blood ßow and oxygen consumption were measured that 
activity-dependent changes were observed. Interestingly, this phenomenon 
was demonstrated by an unusual clinical case of a patient who had 
unsuccessful surgery to remove a malformed blood vessel in his visual cortex 
(Fulton, 1928). The surgery left the patient with an auscultatory bruit that 
became more prominent after exposure to visual stimuli. The increased 
prominence of the bruit was due to enhanced regional blood ßow to the visual 
cortex in the occipital lobe. This was long before the same response was 
demonstrated with the modern neuroimaging techniques of positron emission 
tomography (PET) (Shulman et al., 1997) and magnetic resonance imaging 
(MRI) (Kruger et al., 1996). 
As well as increases in blood ßow and oxygen consumption, regional activity 
increases glucose utilisation which can be measured by PET (Wienhard et al., 
1985). Surprisingly, the increases in glycolysis and oxidative phosphorylation 
are not of the same magnitude (Fox et al., 1988; Frahm et al., 1996). The 
increase in oxygen consumption is not as great as that for glucose. The 
mismatch between increases in glycolysis versus oxidative metabolism are 
thought to be responsible for the increase in lactate observed during and after 
neural activation and will be further discussed in Chapters 4 and 5. 
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1.2.2 The Blood-Brain Barrier (BBB)
The blood-brain barrier is an anatomical and physiological barrier that 
separates the brain from circulating blood. The BBB is formed by capillary 
endothelial cells which are in close contact with astrocytes (Hawkins and 
Davis, 2005). Molecules in the blood that have free access to other tissues are 
often not able to cross into the brain. Substances that can cross into the brain 
from the blood are limited to those that can diffuse across the BBB or those 
that are substrates for transporters expressed in the BBB. Energy metabolism 
in the brain is dependent upon the BBB due to this selective permeability. 
Sugars are transported across the BBB to enter the brain, although this process 
is not usually rate-limiting for cerebral energy metabolism (Buschiazzo et al., 
1970). Glucose is transported by a family of membrane-bound transporters 
known as GLUTs which exist in a number of isoforms (Barros et al., 2007). The 
importance of glucose transport into the brain is demonstrated by a clinical 
condition in which a deÞcit in the GLUT1 transporter in the BBB of infants 
leads to low glucose concentrations in CSF, seizures and impaired 
development (De Vivo et al., 1991). The deÞciency in glucose transport results 
in the brain being more dependent on ketone bodies as a fuel. 
The structure of the BBB has been found to be disrupted in a variety of 
neurological disorders (Hawkins et al., 2005). Post-concussion syndrome 
(Korn et al., 2005), epilepsy (van Vliet et al., 2007), depression (Niklasson and 
Agren, 1984) and stroke (Sandoval and Witt, 2008) are all conditions where an 
increase in the permeability of the BBB has been observed. Disruption of the 
BBB has also been suggested as the cause of seizures in some patients that 
receive Interferon-alpha therapy (Pavlovsky et al., 2005). Increased 
permeability of the BBB alters the composition of the extracellular ßuid within 
in the brain, affecting the osmolarity, resulting in increased excitability and 
seizures (van Vliet et al., 2007). The opening of the blood brain barrier also 
affects energy metabolism by removing Þne control of the substrate 
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availability in the brain and allowing in toxins such as billirubin that impair 
mitochondrial function (Wennberg et al., 1991; Hansen, 2001).
1.2.3 Glial Support of Neurons
Glia is the collective name give to non-neuronal cell types within the nervous 
system (Hartline, 2011). For many years after glia had been identiÞed they 
were somewhat neglected despite there being an equal number of glia and 
neurons in the human brain (Azevedo et al., 2009). The term glia arose because 
these cells were regarded as simply the ÒglueÓ of the nervous system. 
Although, not all early research dismissed functional roles for glia. Ramon y 
Cajal postulated that they may have a role in executive brain function (Garcia-
Martin et al., 2007). However, it was as techniques improved and more 
research was conducted into glial cells that their importance truly emerged. 
When the modern understanding of glial biology was in its infancy it was 
recognised that these cells play vital roles in brain function (Ransom and 
Sontheiemer, 1992). The way glial cells are now viewed ascribes them 
prominent and active roles in the brain and the way it works. The functional 
abilities of the human brain are now, to an extent, thought to depend upon the 
functional and anatomical complexity of astrocytes in comparison to the 
equivalent cells in rodents (Oberheim et al., 2009). 
There are two main categories of glia: microglia and macroglia. Microglia are 
frequently referred to as the immune system cells of the CNS, but this view 
may be too simplistic (Graeber and Streit, 2010). Types of macroglia include: 
the aforementioned astrocytes as well as oligodendrocytes, radial glia and 
ependymal cells. These are all found in the CNS. The PNS macroglia 
population consists of: Schwann cells, satellite cells and enteric glial cells. The 
roles of glial cells are diverse but a brief overview of some examples is 
provided below.
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The idea that glia were passive constituents of the nervous system could be 
not be maintained after the discovery of gliotransmission. Glial cells are 
capable of releasing chemicals such as glutamate, ATP and D-serine which are 
able to modulate neurons and other glial cells (Angulo et al., 2004; Newman, 
2003; Mustafa et al., 2004). Astrocytes are the cell type most associated with 
gliotransmission. They can be considered as a component of the Òtripartite 
synapseÓ, along with the neuronal pre- and post-synaptic terminals (Araque et 
al., 1999). In this model the astrocyte can provide signals to the neurons and 
receive them too, allowing Þne control of excitability. This type of 
communication between neurons and glia is important in a diverse array of 
physiological processes including nociception (Foley et al., 2011), regulation of 
breathing (Housley, 2011) and memory (Henneberger et al., 2010). 
Important functions performed by glia are not restricted to the astrocytes. 
Glial cells produce myelin which wraps around axons and acts as an electrical 
insulator speeding up action potential velocity. In the CNS oligodendrocytes 
are responsible for myelinating axons and a similar role is performed by 
Schwann cells in peripheral nerves. The presence of myelin is critical for 
normal nervous system function. When myelin is disrupted or defective, such 
as is seen in multiple sclerosis, neurological function is impaired due to 
disrupted axonal signalling (Steinman, 1996). While myelin is important to the 
axons it ensheaths not all axons are myelinated. Peripheral nerves and CNS 
white matter contain un-myelinated axons (Murrinson and GrifÞn, 2004; 
Ziskin et al., 2007). When space is at a premium, small un-myelinated axons 
offer an advantage with their compact size (Wyatt et al., 2005). Large 
myelinated axons appear to be necessary for neurons that form vast numbers 
of synaptic connections (Harris and Atwell, 2012).  
Further to providing insulation for axons in the form of myelin it has been 
suggested that oligodendrocytes may provide trophic support to the axons 
that they ensheath (Nave, 2010). This intercellular support is a two-way 
relationship. For example, neurons release growth factors that promote 
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oligodendrocyte survival (Fernandez et al., 2000). The provision of energy 
substrate from glia to neurons has been explored in great detail with regards 
to astrocytes. Astrocytic glycogen and lactate are thought to be important 
substrates for neurons, although, the extent of this is hotly debated (see below, 
1.2.4-5). The role of glial cells in nervous system energy metabolism is 
discussed throughout this thesis. Discoveries concerning glial biology have 
revealed a previously unknown level of complexity for cellular interactions in 
the brain. 
1.2.4 Lactate in the Brain
The ability of the brain to use lactate as an energy substrate has been shown in 
vitro where it supports synaptic activity (Schurr et al., 1989) and axonal 
conduction (Brown et al., 2001). There is also evidence of lactate utilisation in 
vivo, Plasma lactate may be a major fuel for the brain of newborn mammals 
(Hellmann et al., 1982). Transport of lactate into the brain declines during 
development into adulthood (Cremer et al., 1976), but the adult human brain 
still retains some capacity for lactate uptake from blood (Rivers et al., 1991). 
At rest there is a net lactate release from the brain, but during exercise when 
blood lactate rises the brain takes up blood-borne lactate and uses it as a fuel 
(Quistorff et al., 2008; van Hall et al., 2009). Lactate is capable of 
supplementing glucose as a fuel during hypoglycemia, lowering the glucose 
concentration at which deterioration in brain function is seen (Maran et al., 
1994). Despite some lactate uptake and metabolism, the limited permeability 
of the BBB for lactate is the main reason why lactate is not capable of fully 
substituting for plasma glucose (Lubow et al., 2006). 
Lactate is also produced locally within the brain (Hu and Wilson, 1997; 
Leegsma-Vogt et al., 2003) and is present in the brain, typically at a 
concentration of around 1.5 mM (Medina et al., 1975). Lactate production 
increases with neural activity (During et al., 1994). The fate of lactate produced 
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within the brain has been at the centre of an intense debate. There is evidence 
that lactate is oxidised away from its site of production to yield more ATP 
(Wyss et al., 2011). 
The most contentious of the hypotheses which this Þeld has generated is the 
astrocyte-neuron lactate shuttle hypothesis (Pellerin and Magistretti, 1994). 
1.2.4.1 Astrocyte-Neuron Lactate Shuttle Hypothesis (ANLSH) 
The astrocyte-neuron lactate shuttle hypothesis (ANLSH) has been responsible 
for igniting one of the most ferocious debates in neuroscience of recent years. 
In 1994 Pellerin and Magistretti proposed that astrocytes were responsible for 
glucose uptake from the blood and that this glucose underwent glycolysis in 
the astrocytes resulting in the formation of lactate (Pellerin and Magistretti, 
1994). They went on to propose that this lactate was then released into the 
extracellular space where it was then transported into neurons and used as a 
fuel for oxidative metabolism. The theory has undergone several 
modiÞcations since its inception (Magistretti et al., 1999; Pellerin and 
Magistretti, 2003) but still persists, neither having been fully discredited or 
fully accepted.
In its current form the model states that glutamate released during synaptic 
activity triggers astrocytes to release lactate to support the energy 
requirements of neurons (Bouzier-Sore et al., 2002). Lactate produced by 
glycolysis in the astrocytes is released into the extracellular space before being 
taken up, converted into pyruvate and oxidised by neurons. The pathway is 
shown in Fig. 1.5. It is now well established that lactate can support neuronal 
activity (e.g. Brown et al., 2001). Henry McIlwain observed this in brain slices 
in the 1950s (McIlwain, 1953). However, the relative contribution that this 
pathway provides to normal neuronal energy metabolism is central to the 
ANLSH debate. 
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Figure 1.3 Diagram of the astrocyte-neuron lactate shuttle hypothesis. Astrocytes 
take up glucose (Glc) which then passes through the glycolytic pathway via pyruvate 
(Pyr) to produce lactate (Lac). The ATP produced is used to fuel the uptake of 
glutamate (Glu) and its conversion to glutamine (Gln). Lactate is released from the 
astrocyte into the extracellular space where it is taken up by the neuron by 
monocarboxylate transporters (MCT). Lactate in the neuron is converted to pyruvate 
which yields energy via oxidative phosphorylation. This pathway can co-exist with 
neuronal glucose uptake and metabolism. Figure adapted from Chih and Roberts 
(2003). 
The ANLSH is supported by evidence drawn from a number of experiments 
and observations which complement the initial discovery of astrocytic lactate 
release. Neurons express the LDH-1 subunit which favours the conversion of 
lactate to pyruvate. This suggests neurons are primed for the oxidation of 
lactate. Astrocytes also contain the LDH-1 subunit but express the LDH-5 
subunit which favours the formation of lactate from pyruvate (Bittar et al, 
1996). The LDH-5 subunit is associated with glycolytic, lactate-producing cells 
which is the role given to astrocytes in the ANLSH model.
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The distribution of MCTs also has been used to support the theory that 
astrocytes predominantly release lactate into the extracellular space and 
neurons are responsible for its uptake (Pellerin and Magistretti, 2003). 
Neurons express high levels of MCT2 (Debernardi et al., 2003), whereas, 
astrocytes express MCT 1 and MCT4 (RaÞki et al., 2003). As neurons express 
the MCT (MCT2) with the greatest afÞnity for lactate it has been suggested 
neurons are less suited to lactate release and will retain and oxidise lactate. 
Meanwhile, MCT4 expressed by astrocytes is able to rapidly release lactate 
when the intracellular concentration rises (Broer et al., 1997). However, 
whether this supports the model of lactate ßow from astrocytes to neurons is 
not universally accepted (Hertz and Dienel, 2005). Evidence that does appear 
to support the idea of a lactate shuttle comes from the results of experiments 
which have used MCT inhibitors to block lactate transport. This approach has 
revealed that, in both rodent optic nerve and hippocampal slices, lactate 
trafÞcking is important for neuronal survival when the supply of energy 
substrate is restricted (Tekkok et al., 2005; Cater et al., 2001).Knockdown of 
MCTs by antisense nucleotides disrupts long-term memory formation, 
indicating that lactate transport has a role in this physiological function 
(Suzuki et al., 2011). 
A further criticism of evidence used to support the ANLSH is that the majority 
of it comes from in vitro experiments such as cell culture systems that are far 
departed from the situation in vivo (Chih and Roberts, 2003). However, the use 
of labelled lactate and glucose has shown that even in vivo lactate is oxidised 
in an activity-dependent manner (Wyss et al., 2011). Wyss et al. concluded that 
the brain preferentially utilises lactate over glucose as an energy substrate 
when they are both available. Measurement of brain glucose and lactate 
uptake and release during exercise in human subjects has also revealed an 
activity-dependent increase in lactate consumption by the brain (Rasmussen et 
al., 2011).
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The role of lactate in the brain is not fully established and forms the focus of 
Chapters 4 and 5 where it is discussed in further detail. 
1.2.5 Brain Glycogen
As discussed above (1.1.1.3) glycogen is a storage carbohydrate that can be 
used as an alternative supply of glucose molecules. The brain contains 
glycogen at a concentration that is relatively low in comparison to that seen in 
liver and skeletal muscle. Glycogen contributes about 0.1 % of total brain 
weight, whereas, in muscle it accounts for 1 - 2 % of tissue mass (Brown, 2004). 
The low concentration of glycogen in the brain led to it largely being 
overlooked in terms of playing an important role in energy metabolism in this 
organ. In recent years brain glycogen has emerged as a topic which has 
received substantial interest (Brown, 2004). A variety of experiments have 
shown that nervous tissue contains glycogen and this glycogen content can be 
metabolised to provide energy substrates under both pathological and 
physiological conditions. 
Glycogen in the brain is almost exclusively located in astrocytes (Brown and 
Ransom, 2007). Astrocytes also express the enzyme GPBB, necessary for 
glycogenolysis (Pfeiffer et al., 1990). Cultured astrocytes have been extensively 
used as a model to investigate factors affecting brain glycogen. Astrocytes are 
able to take up a number of substrates and synthesise glycogen (Dringen et al., 
1993) and this process is sensitive to modulation by insulin (Kum et al., 1992). 
Glycogenolysis is stimulated by the action of some neurotransmitters. 
Vasoactive intestinal peptide (VIP) and noradrenaline both act on cultured 
astrocytes to induce glycogenolysis (Magistretti et al., 1993; Pellerin et al., 
1997). Noradrenaline-induced glycogenolysis has also been observed in 
isolated rat pineal glands (Eugenin et al., 1997). Furthermore, the toxic effects 
of ammonia in the brain may be mediated by its inhibition of glycogenolysis 
(Dombro et al., 1993) These experiments demonstrate that astrocytic glycogen 
is labile and under the dynamic control of neurotransmitters.
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Glycogen has been shown to be utilised as an energy substrate in the rodent 
optic nerve to support high frequency Þring or conduction under aglycemic 
conditions (Wender et al., 2000; Brown et al., 2003). Glycogen is known to play 
an important role in the developing brain (Rust, 1994), for example, 
preventing glycogen breakdown interferes with memory consolidation in 
young chicks (Gibbs et al., 2006; Hutchinson et al., 2008). This process is 
mediated by beta2-adrenoceptors (Gibbs et al., 2008), which corroborates the 
observations from astrocyte cultures. In the adult brain transport of glycogen-
derived lactate has been shown to be necessary for the maintenance of long-
term potentiation, a process suggested to be linked to memory formation 
(Suzuki et al., 2011). Evidence continues to emerge that adds more weight to 
the argument that brain glycogen plays important physiological roles. 
1.2.6 Functional Neuroimaging
An understanding of energy metabolism in the brain is vital in order to fully 
appreciate and understand the results of functional imaging studies. Non-
invasive functional imaging has become one of the most widely used 
techniques in neuroscience and psychology (Raichle, 2003). The widespread 
use of functional neuroimaging has been, in part, responsible for much of the 
interest in brain energy metabolism. The local changes in glucose and oxygen 
consumption which occur in response to brain activity form the principal 
behind functional neuroimaging (Magistretti and Pellerin, 1999). The debate 
surrounding brain lactate has been fuelled by experiments that have sought to 
understand the energetics behind neuroimaging signals. Although functional 
imaging does not form the focus of the work described in the following 
chapters, it is important to consider that any enhancement in our knowledge 
of brain energy metabolism holds the possibility of helping further 
understand the basis of neuroimaging.
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1.3 Energy Metabolism and Pathology
Increasing knowledge of energy metabolism in the nervous system holds the 
possibility of better understanding and ultimately treating diseases. 
Alterations in nervous system energy metabolism have been associated with a 
vast array of pathologies (Blass et al., 1988; Sas et al., 2007). Some conditions 
appear to be triggered by disruptions in energy metabolism, whereas, others 
the changes in energy metabolism are secondary to the disease. Disruptions in 
energy metabolism are most obvious in cerebral hypoxia, traumatic brain 
injury and stroke (Zauner et al., 2002). In these conditions the supply of 
oxygen, in the case of hypoxia, and both oxygen and glucose for trauma and 
stroke, is interrupted. This leads to impaired energy metabolism and 
pathological damage in brain tissue. An example of a secondary disruption in 
brain energy metabolism is seen in diabetic patients who can be unaware of 
their hypoglycemia (Boyle et al., 1995). During a hypoglycemic episode brain 
glucose falls and this can lead to seizures and coma (Bingham et al., 2005). 
Evidence is emerging that metabolic dysfunctions may form part of the 
aetiology and pathophysiology of psychiatric syndromes, including major 
depression, obsessive-compulsive disorder, bipolar disorder and 
schizophrenia (Saxena et al., 2001; Martins-de-Souza et al., 2011). 
Schizophrenia is a condition of which the precise causes still remain an 
enigma, but mitochondrial dysfunction is frequently observed in affected 
brain areas (Bubber et al., 2011; Clay et al., 2011). Glycogen metabolism in 
astrocytes has also been identiÞed as potentially disrupted in schizophrenia 
(Lavoie et al., 2011). A direct effect on energy metabolism may underlie the 
therapeutic effects of anti-psychotics (Ma et al., 2009) and anti-depressants 
(Moretti et al., 2003), but some of the major side-effects of these drugs, such as 
weight gain, are also caused by their effects on metabolic pathways (Baig et 
al., 2010). A similar body of evidence emphasising the importance of energy 
metabolism in neurodegenerative diseases, such as AlzheimerÕs, has appeared 
(Allaman, 2011). As perturbations in energy metabolism may underlie 
Chapter 1
25
numerous disease states, clear and accurate understanding of energy 
metabolism in the brain is needed in order to develop future treatments.   
1.3.1 Hypo/aglycemia
Blood glucose concentration is tightly regulated by hormonal homeostatic 
mechanisms. The normal range for humans is between 4 - 7.2 mM. The critical 
nature of normoglycemia (i.e. normal blood glucose) means that 
hypoglycemia is seldom seen outside of patients who are treated with drugs 
that lower plasma glucose. Hypoglycemia may be rare, but non-systemic 
shortages of glucose can occur under other conditions. Interruptions in the 
supply of blood to tissue cause ischemic injury by depriving cells of glucose 
and oxygen. Ischemic events are particularly notable in the CNS due to its 
critical dependence upon blood-borne glucose. Stroke and traumatic brain 
injury are two notable causes of ischemic brain injury which result in 
signiÞcant levels of disability and mortality for sufferers worldwide.   
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1.4 Considerations in White Matter
The majority of the brain is composed of either one of two types of tissue, grey 
or white matter. Grey matter contains neuronal cell bodies and synapses 
whereas, white matter is mostly made up of myelinated axons. White matter 
accounts for 50% of the volume of the central nervous system (CNS). The total 
length of myelinated Þbres in a 20 year old male has been calculated as 
176,000 km (Marner et al., 2003). In terms of the focus of research into both 
health and disease, white matter has often played second Þddle to grey matter. 
The bias towards grey matter is probably understandable if white matter is 
seen as merely tissue that connects different areas of grey matter. However, 
dysfunction in white matter is an important factor in a number of pathologies 
that affect the brain. Injury to white matter causes a large proportion of the 
functional deÞcit seen in patients who have suffered an ischemic stroke 
(Goldberg and Ransom, 2003). White matter anomalies have been documented 
in cases of chronic schizophrenia (Agartz et al., 2001) and in the brains of 
children diagnosed with attention deÞcit hyperactivity disorder (Silk et al., 
2009). Changes in white matter also accompany the ageing process and the 
development of dementia (Malloy et al., 2007). These Þndings have been 
achieved by applying neuroimaging techniques to white matter. Therefore, as 
for grey matter, understanding the bioenergetic basis of imaging signals in this 
tissue is essential. 
It cannot be assumed that white matter energy metabolism is the same as that 
in grey matter. The differences in structure and function of white matter mean 
that the tissue has different energetic demands and perhaps different ways of 
fuelling these. The ANLSH (1.2.2.1) is an example of this. The hypothesis ties 
lactate production to re-uptake of synaptic glutamate, which is a process that 
does not occur in white matter as it is devoid of synapses. The processing of 
neurotransmitters has been estimated to consume 20 - 30 % of the energy 
usage of the whole brain (Ames, 2000), which will not be the case for white 
matter. In white matter the energy required for ion ßuxes and axonal transport 
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will be proportionally greater and ion movement is likely to be the most 
activity-dependent consumer of energy. 
 
1.5 Energy Metabolism in Peripheral Nerves
The importance of energy metabolism is not restricted to the axons of the 
CNS. The peripheral nervous system (PNS) is affected by conditions which 
lead to alterations in its energy metabolism (Low et al., 1997). Due to 
differences in the structure and physiology of the PNS, the physiological and 
pathological alterations which affect energy metabolism are not the same as 
those in the CNS. An immediately visible difference is that the PNS is not 
surrounded by the blood brain barrier or any structure with a similar role. The 
glial cell population in the PNS is also composed of different types of cells 
(Barron et al., 1990). Myelination in the PNS is performed by Schwann cells 
rather than oligodendrocytes. Each myelinating Schwann cell is associated 
with one axon, whereas, CNS oligodendrocytes contribute to the myelination 
of many axons. There are also Schwann cells which surround un-myelinated 
axons in peripheral nerves, forming structures called Remak bundles 
(Murrinson and GrifÞn, 2004) Differences between these two areas of the 
nervous system raise questions as to whether adaptations in energy 
metabolism vary between the tissues. The role of glycogen in the CNS has 
received growing attention. However, the same is not true of peripheral nerve 
glycogen. The role of glycogen in CNS axons has been mostly examined in the 
adult rodent optic nerve which contains exclusively myelinated axons. 
Studying the role of glycogen in a peripheral nerve will allow a comparison to 
be made between myelinated and un-myelinated axons. The aim of Chapter 6 
was to begin to explore whether peripheral nerves possess glycogen and if the 
role of glycogen is analogous to that seen in the CNS. 
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1.6 Aims and Hypotheses
The central aim of this thesis was to investigate the role of glycogen and 
lactate in supporting action potential conduction in both central white matter 
and peripheral nerves. Axonal activity in peripheral and central nerves will be 
monitored by recording CAPs using the suction electrode technique (Stys et 
al., 1991). A brief overview of the aims of the work carried out in this thesis is 
given here. SpeciÞc aims and their backgrounds are given in the introduction 
for each results chapter. 
The Þrst group of aims focus on the role of glycogen and lactate in central 
white matter. This subject has been explored previously using the MON as a 
model CNS white matter tract (Wender et al., 2000; Brown et al., 2003; Tekkok 
et al., 2005). The objectives to be set out here build on this prior knowledge by 
using the same model. From this previous work it is known that glycogen in 
the mouse optic can support axonal activity during aglycemia. My aim is to 
compare and contrast the neuroprotective role of glycogen against that of 
temperature. As moderate hypothermia (~ 2℃) is a clinically utilised 
neuroprotective strategy (Levi et al., 2009), it is hoped that showing similar 
beneÞts from glycogen will highlight its potential. 
During aglycemia, glycogen in astrocytes is metabolised to form lactate which 
is then released into the extracellular space and taken up by axons to sustain 
their energy demands. Lactate concentration in the MON has not been directly 
measured. It is an aim of this thesis to measure extracellular lactate in the optic 
nerve using an enzyme-based biosensor. The lactate dynamics during 
aglycemia will be investigated together with the effect of up- and down-
regulating the availability of glycogen. As neural tissue produces lactate 
during times of increased activity. I will use the biosensor measurement of 
lactate to see whether this is true in the MON and begin to explore 
mechanisms which underlie any changes in lactate production.
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Finally, I will examine the role of glycogen in peripheral nerves by using the 
mouse sciatic nerve (MSN) as a model. I will replicate the original experiments 
that demonstrated a functional role for glycogen in CNS white matter in the 
peripheral nerve. It is likely that glycogen will be present in the sciatic nerve 
as it expresses enzymes necessary for glycogen metabolism (Pfeiffer-Guglielmi 
et al., 2007). A functional role for glycogen in supporting axonal conduction is 
also expected as the structure of peripheral nerves can leave them susceptible 
to metabolic isolation (Low et al., 1997; Nave, 2010). As CNS glycogen is 
located in astrocytes and these cells are not present in the PNS it will be 
necessary to determine the location of glycogen. Due to the large extracellular 
spaces in peripheral nerves and also the size of axons it would not be 
surprising if glycogen was located in the axons rather than surrounding glia. 
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Chapter Two
Methods
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This chapter provides an overview of all methods used within this thesis. 
Minor points, which are speciÞc to individual chapters, are detailed prior to 
the relevant results. 
2.1 Animals
All procedures involving animals were carried out in accordance with the 
Animals (ScientiÞc Procedures) Act 1986. 
All animals used in these studies were adult male CD-1 mice (Charles Rivers, 
UK) weighing between 35-45 g (aged 40 days plus) and were killed by 
Schedule 1 dislocation of the cervical vertebrae. 
2.1.1 Optic Nerve 
Optic nerves were obtained by making an incision at the rear of the orbit and 
cutting each optic nerve at the eye. The skull was then opened and the brain 
reßected to expose the optic chiasm and the optic nerves which were cut free 
and gently removed. The dissection process took approximately three minutes 
from sacriÞce till the nerves were placed in the tissue bath. Each nerve was 
approximately 8 mm in length. 
2.1.2 Sciatic Nerve
After sacriÞce, mice were placed prone and the limbs secured to a cork board 
with dissecting pins. Sciatic nerves were obtained by dissecting the overlying 
tissue to expose the nerve in the thigh. The nerve was cut proximally near the 
sciatic notch and distally near the knee, and was then gently freed from 
surrounding connective tissue and gently removed. This dissection took a 
maximum of Þve minutes to fully remove the nerve and place in the tissue 
bath. The length of sciatic nerve removed was typically between 1.5 - 2 cm. 
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2.2 Electrophysiology
2.2.1 Stimulus-Evoked Compound Action Potential
2.2.1.1 Background of the Compound Action Potential
The primary function of axons in CNS white matter and peripheral nerves is 
the conduction of action potentials. This process consumes most of the energy 
required by these tissues (Ames, 2000) and is therefore impacted by 
disruptions in the supply of energy substrate. Recording the 
electrophysiological activity of an isolated nerve provides an index of nerve 
function that can be used to assess the effects of different metabolic conditions 
on the viability of CNS white matter. 
Conduction in isolated nerves can be studied by using a pair of electrodes and 
stimulating the nerve at one end whilst recording the evoked response 
distally. Such extracellular recording techniques allow monitoring of all the 
axons in the nerve. The evoked response is called the compound action 
potential (CAP). The CAP is the summation of all the individual action 
potentials in the axons comprising the nerve (Stys et al., 1991). The CAP 
encodes information about various parameters of the nerve and its individual 
Þbres; information that relates to characteristics such as the number of axons 
activated by the stimulus and their conduction velocities.
The CAP recorded from peripheral nerves has a distinctive proÞle when 
recorded with extracellular electrodes. Fig. 2.1 shows the CAP recording from 
a rat sural nerve by Potocnik et al. (2006). It shows that the CAP from the sural 
nerve consists of one main peak with a small peak merging with it (Fig. 2.1.A). 
A much smaller peak (around a tenth of the amplitude of the Þrst peak) can be 
seen when the time scale is extended (Fig. 2.1.B). A similar pattern of peaks 
can be seen in human nerves when CAPs are recorded by electrodes placed on 
the skin of healthy subjects (Van Veen et al., 1995). Axons of fast conducting, 
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thick, myelinated nerve Þbres with a conduction velocity of greater than 40 
ms-1 produce the high amplitude Þrst peaks with slower, smaller, un-
myelinated Þbres generating the later peaks which are of much smaller 
amplitude (Schoonhoven and Stegeman, 1991). 
Figure 2.1 Compound action potential (CAP) recorded from the rat sural nerve by 
Potocnik et al. (2006). CAPs were recorded with hook electrodes applied to isolated 
nerves in a liquid parafÞn bath. A. The fast component of the CAP consists of a large 
positive peak (i) and is generated by myelinated axons, a slight shoulder to this peak 
can be seen (ii) which is the response of slightly slower sub-population of myelinated 
axons. B. There is a third component (iii) which is the response of un-myelinated 
axons and is roughly a tenth of the amplitude of the fast response and ten times 
slower. Figure is adapted from Potocnik et al. (2006). 
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Some nerves exhibit CAPs which have considerably different proÞles 
compared to that seen in the sural nerve. When recording from the rodent 
optic nerve the CAP observed is formed by three large positive peaks which 
overlap, in contrast to the main single peak seen in the example in Fig. 2.1. 
Fig. 2.2 shows the typical CAP recorded in response to a supramaximal 
stimulus in the mouse optic nerve. The contrast in the number of peaks seen is 
due to differences in the diameter and conduction velocities of axons which 
make up the nerve. The time at which a peak occurs after the stimulus acts as 
an index of sub-population conduction velocity. 
Figure 2.2 The compound action potential recorded from rodent optic nerve. The 
CAP consists of three positive peaks (i, ii and iii), which are thought to originate from 
three distinct sub-populations of axon. The peak marked * is the stimulus artefact. The 
inset shows how the three peaks are each described accurately by a Gaussian 
function, where the dotted lines are the individual Gaussian best Þt functions, and the 
solid line is the recorded CAP. Figure adapted from Allen et al. (2006) and Brown 
(2006). 
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Nerves can vary widely in the number of axons they contain, and in the 
degree that speciÞc sub-populations of axons contribute to the CAP proÞle. 
Anatomical studies have produced histograms to describe in detail the 
distribution patterns of these individual Þbres that make up a nerve (see van 
Veen et al., 1995 and Allen et al., 2006). The difference in the CAP traces seen 
between the peripheral nerve and the optic nerve would suggest that there are 
indeed fundamental differences in the axon populations relating to 
myelination and conduction velocity. The rodent optic nerve has been studied 
in great anatomical detail and contains around 24,000 axons in mice (Allen et 
al., 2006) and around 100,000 in the rat (Lam et al., 1982). The nerve Þbres in 
the adult rodent optic nerve are all myelinated (Foster et al., 1982), whereas, 
peripheral nerves such as the sural nerve contain un-myelinated Þbres (van 
Veen et al., 1995). It is these differences that result in contrasting CAP proÞles. 
Analysis of the CAP can then be used to make inferences about the axon 
composition of the nerve, and the effects of experimental paradigms on sub-
populations of axons.
2.2.2.2 Analysis of Compound Action Potentials
Interpretation of CAPs requires mathematical and electrical models in order to 
obtain data suitable for analysis. When CAPs were Þrst used to measure 
electrical activity in the rat optic nerve using suction electrodes the amplitude 
of the CAP seen under control conditions was highly variable over time. An 
electrical model was required which took into account factors such as changes 
in resistance and stimulus artefacts that contribute to CAP variability. Stys et 
al. (1991) devised a model which took into account these factors and allowed 
reproducible recordings to be made. The model was validated experimentally 
and has formed the basis for other studies using suction electrodes and 
isolated nerves (e.g. Stys et al., 1992; Brown et al., 2003; Meakin et al., 2007). 
Modelling is required for detailed CAP analysis since the summation of all the 
individual action potentials to form a CAP is not straightforward as axons 
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contribute voltage according to their size. Some of the models commonly used 
for this purpose are extensively reviewed by Schoonhoven and Stegeman 
(1991). Whilst detailed analysis of the CAP is possible, the amplitude of the 
range of CAP peaks, and the conduction velocity measured by the latency of 
these peaks, provides a simple, but effective, measure of how nerve activity is 
affected by physiological or pathological interventions. 
As described above, several characteristics of the compound action potential 
can be considered for analysis. These include the stimulus-response latency, 
the peak amplitude of the response or an area under the curve. When the 
mouse or rat optic nerve is used, a response with three identiÞable peaks is 
always seen, which raises the question of whether to interpret the response as 
a whole or to look at the individual peaks. Dong and Hare (2005) elected to 
use the area under the curve for the complete compound action potential 
response despite the presence of three peaks. They noted that whilst the 
compound action potential could change in its timing and amplitude without 
a change in overall area under the curve, total area under the curve still 
provided a useful measurement for their purpose of investigating the 
contribution of Na+ to ischemic injury. On the other hand, monitoring changes 
in the individual peaks has previously allowed conclusions about speciÞc sub-
populations of axons in the nerve to be made. For example, it was found that 
the large axons, which make up the Þrst peak in the mouse optic nerve 
compound action potential, are not supported by fructose (Allen et al., 2006; 
Meakin et al., 2007). This information can only be gathered by considering 
each peak as an individual population of axons (see Fig. 2.2). A method for 
interpreting CAPs in this manner has been described (Brown, 2006; Evans et 
al., 2010). 
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2.2.2.3 Protocol for Recording CAPs
After removal from the animal, nerves were immediately placed in a laminar 
ßow interface perfusion chamber (Harvard Apparatus) supplied with a 
constant ßow (2 ml / min) of artiÞcial cerebrospinal ßuid (aCSF) maintained 
at 37℃ and bubbled with a gas mixture of 95% O2 / 5% CO2. The aCSF 
comprised of a solution of (in mM): 126 NaCl, 3 KCl, 2CaCl2, 2 MgCl2, 1.2 
NaH2PO4, 26 NaHCO3 and 0 - 10 glucose, pH 7.4. When required for 
aglycemic conditions an aCSF solution omitting 10 mM glucose was used. For 
other experiments the glucose concentration was adjusted or further 
compounds added as necessary (see protocol sections in other chapters). Since 
the manipulation of glucose did not alter osmolarity by more than 5% no 
osmotic compensations were made. Historic data revealed no difference 
between results whether osmotic compensation was made or not (Wender et 
al., 2000). 
Axonal conduction was monitored in both optic and sciatic nerves using 
suction electrodes to record the stimulus-evoked CAP in a manner similar to 
that described by Stys et al. (1991). A diagram of the setup is shown in Fig. 2.3. 
Suction electrodes back-Þlled with the appropriate aCSF were used for 
stimulation and recording. One electrode was attached to the rostral end of the 
nerve for stimulation and the second suction electrode was attached to the 
caudal end of the nerve to record the CAP, thus all recordings were 
orthodromic. A WPI Isostim A320 constant current stimulator (WPI, 
Stevenage, UK) was used to generate a stimulus of 30 !s duration and the 
strength adjusted to evoke the maximum CAP possible and then increased 
another 25% (i.e. supramaximal stimulation, Stys et al. 1991). During an 
experiment, the supramaximal CAP was elicited every 30 seconds. The signal 
was ampliÞed 10x by an Axoprobe 1A ampliÞer, then ampliÞed a further 100x 
by an SRS560 PreampliÞer (Stanford Research Systems, Inc., Sunnyvale, CA, 
USA), Þltered at 10 kHz and acquired at 20 kHz (Digidata 1320A with 
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Clampex 9.2, Molecular Devices, Wokingham, UK). Optic nerve axon function 
was monitored quantitatively as the area under the supramaximal CAP. The 
area under the CAP represents the best measure of the number of active axons 
because currents generated by individual axons within a Þbre tract are 
considered to sum linearly (Cummins et al. 1979; Stys et al. 1991). The curve 
Þtting routine for detecting the latency to CAP failure has previously been 
described (Wender et al. 2000) and involves measuring where the CAP falls to 
95 % of its baseline area. For the sciatic nerve CAP area was not used, but 
rather CAP amplitude, see Chapter 6 for details. All CAP areas or amplitudes 
were normalised to control conditions unless indicated.  
Figure 2.3 Illustration of the experimental setup used to record compound action 
potentials from rodent optic nerves. Figure adapted from Dong and Hare (2005) and 
represents an updated diagram of the setup used by Stys et al. (1991). 
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2.3 Lactate Biosensor Measurements
2.3.1 Principles of Biosensor Measurement of Lactate
The measurement of speciÞc compounds within the brain and how their 
concentrations are affected by physiological variables is an important tool in 
neuroscience. In the Þeld of nervous system energy metabolism, measurement 
of brain lactate concentration can provide evidence as to the role of lactate in 
brain physiology. Monitoring of lactate has often been performed by using 
microdialysis, but this technique has its limitations (See Chapter 4 for 
discussion). In the experiments described here an enzyme-based biosensor 
was used to measure lactate in nervous tissue. The principles that underlie 
biosensor measurement of chemicals combine a biological component and a 
physical component. In the case of the lactate biosensor utilised here, the 
biological component is the interaction of lactate with the enzyme lactate 
oxidase which is immobilised in the tip of the sensor. Lactate oxidase catalyses 
the formation of pyruvate from lactate and oxygen, forming hydrogen 
peroxide (H2O2) in the process. The physical component of the sensor is the 
amperometric detection of hydrogen peroxide by a polarised platinum 
electrode. The current produced, by the oxidation of H2O2 is proportional to 
the concentration of lactate present at the sensor tip. Biosensors are designed 
such that a selectively permeable layer surrounds the enzyme layer and 
electrode, which allows for recording speciÞc signals from the analyte of 
choice.  
2.3.2 Biosensor protocol in the MON
Lactate in the vicinity of the MON was quantiÞed amperometrically by using 
an enzyme-based lactate biosensor. Biosensor experiments were performed 
simultaneously alongside CAP recordings in the perfusion chamber set up 
described above. Commercially available lactate biosensors (2 mm length, 50 
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!m diameter) were purchased from Sarissa Biomedical (Coventry, UK). Prior 
to experimental use a sensor was rehydrated in a buffer composed of: 10 mM 
NaPi, 100 mM NaCl, 1 mM MgCl2 and 2 mM glycerol, the pH was adjusted to 
7.4. After rehydration experiments were carried out in aCSF (see above) with 
the addition of 2 mM glycerol.
At the start of an experiment a rehydrated sensor was mounted on a micro-
manipulator and gently lowered into the perfusion chamber so that the 
sensing tip was fully submerged in aCSF. The sensor was connected to a 
potentiostat (Micro C, WPI, Sarasota, FA, USA) and polarised to + 500 mV 
relative to the Ag/AgCl reference electrode located in the bath. The 
potentiostat output was digitised and acquired at 1 Hz (Digidata 1320A with 
Clampex 9.2, Molecular Devices, Wokingham, UK)
Before commencing measurements from tissue the sensor was cycled and 
calibrated. Cycling was achieved by using an external signal generator to 
apply a current to the sensor. This process helps to sustain the useful life of the 
sensor. When the current from the sensor was stable calibration was 
performed by pipetting a 1 mM solution of lactate onto the sensor in situ, this 
process was repeated at the end of the experiment to determine if sensitivity 
was lost during the experiment. Following calibration, the sensor was slowly 
positioned against the nerve and the output was again allowed to stabilise for 
30 minutes. The sensor was positioned relative to the nerve so that the 
maximum area of the sensing tip came into contact with the outside of the 
nerve (Fig. 2.4). Time for further equilibration was needed because after initial 
positioning of the sensor in contact with the nerve the lactate signal increased 
before returning to a stable value. The cause of this raised signal is most likely 
due to mechanical disruption of the tissue causing lactate release. 
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Figure 2.4 Schematic of the arrangement of nerve, biosensor and suction 
electrodes within the tissue bath. 1. Suction electrodes. 2. Optic or sciatic nerve. 3. 
Lactate biosensor; the biosensor tip was ßexed to Þt alongside the nerve, the shaded 
area represents the sensing tip. 
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2.4 Glycogen assay
A biochemical assay was used to quantify nerve glycogen content. The assay 
was based on that described by Brown et al. (2003) with nerve glycogen 
content being expressed as pmol glycogen (!g protein)-1. 
Nerves were obtained as described above (2.1) and at completion of the 
relevant experimental paradigm the nerves were placed in a ice-cold solution 
of 85% ethanol / 15% 30 mM HCl Ð this solution prevents glycogen 
metabolism occurring. Nerves were stored in solution at -30℃ until required 
for assay. A total of 5 pairs of optic nerves or 2 pairs of sciatic nerves, a total 
net weight of 10 mg, were pooled for each data point. 
On the day of the assay tissue was washed in 30 mM HCl and then transferred 
to ice-cold 0.1 M NaOH/0.01% SDS. The tissue was sonicated and re-acidiÞed 
with 1M HCl. At this point the homogenate was divided into two equal 
volumes, one used to determine glycogen content the other for protein 
quantiÞcation. The protein assay was performed following the instructions 
supplied with the BCA protein assay (BioRad), in which a BSA standard was 
used and the samples read at a wavelength of 740 nm on a spectrophotometer.
Glycogen content was determined by Þrst further dividing the homogenate 
and treating one sample with amylo-α-1,4-α-1,6-glucosidase (0.08 units per 
sample) (AG: EC 3.2.1.3) to digest glycogen to glucose. This step was 
performed at 37℃ with gentle agitation. Leaving one sample untreated with 
AG allowed determination of any background glucose in the tissue, which 
was subtracted from the value obtained in the AG-treated samples. Samples 
were then added to a reaction mixture containing 260 !M ATP, 50 !M NADP 
and 2.27 and 6.25 units of the enzymes glucose-6-phosphate dehydrogenase 
(EC 1.1.1.49) and hexokinase (EC 2.7.1.1), respectively. Addition of glucose to 
the reaction mixture results in the formation of NADPH from NADP. NADPH 
can be detected by monitoring absorbance on a spectrophotometer at 340 nm. 
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The concentration of glucose was estimated by comparison with a standard 
curve of increasing glucose concentrations (0 - 200 !M). The glucose 
concentration was then factored for the dilutions which occurred during the 
assay and divided by the homogenate protein concentration to establish the 
Þnal glycogen concentration. 
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2.5 Microscopy
2.5.1 Transmission Electron Microscopy
Following electrophysiological recordings, optic or sciatic nerves were 
removed from chambers and Þxed with 4% glutaraldehyde in 140 mM 
SorensenÕs phosphate buffer, post-Þxed with OsO4, and embedded in plastic 
resin according to standard procedures.  Semi-thin (0.5 !m) and ultra-thin (70 
- 90 nm) cross-sections of sciatic nerves were cut.  Ultra-thin sections were 
stained with uranyl acetate and lead citrate and examined with a JEM-1011 
electron microscope (JEOL USA, Peabody, MA) operating at 80 kV.  Images 
were acquired at 10,000x magniÞcation with an AMT-TR-111 digital camera 
(Advanced Microscopy Techniques, Danvers, MA). 
2.6 Statistical Analysis
Data presented as the mean ± the standard deviation. Paired Student t-tests 
were used to determine signiÞcance between control and treated CAPs 
(Microsoft Excel for Mac). Differences between control and multiple 
conditions were calculated using one way ANOVA with the appropriate post-
hoc test (Graphpad Prism for Mac). 
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Chapter Three
Neuroprotective effect  
of hypothermia and 
glycogen in the mouse 
optic nerve
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3.1 Introduction
The human brain is reliant on the blood-borne delivery of glucose and oxygen 
at levels in excess of demand in order to function normally. Blood-glucose 
concentration can fall and be incapable of meeting the energy requirements of 
the brain in patients receiving intensive insulin treatment for Type-1 diabetes. 
This is due to management of blood-glucose concentration; patients inject 
insulin to prevent hyperglycaemia which carries the risk of accidental 
hypoglycemia (Frier and Fisher, 2007). Insulin-induced hypoglycemia leads to 
a rapid deterioration of brain function, evidenced by the appearance of 
symptoms such as confusion, anxiety and lethargy (Hepburn et al, 1991). 
Historically research has focused on the effects of hypoglycaemia in CNS grey 
matter due to its close association with the cognitive processes that appear to 
be Þrst affected by the drop in glucose availability. However, evidence has 
emerged to suggest that white matter is also vulnerable to hypoglycaemic 
injury and should not be over-looked (Mori et al, 2006).
3.1.1 Aglycemic Injury in White Matter
Studying white matter in isolation is possible with the acutely isolated rodent 
optic nerve preparation. The optic nerve is ideal as a white matter model as it 
lacks the constituents of grey matter: neuronal cell bodies and glutamatergic 
synapses. The rodent optic nerve can be maintained in vitro for many hours 
with physiological variables controlled as determined by the experiment. 
Nerve conduction during this time can be monitored by recording stimulus-
evoked compound action potentials (CAPs). Using these methods the 
mechanisms behind aglycemic injury in rodent optic nerve have been 
identiÞed as (1) toxic Ca2+ inßux via L-type Ca2+ channels, and (2) reverse 
operation of the Na+-Ca2+ exchanger (Brown et al, 2001). The mechanisms of 
aglycemic injury can be delayed; temperature can inßuence the injury process 
as can endogenous stores of energy in the form of glycogen. 
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3.1.2 The Effect of Temperature on Nerve Conduction and 
Injury
Temperature is one of the most important physiological variables, as it 
inßuences all cellular processes, and exposure to a temperature outside 
optimal range can result in cell or organism death. The effect of temperature 
on individual action potentials was investigated as part of the pioneering 
work on conduction in the squid giant axon (Hodgkin and Katz, 1949). 
Variations in temperature altered the proÞle of action potentials, with the 
falling phase most sensitive. The effect of temperature on mammalian nervous 
tissue has also been examined: peripheral nerves (Kiernan et al., 2001) and 
brain EEG activity (Kochs, 1995) are both temperature sensitive. 
Changes in temperature slow down or speed up the ionic mechanisms that 
underlie aglycemic injury. The effect of temperature on injury in the CNS has 
been used as a therapeutic strategy, as controlled cooling of the body can help 
protect against cell death (Levi et al., 2009). Preventing increases in 
temperature is another rationale behind cooling as transient hyperthermia 24 
hours after ischemia greatly increases the neuronal injury that occurs (Baena et 
al., 1997). Additionally, moderate hypothermia post-ischemia can reduce the 
extent of brain injury and cell death (Edwards et al., 1998). A key factor behind 
the beneÞcial effects of hypothermia during ischemia is likely to be the 
slowing down of metabolism and reductions in the energy demand and 
oxygen consumption that have been demonstrated to occur during 
hypothermia (Michenfelder and Milde, 1991). The rate of ion transport by the 
Na+-Ca2+ exchanger and the slowing down of enzyme reactions may also 
provide an important role in producing the neuroprotective effects of 
hypothermia (Stys et al., 1992). There is also evidence that Zn2+ ion movement 
which, plays a role in brain injuries, is inhibited by hypothermia and 
enhanced by hyperthermia (Suh et al., 2006). The relative importance of the 
effect of temperature on these processes and their relevance to therapeutic 
hypothermia is likely to be a balance between the contribution they make to 
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cell death and their temperature sensitivity. It is possible that understanding 
the contribution of each of these injury processes could allow selective 
targeting of interventions which will be most effective in ameliorating 
aglycemic injury.
 
3.1.3 The Importance of Brain Glycogen
Recent studies in both human and rodent models have highlighted the 
potential clinical use of brain glycogen as an endogenous therapeutic target 
(Gruetter, 2003; Seaquist and Gruetter, 2002). The inßuence of temperature on 
metabolic rate means that an effect on the utilisation of glycogen stores in 
white matter is likely. Glycogen is used as an energy reserve when glucose is 
withdrawn and can delay conduction failure for up to 30 minutes in the 
rodent optic nerve (Wender et al., 2000; Brown et al, 2003). Glycogen is 
therefore considered an endogenous neuroprotective agent of clinical 
relevance. Up-regulation of endogenous glycogen content has been proposed 
as a potential therapy to stave off hypoglycemic brain injury (Swanson and 
Choi, 1993; Suh et al., 2005; Suh et al., 2007). However, performing such 
therapeutic interventions depends upon the successful development of clinical 
methods of regulating brain glycogen. The track record for many 
neuroprotective therapies transitioning from the lab to the clinic has 
frequently beer poor, notably in the treatment of stroke (Green and Shuaib, 
2006). For this reason caution should be adopted when assessing the clinical 
possibilities of glycogen regulation. 
While interventions targeting glycogen are not yet clinically available to 
prevent neuronal damage, hypothermia is, and has been shown to reduce 
neuronal damage during aglycemia in in vitro models (Shin et al, 2010). 
Comparing the neuroprotective ability of glycogen to that afforded by 
hypothermia may help highlight the potential clinical importance of glycogen. 
Further to this, the effects of hypothermia combined with the neuroprotective 
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effect of glycogen on white matter injury during aglycemia have not been 
previously tested. 
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3.1.4 Aims
The aim of this study was to evaluate the neuroprotective effects of 
hypothermia and glycogen in the optic nerve. Whilst the beneÞt of 
hypothermia and the dangers of hyperthermia occurring during brain injury 
are widely accepted, the role of brain glycogen is overlooked. Demonstrating 
the beneÞcial effect of metabolically available glycogen in astrocytes upon 
prevention of aglycemic injury, and comparing this to the effect of 
temperature will highlight the potential importance of glycogen.  
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3.2 Methods and Protocol
3.2.1 Electrophysiology
Compound action potentials (CAPs) were recorded using suction electrodes 
from isolated mouse optic nerves, which were obtained as described in 
Chapter 2. 
Parameters of CAP failure during aglycemia expressed in Fig. 3.6 and 3.10 
were calculated as described by Wender et al. (2000). A template which used 
the Solver function in Microsoft Excel (Brown, 2001) was used to Þt a 
Boltzman equation to the CAP area during aglycemia which then determined 
the time at which CAP area reached 95 % of its pre-aglycemic value. This 
equation also gave a value for the gradient of the slope of CAP failure which 
indicates the rate of CAP failure. A lower value indicates a steeper slope and 
therefore more rapid CAP failure. CAP recovery was measured as  the CAP 
area at 37℃ remaining post-aglycemia as a percentage of the initial CAP area 
at 37℃. This was the case for all temperatures as at the end of each 
experiment the nerve was returned to 37℃ for the recovery phase.
3.2.2 Control of Temperature
A temperature controller (Model TC 202A, Harvard Apparatus, UK) allowed 
control of temperatures above room temperature of the perfusion chamber, 
thus we chose to carry out experiments at 27℃, 32℃, 37℃ and 42℃. 
Temperature readings were obtained via the dedicated output (100 mV ℃-1). 
The slow time course of the temperature changes illustrated in Fig. 3.4.A 
highlights the delay in heating the chamber. To accelerate the transition of 
temperature changes, the reservoir was drained of water via a sump in the 
base of the unit and water at the desired temperature was injected into the 
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reservoir. In experiments where the temperature sensitivity of aglycemia was 
tested, the bath was allowed to reach the desired temperature prior to 
switching to glucose-free aCSF. 
3.2.3 Oxygen Electrode
The O2 consumption was measured polarographically using Clark oxygen 
electrodes (Rank Brothers, Bottisham, UK). The partial pressure of O2 was 
measured at a polarographic voltage of -600 mV with electrodes calibrated at 
100% saturation in aCSF bubbled with 95% O2 / 5% CO2, and at 0% with 
addition of Na2S2O4. aCSF was bubbled with 95% O2 / 5% CO2 for 2 hours at 
the test temperature to ensure maximal solution saturation of gas. The rate of 
O2 consumption was measured as the change in pO2 over a period of time, 
which being linear, was the pO2 slope. The PO2 was converted to molarities 
based on assumptions of solubility of O2 at 35¡C being 19.82 !moles / mole 
H2O, and 22.90 !moles / mole H2O at 25¡C (Lide 2006), and corrected for 
tissue weight. 
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3.2.4 Morphological Studies 
As described in Chapter 2 electron microscope images of nerves were obtained 
by providing treated tissue to The University of Nottingham Advanced 
Microscopy Unit. 
Axon counting was performed by undergraduate students within the 
laboratory and these data are included here to augment and illuminate the 
functional data. The protocol was carried out as described by Allen et al., 
(2006). Firstly, a transverse section of the MON was viewed at low 
magniÞcation (300x). The hexagonal pattern on the copper grid used to 
support the specimen was used to randomly select areas to record at the 
higher magniÞcation (10,000x). Prior to acquiring the image for analysis the 
samples were focussed at 20,000x then returned to 10,000x. This improves the 
sharpness of the image by reducing the effect of hysteresis in the lens. Two 
Þelds which measured 18.8 !m by 12.5 !m were selected from opposite 
corners of each hexagon. The hexagons can be seen superimposed over an 
image of the MON in Fig. 3.1.A. The total image shown in Fig. 3.1.B shows an 
example Þeld of the measurements described above. Axon counting and 
measurement was then performed in a smaller region of interest (ROI) within 
these Þelds. Each ROI measured 9.0 !m by 6.33 !m (total area 56 !m2). The 
ROI is shown in Fig. 3.1.B by the solid rectangle. Only axons that were judged 
to be more than 50 % inside the ROI were included in the analysis. For 
example, axon 1 (Fig. 3.1.B) would be included in the count, whereas, axon 2 
in the same Þgure would not. The surface area of each axon judged to be 
inside each ROI was measured using Openlab software (Improvision).
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Figure 3.1 Method for axon counting. A. Transverse section of the MON with 
hexagonal grid overlaid. B. High power image of a single rectangular grid from A. For 
analysis two rectangular Þelds were acquired from opposite sides of each hexagon in 
A. Axons were then counted and measured from a smaller region of interest in each 
Þeld, shown by the solid rectangle in B. Axons that were over 50% within the ROI (1) 
were included in the analysis and axons more than 50% outside the ROI (2) were 
excluded. Figure reproduced from Allen et al., 2006. 
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3.3 Results
3.3.1 Extent of aglycemic injury is dependent on duration 
of aglycemia 
The effects of aglycemia on axon conduction were assessed by exposing 
MONs to either 1 or 2-hour periods of aglycemia followed by 1-hour recovery 
in control aCSF containing 10 mM glucose. Figure 3.2.A-B (insets) illustrates 
that the control CAP is composed of three peaks, an initial 1st CAP peak, a 
larger 2nd CAP peak, and a smaller 3rd CAP peak. Figure 3.2.A shows that in 
MONs exposed to aglycemia, the CAP began to fall after 21.0 ± 3.7 minutes (n 
= 6) and fell rapidly to zero, where it remained for the duration of the 
aglycemic insult (Fig 3.2.A-B). In MONs that were exposed to 1 hour of 
aglycemia followed by a 1 hour recovery period in 10 mM glucose aCSF, the 
CAP area slowly increased and recovered to 45.5 ± 18.8 % by the end of the 1 
hour recovery period (Fig. 3.2.A, n = 6,). In MONs exposed to 2 hours of 
aglycemia the CAP fell after 19.3 ± 3.4 minutes, and recovered to 16.6 ± 7.7 % 
of control (Figure 3.2.B, n = 5) Figure 3.3 shows that the difference between the 
CAP area prior to aglycemia and post-insult was signiÞcant for both 1 and 2 
hours of aglycemia (for 1 hour p = 0.00024 vs. baseline and p = 0.00005 vs. 
baseline for 2 hours). The difference between CAP area recovery between a 1 
hour and a 2 hour glucose withdrawal followed by a 1 hour recovery in 10 
mM glucose aCSF was also signiÞcant (p = 0.018). 
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Figure 3.2 The effect of aglycemia on axonal conduction.  A. Exposure to 1 hour of 
aglycemia followed by a 1 hour recovery in 10 mM glucose aCSF resulted in a delayed 
fall followed by incomplete recovery of the CAP (n = 6). Inset shows the control 
triple peaked CAP (a) and the attenuated CAP after the recovery phase (b). B. 
Aglycemia for 2 hours resulted in total abolition of the CAP with minimal recovery (n 
= 5). Inset shows a control CAP (a) and the post-aglycemia CAP (b). Scale bars for 
insets are 2 mV (y-axis) and 1 ms (x-axis).
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Figure 3.3 Functional recovery of the MON depends upon the duration of 
aglycemia. The degree of CAP recovery was dependent upon the duration of 
aglycemia, with 1 hour producing greater recovery than 2 hours. * denotes p < 0.05, 
see text for details. White bars show CAP area before aglycemia and shaded bars 
show CAP area after 1 hour of recovery in 10 mM glucose aCSF; (n = 6 for 1 hr and 
n = 5 for 2 hr). 
3.3.2 Effect of temperature on the CAP proÞle.
The effect of temperature on the CAP proÞle was examined by recording the 
CAP at 27¡C then increasing the temperature in 5¡C steps to 42¡C. Figure 3.4 
clearly shows an inverse relationship between temperature and CAP area. 
Individual CAPs recorded at the four test temperatures are illustrated in Fig. 
3.4.C, demonstrating that whereas conduction velocity decreases with 
hypothermia the CAP amplitude increases. The CAP area is plotted versus 
temperature to illustrate the non-linear relationship (Fig. 3.4.B, n = 4).  
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Figure 3.4 Effect of temperature on MON CAP proÞle. A. CAP area was 
temperature sensitive, hypothermia resulting in increased CAP area. The open squares 
denote individual CAP areas (right y-axis), the solid line denotes temperature (left y-
axis). B. CAP area plotted against temperature. C. Example CAPs recorded at 27¡C, 
32¡C, 37¡C or 42¡C, with the CAPs at the back of the stack recorded at the lower 
temperatures. Scale bars 2 mV (y-axis) and 1 ms (x-axis). 
3.3.3 Temperature-dependence of aglycemic injury
In order to test the temperature-dependence of aglycemic injury, MONs were 
incubated in 10 mM glucose aCSF for 90 minutes, whereupon 0 mM glucose 
aCSF was introduced. At 60 minutes the temperature was altered from 37¡C to 
the test temperature, where it remained until 150 minutes. At 150 minutes the 
temperature was returned to 37¡C and 10 mM glucose aCSF was reintroduced, 
thus the temperature had stabilised to the test temperature at the onset of 
aglycemia and remained stable at that temperature for the duration of the 
aglycemic insult (see Fig. 3.5). The temperature-dependence was reßected in 
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both the latency to CAP failure and the degree of CAP recovery. Decreasing 
temperatures were associated with increased latency durations: at 27¡C, 32¡C, 
37¡C or 42¡C, respectively, the latencies to failure were 19.9 ± 4.5, 17.7 ± 3.8, 
15.7 ± 2.9 or 13.0 ± 4.3 minutes, respectively (Fig. 3.5 & 3.6.A). Similarly the 
slope of the CAP failure was temperature-dependent indicating that the CAP 
fell most rapidly at higher temperatures (Fig. 3.6.B). The degree of recovery of 
the CAP after the aglycemic injury was temperature dependent, not 
surprisingly showing that MONs incubated at lower temperatures during 
exposure to aglycemia displayed greater recovery: at 27,¡C 32¡C, 37¡C or 42¡C, 
respectively, the CAP recovery was 73.8 ± 5.9, 50.3 ± 9.9, 34.7 ± 3.8 or 15.6 ± 5.3 
%, respectively (Fig. 3.6.C, n = 4 for each temperature).
Figure 3.5 The effect of temperature on CAP area during aglycemia. Plot of average 
CAP area versus time during exposure to aglycemia at 27¡C (), 32¡C (), 37¡C 
() or 42¡C (). The dotted line indicates the period of test temperature, and the 
numerals denote the aCSF  [glucose] in mM (n = 4 for each condition). 
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Figure 3.6 The effect of temperature on CAP area for a 1 hour period of 
aglycemia. A. Latency to CAP failure. B. Slope of CAP fall. C. Recovery of CAP after 1 
hour 10 mM glucose post-aglycemia. (n = 4).
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3.3.4 Temperature-dependence of MON metabolism
Glycogen is present in the MON and prolongs latency to CAP failure during 
periods of aglycemia (Brown et al., 2003). Thus, isolation of the 
neuroprotective effects of glycogen from the aglycemia-induced injury 
mechanism was sought. As a Þrst step the effect of increasing temperature on 
glycogen breakdown during aglycemia was measured. MONs were 
maintained as described in Fig. 3.5 at 37¡C or 27¡C and harvested at 110 
minutes, thus nerves were exposed to aglycemia for 20 minutes at either 27¡C 
or 37¡C. Figure 3.7.A shows that there was a signiÞcant decrease in the 
glycogen content of MONs incubated at 37¡C (2.92 ± 0.58 pmoles !g protein-1) 
compared to 27¡C (6.18 ± 0.61 pmoles !g protein-1, p = 0.009, n = 3), indicating 
that at lower temperatures the rate of glycogen metabolism is decreased. 
As a second step in isolating the neuroprotective effects on glycogen MONs 
were incubated in aCSF containing either 2 mM glucose or 10 mM glucose for 
2 hours at 37¡C (Fig. 3.7.B). Glycogen content was 7.18 ± 0.13 pmoles !g 
protein-1 in MONs incubated in 10 mM glucose, whereas content fell 
signiÞcantly to 2.61 ± 0.65 pmoles !g protein-1 in MONs incubated in 2 mM 
glucose (p = 0.0003, n = 3). Thus incubating MONs in low glucose aCSF is an 
effective means of depleting glycogen content and could be performed prior to 
examining the effect of temperature on aglycemic injury. 
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Figure 3.7 Glycogen metabolism is affected by temperature and ambient glucose 
concentration. A. Glycogen content (pmoles μg protein-1 Ð also applies to B) of 
MONs incubated for 20 minutes at either 37¡C or 27¡C in the absence of glucose. 
Glycogen stores are used less rapidly during aglycemia at lower temperatures (n = 3). 
B. Glycogen content of MONs incubated for 2 hours in either 10 mM glucose or 2 
mM glucose (n = 3). The glycogen content of the MON can be modulated prior to 
aglycemia by changing the ambient glucose concentration. * denotes p < 0.05. 
Recording oxygen uptake can be used to monitor tissue metabolic rate. 
Accordingly, the oxygen consumption of MONs incubated at either 27¡C or 
37¡C, in the presence and absence of glucose was measured. MONs incubated 
at 27¡C in the presence of 10 mM glucose had a signiÞcantly lower rate of O2 
consumption than MONs incubated at 37¡C (1.09 ± 0.28 vs. 2.09 ± 0.85 !moles 
O2 g-1 min-1, p = 0.020, n = 5, Fig. 3.8.A). Similarly in MONs incubated in the 
absence of glucose the O2 consumption was signiÞcantly lower at 27¡C than 
37¡C (1.13 ± 0.49 vs. 1.82 ± 0.45 !moles O2 g-1 min-1, p = 0.040, n = 5, Fig. 3.8.B). 
There was no signiÞcant difference in the rate of O2 consumption at either 
Chapter 3
63
temperature of MONs incubated in the presence or absence of glucose (27¡C - 
1.13 ± 0.49 vs. 1.09 ± 0.27 !moles O2 g-1 min-1; 37¡C - 1.82 ± 0.45 vs. 2.01 ± 0.85 
!moles O2 g-1 min-1) (Fig 3.8.B), indicative of glycogen metabolism in the 
glucose-free MONs requiring equivalent oxygen as does glucose metabolism. 
Figure 3.8 Temperature sensitivity of oxygen consumption in the MON.  A. Oxygen 
consumption of MONs incubated in aCSF containing 10 mM glucose at 27¡C (black 
line) or 37¡C (grey line). B. Oxygen consumption (μmoles O2 g-1 min-1) in MONs 
incubated at either 27¡C (grey columns) or 37¡C (open columns) in the presence (+) 
or absence (-) of 10 mM glucose. * denotes p < 0.05, n = 5. 
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3.3.5 Temperature-dependence of aglycemic injury in 
glycogen-depleted nerves
The presence of glycogen in the MON and the slowing down of the metabolic 
rate at low temperatures means that the exact relationship between 
temperature and injury mechanisms may be masked. Glycogen content was 
therefore depleted from the nerves prior to exposing them to aglycemia to 
reduce its inßuence. Depletion of glycogen was achieved by incubating nerves 
for 2 hours in 2 mM glucose aCSF, which has previously been shown to reduce 
glycogen to its nadir (Brown et al 2003). MONs were incubated in 10 mM 
glucose for 60 minutes then 2 mM glucose aCSF was introduced for 120 
minutes (60 Ð 180 minutes), whereupon glucose-free aCSF was introduced 
(180 Ð 240 minutes), followed by a 60-minute recovery period in 10 mM 
glucose aCSF (240 Ð 300 minutes, see Fig. 3.9). MONs were maintained at 37¡C 
until 165 minutes when temperatures were changed to the test temperature. 
At 240 minutes the temperature was restored to 37¡C to coincide with the 
period of recovery. Qualitatively the effects of temperature were similar to 
those shown in Fig. 3.5 and 3.6, however, there were signiÞcant quantitative 
differences. The latency to CAP failure at 27¡C, 32¡C, 37¡C or 42¡C, 
respectively, was 11.2 ± 1.0, 9.4 ± 1.9, 8.0 ± 2.5, or 5.3 ± 3.2 minutes, respectively 
(Fig. 3.9 & 3.10.A). The rate of CAP failure was temperature-dependent, being 
fastest at higher temperatures (Fig. 3.11.B), and the greatest CAP recovery 
occurred when exposure to aglycemia occurred at low temperatures. The 
CAP recovery at 27¡C, 32¡C, 37¡C or 42¡C, respectively, was 61.0 ± 8.5, 37.7 ± 
13.4, 13.2 ± 6.0 or 0 ± 0%, respectively (Fig. 3.11.C, n = 4 for all temperatures).
Chapter 3
65
Figure 3.9 The effect of temperature on CAP area during aglycemia for glycogen-
depleted nerves. Plot of average CAP area versus time during exposure to aglycemia 
at 27¡C (), 32¡C (), 37¡C () or 42¡C (). The dotted line indicates the period 
of test temperature, and the numerals denote the aCSF  [glucose] in mM (n = 4 for 
each condition).
3.3.6 Comparison between control and glycogen-depleted 
MONs
Comparing the data shown in Figs 3.5 and 3.9 allows us to quantify the 
neuroprotective effects of glycogen at all four test temperatures using 
unpaired t-tests. For CAP recovery at 27¡C, 32¡C, 37¡C or 42¡C the p values 
were 0.287, 0.182, 0.003, 0.007, respectively: for the slope at 27¡C, 32¡C, 37¡C or 
42¡C the p values were 0.048, 0.347, 0.403, 0.519, respectively, and for the 
latency at 27¡C, 32¡C, 37¡C or 42¡C the p values were 0.042, 0.046, 0.013, 0.048, 
respectively. 
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Figure 3.10 The effect of temperature on CAP area parameters for a 1 hour period 
of aglycemia; comparison of control and glycogen-depleted nerves. A. Latency to CAP 
failure. B. Slope of CAP fall. C. Recovery of CAP after 1 hour 10 mM glucose post-
aglycemia. Open squares show glycogen-depleted MONs and control values from Fig. 
3.6 are shown by open triangles for comparison. * denotes p < 0.05 for comparisons 
between control and glycogen-depleted MONs at the same temperature (n = 4).
Chapter 3
67
3.3.7 Morphology of aglycemic injury at 37ûC
MONs showed good preservation upon Þxing as previously described (Allen 
et al., 2006). Figure 3.11.A shows a transverse section of a control MON, which 
was incubated in 10 mM glucose. All axons are myelinated in the adult MON, 
with myelin visible as a dark ring surrounding the axoplasm, in which 
mitochondria are sometimes visible. A frequency histogram of axon surface 
area showed that surface area distribution was skewed towards larger areas 
(Fig. 3.11.B), with a modal surface area of 0.35 - 0.40 !m2. Data from 3 nerves 
with a total of 44 ROIs; total number of axons was 2465 with an average of 
56.0 ± 15.3 axons per ROI. The mean surface area of all the axons was 28.6 ± 7.3 
!m2 per ROI, thus the average surface area of each axon was 0.525 ± 0.131 
!m2. 
In MONs exposed to 1 hour of aglycemia followed by a 1 hour recovery 
period in 10 mM glucose aCSF, axons were visibly different to control axons. 
Axons were more rounded in proÞle, and there appeared to be more axons 
with a large surface area (Fig. 3.11.C). However the frequency histogram 
revealed that the peak frequency moved in the direction of smaller sized 
axons, in contrast to initial impressions based on the obvious presence of more 
large axons. The population of large axons is represented by surface areas of 
2.5 !m2 or larger, of which there are a larger proportion (3.1% vs. 1.1%) than 
the control (Fig. 3.11.D), and modal surface area was 0.25 - 0.30 !m2. Data 
from 4 nerves with a total of 42 ROIs; total number of axons was 1914 with an 
average of 45.6 ± 13.0 axons per Þeld. The mean surface area of all the axons 
was 27.5 ± 6.1 !m2 per ROI, thus each axon had on average a surface area of 
0.643 ± 0.209 !m2. 
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Figure 3.11 Morphological effects of aglycemia on MON axons at 37¡C. A. Control 
nerves incubated in 10 mM glucose showed good preservation with all axons 
myelinated and mitochondria present in the axoplasm. C & E. MONs exposed to 
aglycemia for 1 or 2 hours, respectively, showed large, rounded, swollen axons, but 
also an increase in smaller sized axons. Scale bars 2 μm. B, D & F. Frequency 
histograms showing the size distribution of the axons. G. Longitudinal section of 
MON exposed to aglycemia for 1 hour showing Ôstring of pearlsÕ indicative of 
localised ballooning of axons. Scale bar 2 μm. H. The cumulative probability of axon 
counts shows a sigmoidal relationship for control axons (black line), but aglycemia 
exposure for 1 (grey line) or 2 hours (dotted line) resulted in an increase in smaller 
sized axons (> 0.4 μm2) and an increase in the proportion of larger (> 2.5 μm2) 
axons. 
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This pattern was augmented in the MONs exposed to aglycemia for 2 hours. 
The modal surface area was 0.15 Ð 0.20 !m2 from 31 ROIs from 3 nerves with 
5.2% of axons 2.5 !m2 or greater. Total number of axons was 1566 with an 
average of 50.5 ± 11.5 axons per Þeld. The mean surface area of all the axons 
was 33.1 ± 6.1 !m2 per ROI, thus each axon had on average a surface area of 
0.693 ± 0.215 !m2.
The cumulative probability provides an alternate representation of the data. In 
control conditions the curve is sigmoidal in shape with the 0.5 probability 
occurring at about 0.35 !m2. Exposure to aglycemia shifts the curve to the left 
at surface areas less than 0.4 !m2, indicative of an increase in the number of 
smaller axons. For example 8.4% of axons have a surface area of 0.2 !m2 or 
less in control conditions, but this increased to 28.5% in nerves exposed to 
aglycemia for 1 hour. However, at surface areas greater than 0.4 !m2 the curve 
is ßattened indicative of an increase in the number of larger axons than in 
control conditions (Fig. 3.11.H). 
3.3.8 Morphology of temperature-dependence of 
aglycemic injury 
The effect of temperature on axon morphology in MONs exposed to 1 hour of 
aglycemia was examined at 27℃, 37℃ and 42℃. Experiments at 37¡C are the 
same as those described above (Fig. 3.11.C and D) with an additional 
illustration of an ROI for comparative purposes (Fig. 3.12.A and B) and data 
are as previously described. In MONs exposed to aglycemia at 27¡C the axon 
morphology appeared similar to control tissue with smaller sized axons and 
less ballooning of axons (Fig. 3.12.C). The frequency histogram shows the 
modal surface area at 0.25 Ð 0.30 !m2 from 2 MONs with 32 ROIs and 1098 
axons, thus an average of 34.3 axons per Þeld. The mean surface area of all 
axons was 16.49 !m2 thus each axon had a surface area of 0.480 !m2, with only 
0.75% of axons having a surface area of 2.5 !m2 or greater. In MONs exposed 
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to aglycemia at 42¡C axons appeared grossly swollen. The modal surface area 
was 0.40 Ð 0.45 !m2 from 3 MONs with 1261 axons in 39 ROIs, an average of 
32.3 axons per Þeld. The mean surface area of all axons was 20.47 !m2 thus 
each axon had a surface area of 0.636 !m2, with 2.2% of axons were 2.5 !m2 or 
greater. The cumulative probability showed that temperature had the effect 
expected based on the data in Fig 3.12.H, namely that decreasing temperature 
led to decreased probability of large surface area, whereas the converse 
occurred at higher temperatures. 
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Figure 3.12 Temperature-dependent effects of aglycemia. A. MONs exposed to 1 hr 
aglycemia at 37¡C showed moderate axonal swelling. C. In MONs exposed to 
aglycemia for 1 hour at 27¡C the pathological effects were less evident with MONs 
lacking grossly swollen axons. E. MONs exposed to aglycemia at 42¡C showed grossly 
swollen axons, swollen intra-axonal mitochondria, as well as numerous small axons. 
Scale bars 2 μm. B, D and F. Frequency histograms of axons exposed to aglycemia at 
37¡C, 27¡C or 42¡C, respectively. G. Cumulative probability of axon counts shows 
that MONs exposed to aglycemia at 42¡C (dotted line) display more small axons, as 
well as larger axons compared to MONs exposed to aglycemia at 37¡C (black line). 
Conversely the neuroprotective effects of hypothermia (27¡C) are demonstrated by 
the decreased proportion of larger axons (grey line).
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3.4 Discussion
I set out to test the hypothesis that hypothermia and glycogen content are 
neuroprotective in the isolated mouse optic nerve (MON) during periods of 
aglycemia. The MON contains glycogen, which acts as an endogenous energy 
reserve, thus the aims were several-fold. Firstly, to demonstrate that 
hypothermia and glycogen are neuroprotective, secondly to demonstrate the 
effect of hypothermia on oxygen consumption and glycogen metabolism, and 
Þnally to compare the relative scale of any beneÞcial effects of glycogen 
content or hypothermia 
3.4.1 Prevention of Injury During Aglycemia
During aglycemia or hypoglycemia glucose delivery to tissue is below that 
required for normal tissue function, resulting in tissue glucose levels falling 
below the concentration required to saturate hexokinase, which in turn causes 
the rate of glucose metabolism to fall (Dienel, 2009). This sequence of events 
then leaves a shortfall in the energy supply required for normal tissue 
function. Without a sufÞcient energy supply, function is lost and a series of 
pathological events are set in motion, which cause tissue injury and cell death. 
Neurological deÞcits due to loss of myelin and axonal damage can result from 
this kind of injury to CNS white matter (Mori et al., 2006). There is an effort 
ongoing to understand these injury processes and prevent or minimise any 
impact. 
Aglycemia can be induced experimentally in the MON and its effects are seen 
as a fall in CAP area over time as axonal conduction fails. Axonal conduction 
can be restored by restoring the glucose supply to the nerve but often recovery 
is incomplete, an indication of irreversible axon injury. The degree of the 
recovery is inversely related to the duration of the aglycemic episode. 
Clinically the central symptoms of hypoglycemia, predominantly caused by 
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iatrogenic insulin injection, can progress from confusion and memory 
impairment ultimately to seizure, coma and death in the absence of 
intervention (Frier and Fisher, 2007). There is currently no therapeutic strategy 
to combat systemic hypoglycemia, aside from rapid restoration of euglycemia 
by introduction of exogenous glucose. The MON can be used to evaluate and 
explore possible interventions which may either delay conduction failure, 
prevent permanent injury or both in CNS white matter. 
3.4.2 The Protective Role of Hypothermia 
The results presented in this chapter demonstrate that whereas mild 
hypothermia protects MON axons exposed to aglycemia, hyperthermia 
aggravates aglycemic injury. Mild hypothermia has been reported as 
neuroprotective during such brain trauma as ischemia (Busto et al., 1987) and 
seizures (Liu et al., 1993). Both of these conditions can result in energy 
imbalance where the energetic demands of the tissue are not met by blood 
borne supply of glucose and oxygen. In vitro studies have shown that in both 
grey and white matter mild hypothermia is neuroprotective during ischemia 
(Busto et al., 1987), and anoxia (Stys et al., 1992) or hypoglycemia (Shin et al., 
2010) in isolation. The most obvious reason for this neuroprotection induced 
by hypothermia is by decreasing the metabolic requirement of the tissue. 
In grey matter the mechanism of hypoglycemic injury is excitotoxicity, where 
decreasing ATP levels lead to elevations of extracellular glutamate, which 
activates post-synaptic glutamate receptors. This leads to a multiple step 
process involving Ca2+ inßux, mitochondrial Ca2+ deregulation, reactive 
oxygen species production, DNA damage, polyADP-ribose polymerase-1 
activation, mitochondrial permeability transition and mitochondria-to-nucleus 
translocation of apoptosis-inducing factors (Shin et al., 2010). There is also 
accumulating evidence that inßux of zinc, which can lead to ROS and PARP-1 
production, plays a key role in neuronal death (Suh et al., 2008). In contrast, 
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the mechanism of axon death in white matter appears to be via a non-
excitotoxic mechanisms involving toxic Ca2+ inßux via L-type Ca2+ channels 
that are activated by the membrane depolarization following ATP exhaustion 
(Brown et al., 2001a; Brown et al., 2001b; Fern et al., 1995), and reversal of the 
Na+-Ca2+ exchanger activated by increasing intracellular Na+ levels (Brown et 
al., 2001a; Stys et al., 1992). The sequence of events leading to cell death 
following Ca2+ inßux in white matter is unknown but are likely to resemble 
those of grey matter. 
3.4.3 Morphometric Analysis of Nerve Injury
Morphometric analysis of aglycemic injury consisted of axon counts in 
combination with measures of cross sectional surface area from transverse 
sections of MON. Our goal in these studies was not to investigate the sub-
cellular effects of aglycemia, but rather to correlate aglycemia-induced 
changes in axon morphology with measurements of axon conduction. We 
have chosen to express axon size in terms of surface area rather than diameter 
for the following reasons. Measuring axon diameter at the shortest distance 
bisecting the axon will tend to underestimate the surface area calculated from 
this diameter as not all axons will be cut perpendicular to the axon cylinder, 
and thus not all axons will appear spherical, rather they will appear as 
oblongs, and such diameter measurement would underestimate the surface 
area (James et al., 2010). The distribution of axon size was skewed in the 
direction of larger axons as previously reported in mouse (Allen et al., 2006), 
rat (Garthwaite et al., 1999) and hamster (James et al., 2010). All axons are 
included in counts and those considered pathological were not excluded due 
to the subjective nature of such judgements. Initial impressions of MONs 
exposed to aglycemia at 37℃ were of an overall increase in axon surface area. 
However although some axons did indeed swell there were a large number of 
smaller axons. Indeed our cumulative probability data shows an increase in 
the number of smaller axons in MONs exposed to aglycemia compared to 
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control MONs. This may be explained with reference to the longitudinal 
section of the aglycemic MON, where a Ôstring of pearlsÕ appearance of axons 
is seen. This phenomenon has been previously demonstrated in ischemic 
MON axons, where the swelling of axons was focal with the intervening 
sections of axons appearing shrunken (Garthwaite et al., 1999). This almost 
certainly explains the shift in the frequency distribution of axon sizes towards 
smaller axons rather than towards larger axons. A similar less than expected 
shift in frequency distribution has been reported in ischemic MON axons 
(Garthwaite et al., 1999). This effect was augmented in MONs exposed to 2 
hours of aglycemia. The cumulative probability of MON surface area 
demonstrates a less steep relationship in MONs exposed to aglycemia with a 
crossover at 0.4 !m2 resulting in greater frequency of axons below 0.4 !m2 and 
less above 0.4 !m2 compared to control. However reference to the frequency 
histograms shows more axons > 2.5 !m2 in aglycemia treated axons, 
indicating the development of larger swollen oedematous axons. Similarly the 
effects of temperature reveal morphological differences. In MONs exposed to 
1 hour of aglycemia at 37¡C there is the appearance of large swollen axons, 
whose numbers decrease if the temperature was decreased to 27℃ during the 
aglycemic episode. Conversely increasing the temperature to 42℃ during the 
aglycemic insult resulted in an increase in the number of axon > 2.5 !m2. 
Reference to the cumulative probability highlighted this trend, namely that 
decreased temperature led to smaller number of swollen axons, but that 
hyperthermia led to an increased number of swollen axons. Calculations of 
axons size showed that the average axon surface area increased upon 
exposure to aglycemia, and that the duration of aglycemia led to greater 
surface area. Similarly hypothermia led to decreased surface area of MONs 
exposed to aglycemia, whereas hyperthermia had the opposite effect. These 
results complement the electrophysiology results indicating the 
neuroprotective effects of hypothermia. 
A possible limitation of this study was that the effect of temperature alone on 
axon morphology was not examined. This decision was made due to the fact 
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that changes in temperature which lasted for the length of time used within 
these experiments had no irreversible effect on CAP area. The assumption was 
made that if axons were undergoing morphological changes as an effect of the 
change in temperature, these would be represented by a change in the proÞle 
of the CAP.  
3.4.4 The Role of Brain Glycogen
MONs contain endogenous glycogen, located in astrocytes (Cataldo and 
Broadwell, 1986), which acts as an energy buffer to provide the tissue with 
energy substrate in the face of aglycemia (Brown et al., 2003). However, 
glycogen content is limited and once reserves are exhausted axon conduction 
fails (Wender et al., 2000; Brown et al., 2003). Toxic Ca2+ inßux is subsequently 
triggered, followed by irreversible injury, the extent of injury related to the 
duration of glucose withdrawal (Fig. 3.3 and Brown et al., 2001). Here it has 
been shown that the protective effects of hypothermia are in part mediated by 
a decreased rate of glycogen metabolism. Glycogen content of the MON 
remained elevated after 20 mins of aglycemia at 27 ℃, revealing a slower 
mobilisation of this energy store than at 37℃. This observation is no doubt 
due to the reduced demand for glycosyl units by tissue at lower temperatures. 
Oxygen consumption also reßected this as it was decreased at 27℃ compared 
to 37℃. It is interesting to note that the oxygen consumption was the same for 
nerves in the presence and absence of glucose over a 30 minute period, 
indicating that glycogen can supply glycosyl units at an equivalent rate to that 
of normal glucose consumption. 
Glycogen was neuroprotective at all temperatures tested with regards to 
delaying CAP failure, with depletion of glycogen prior to aglycemia 
accelerating loss of axonal conductivity. This is an important observation with 
clinical relevance as disruption in action potential conduction is likely to lead 
to some of the symptoms of hypo/aglycemia discribed above. The ability of 
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glycogen to delay CAP failure was greater at 42℃ than even a reduction in 
temperature to 27℃ in glycogen-depleted nerves. The results of this study 
suggest that the possibility that brain glycogen content may help protect 
against symptoms of hypoglycemia should be further explored. 
Post-injury recovery was also inßuenced by the availability of glycogen, but 
this was only signiÞcant at 37℃ and 42℃. The extent of the neuroprotection 
offered by glycogen stores can be seen by comparing CAP recovery between 
different conditions. MONs which were glycogen-depleted prior to aglycemia 
showed less recovery at 37℃ than those with glycogen present which were 
exposed to aglycemia at 42℃. The harmful effects of hyperthermia are well 
documented but this result shows that the presence of glycogen is equally 
important for post-aglycemia recovery of axonal function in white matter. 
This raises clinical considerations for patients prone to insulin-induced 
hypoglycaemia. If brain glycogen in these patients is below normal then they 
may be more vulnerable to the CNS effects of hypoglycemia. It is a well 
known aspect of hypoglycemia that because of hypoglycemia unawareness, 
one episode of hypoglycemia increases the probability of other subsequent 
hypoglycemic events (Frier and Fisher, 2007). The signiÞcance of this clinical 
observation in relation to these results is that the glycogen depletion that 
occurs during hypoglycemia may not be replenished to baseline levels before 
the next hypoglycemic episode. It may be possible to develop methods to 
restore or up-regulate brain glycogen to protect against hypoglycemic 
symptoms. Controlling glycogen content of the brain is a much more realistic 
and practical method of reducing the likelihood and severity of aglycemic 
injury since dietary or pharmacological methods affecting glycogen content 
would be easier to implement than therapeutic cooling. 
Chapter 3
78
3.4.5 Summary
In conclusion these results demonstrate that ambient temperature inßuences 
the degree of injury incurred by adult MON during aglycemia, with 
hyperthermia aggravating axonal injury, whereas, hypothermia reduces 
injury. A major contributory factor in the neuroprotection afforded by 
hypothermia is the presence of glycogen, which provides energy substrate to 
axons during periods of aglycemia, and whose decreased utilisation due to 
decreased tissue energy demand during hypothermia prolongs the 
neuroprotective effect. The importance of glycogen in protecting white matter 
from aglycemic injury is clear as glycogen-depletion is as harmful to tissue 
recovery as hyperthermia. This study suggests that there is good reason to 
focus more attention on the role of brain glycogen as an energy substrate and 
neuroprotective agent. 
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Chapter Four
Real-time measurement of 
lactate using biosensors reveals 
that glycogenolysis contributes 
to extracellular lactate in the 
mouse optic nerve. 
Chapter 4
80
4.1 Introduction
4.1.1 Lactate in the CNS
The role of lactate in the CNS is an intensely debated topic that polarises 
researchers. Some see lactate as a minor contributor to brain energy 
metabolism, whereas others support the view that it is an important oxidative 
fuel for neurons. The dogmatic view of glucose metabolism was established 
when the biochemical pathways of energy metabolism were being 
characterised (Pellerin and Magistretti, 2003). Tradition states that the brain 
requires a constant supply of glucose, and that other metabolic substrates for 
energy metabolism play an insigniÞcant role in brain energetics (Greutter et 
al., 1992). SpeciÞcally lactate was regarded as a waste product of anaerobic 
metabolism that served no further useful function (Huckabee, 1958). This view 
was challenged by Pellerin and Magistretti (1994) who claimed that lactate 
was a major energy substrate in the brain, when they put forward their 
astrocyte-neuron lactate shuttle hypothesis (ANLSH). This model introduced 
lactate as an important metabolic substrate and reignited interest in some 
older studies which showed that lactate could support brain function (See 
Chapter 1). The newfound interest in lactate even led to the proposition that 
lactate is always the end product of glycolysis and therefore the substrate for 
mitochondria (Schurr, 2006). This hypothesis is considered a more extreme 
stance but strong arguments dictate that lactate cannot simply be dismissed as 
a metabolic dead-end. 
Lactate is present in the brain at appreciable concentrations, typically around 
0.5 - 1 mM under resting conditions, with some studies reporting up to 3 mM 
(Erlichman and Leiter, 2010). The concentration of lactate rises as a result of 
increased neural activity (Kuhr et al., 1988; During et al., 1994). The relative 
contributions of oxidative and anaerobic metabolism may play a pivotal role 
in lactate dynamics. Increased metabolic demand can occur very rapidly in 
nervous tissue during high frequency action potential Þring. Studies have 
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shown that during neuronal activation an increase in the rate of glycolysis is 
triggered which is greater than the concurrent increase in oxidative 
metabolism (Fox et al., 1988). The up-regulation of glycolysis causes an 
increase in lactate production although oxygen is present in adequate 
quantities. The energy yield from glycolysis is much smaller than that from 
full oxidative metabolism of glucose,. This energy, however, is available 
rapidly. In sub-cellular locations such as astrocyte processes that are too small 
to contain mitochondria, glycolysis may represent the more suitable method 
to generate the energy needed for homeostatic processes such as K+ clearance 
from the extracellular space. In this case lactate may be released from the cell. 
Since, if allowed to accumulate intracellularly the lactate would inhibit key 
metabolic reactions and reduce the rate of glycolysis (Dietl et al., 2010). 
Convention would suggest that lactate produced in this manner is removed 
from the local area or removed from the brain entirely via venous drainage 
(Zimmer and Lang, 1975; Leegsma-Vogt et al., 2003). There are other 
possibilities as to the fate of this lactate, which include oxidation of lactate 
(Madsen et al., 1999), possibly within neurons (Pellerin, 2004). The precise 
contributions of oxidative and non-oxidative metabolism during neuronal 
activation are still under question, a key variable being the nature of the 
stimulus. In white matter it has been reported that some axons can survive 
without oxidative metabolism. In both the mouse and rat optic nerve some 
axonal activity is maintained under anoxic conditions (Tekkok et al., 2003). 
The magnitude of anoxic resistance in the optic nerve declines with age 
(Hamner et al., 2011). Anoxic resistance may be a property of CNS white 
matter as the corpus callosum shows similar anoxic resistance to that observed 
in the optic nerve, whereas, hippocampal grey matter does not (Tekkok and 
Ransom, 2004). The mechanism that underlies white matter resistance to 
anoxia is not fully understood (Hamner et al., 2011). It is also not clear as to 
whether some axons remain able to function normally whilst some lose the 
ability to conduct, or whether all axons have a partial sensitivity to anoxia and 
generate action potentials of reduced amplitude under anoxic conditions 
(Tekkok and Ransom, 2004)..
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4.1.2 Lactate in White Matter
In common with a/hypoglycemic injury (Chapter 3) much of the focus on 
lactate metabolism in the brain has been centred around grey matter. 
However, lactate may be as equally important in white matter. In white matter 
lactate is released from astrocytes and is able to support axonal conduction 
(Tekkok et al., 2005). This raises the consideration that a model similar to the 
ANLSH may apply to white matter. The ANLSHÕs focus on glutamatergic 
synapses may, on initial inspection, appear to rule out any relevance to white 
matter. However, glutamate release and re-uptake, as well as the presence of 
glutamate receptors, have been shown in the optic nerve (a white matter tract) 
(Tekkok et al., 2007). There also exists the possibility that lactate shuttling 
within white matter may exist, but be dependent on a process such as K+ 
clearance rather than glutamate recycling. 
4.1.3 Glycogen is a Source of Lactate
A source of lactate in the CNS is glycogen metabolism. It has been shown that 
during energy deprivation in white matter glycogen stores in astrocytes can be 
mobilised and released as lactate to be taken up by axons to sustain their 
energy demands (Brown et al., 2005; 2007). The same mechanism can provide 
energy for axonal activity during high frequency stimulation (Brown et al., 
2005). A dynamic role for glycogen in brain energetics has also been proposed. 
The glycogen shunt model argues that glycogen is more than a quiescent 
energy store and that prior to entering the glycolytic pathway a signiÞcant 
fraction of glucose passes through glycogen molecules (Walls et al., 2009). 
Recently, glycogenolysis and the associated lactate shuttling have been shown 
to be necessary for memory formation in the rat hippocampus (Suzuki et al., 
2011). The accumulating evidence gives a strong indication that glycogen and 
lactate metabolism in the CNS are important pathways in normal brain 
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functioning, but the precise role and contribution of glycogen has yet to be 
determined.   
4.1.4 Biosensors 
It has proven difÞcult to experimentally conÞrm many of the theories and 
models of brain energy metabolism, with much of the evidence being 
circumstantial or based on modelling studies. This has been in the most part 
due to the complexity of the tissue and the inter-dependence of different cell 
types. Many of the experiments used to investigate the assorted hypotheses 
have involved measurement of lactate in nervous tissue. A range of 
methodologies, including magnetic resonance (Mangia et al., 2003), 
autoradiography (Lear and Kasliwal, 1991), microdialysis (Fray et al., 1996) 
and biosensors (Hu and Wilson, 1997) have been employed to track changes in 
brain lactate under various conditions with each of these having their own 
particular advantages and disadvantages.  
Enzyme-based biosensors have a number of advantages when compared to 
other methods used to measure lactate; they are relatively simple and low cost 
to use, they are small and minimally disrupt tissue, can be applied both in vivo 
and in vitro and have a excellent temporal resolution enabling real-time 
measurement of a speciÞc metabolite. The use of biosensors to determine real-
time concentrations and ßuxes of metabolites and signalling molecules in 
brain tissue has provided important insights in a number of areas (Hu and 
Wilson, 1997; Dale et al., 2005). Biosensors have not yet been used to 
investigate lactate in white matter, and the putative contribution of glycogen 
metabolism, which, as discussed above, is a topic with important unresolved 
questions. 
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4.1.5 Aims
The aim of the experiments in this chapter was to study lactate dynamics in 
white matter by establishing the use of an enzyme-based lactate biosensor to 
monitor lactate release from the mouse optic nerve (MON). The isolated MON 
preparation is a widely used model for white matter, which has been used to 
study both normal physiological and pathological processes (Bolton and Butt, 
2005). The Þrst objective was to evaluate the biosensors, and then to determine 
whether lactate is produced by the MON. Secondly, the relationship between 
glucose availability and lactate production was sought. As lactate is 
implicated in glycogen metabolism, the relationship between glycogen and 
lactate in the MON was also examined. 
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4.2 Methods 
All methods are described in detail in Chapter 2. Brießy; axon conduction in 
the isolated mouse optic nerve was monitored by recording the stimulus-
evoked CAP and expressed as the normalised area under the CAP. 
Simultaneous recording of the extracellular lactate signal was achieved by use 
of an enzyme-based lactate biosensor (see Fig. 2.4). Latency to CAP failure, 
and time to fall of the lactate signal during aglycemia, were measured as the 
time to 50 % normalised CAP area and lactate signal, respectively. 
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4.3 Results 
4.3.1 Biosensor Calibration and SpeciÞcity
The enzyme-based biosensor for lactate used in these experiments is designed 
with a selectivity layer to ensure that the signal is speciÞc for lactate, in 
common with other sensors that share this construction (Dale et al., 2005). 
Before using these sensors to record lactate in the optic nerve they were 
calibrated in the experimental chamber used to record optic nerve CAPs. 
Firstly, the speciÞcity of the signal for lactate was compared against a number 
of compounds which would be used in later experiments. The sensor was 
positioned in the tissue bath constantly perfused with aCSF in the absence of 
any tissue. The compounds tested were: zero glucose aCSF, 10 mM glucose, 10 
mM fructose, 20 mM pyruvate, 5 mM L-lactate and 5 mM D-lactate. D-lactate 
is an optical isomer of L-lactate that is metabolically inert but that will 
compete with L-lactate on binding sites (Tekkok et al., 2005). Fig. 4.1.A shows 
that pipetting compounds onto the sensor caused a small negative deßection 
as an addition artefact and only L-lactate gave a strong signal, with D-lactate 
evoking a small signal. Fig. 4.1.B shows the sensor response when aCSF 
containing 1 mM lactate was perfused into the chamber. A smooth increase in 
lactate signal was observed which then plateaued. Returning to a lactate-free 
aCSF solution caused the lactate signal to return to zero within 3 minutes. 
Performing this experiment provided an indication of the time required for a 
solution to fully perfuse the tissue chamber and therefore the dead space of 
the perfusion system. 
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Figure 4.1 Response of lactate biosensor in the laminar ßow perfusion chamber. A) 
SpeciÞcity of signal; aCSF containing the following compounds were pipetted into the 
chamber (arrow heads) to determine any potential interference. i) zero glucose aCSF 
ii) 10 mM glucose iii) 10 mM fructose iv) 20 mM pyruvate v) 5 mM L-lactate vi) 5 mM 
D-lactate. B) Wash in and wash out times of the perfusion system. 
Secondly, the standard curve for the sensorÕs response to known lactate 
concentrations was determined (Fig. 4.2). The sensor showed a linear current 
response to lactate concentrations in the range of 10 - 800 !M, which was in 
agreement with their advertised sensitivity (http://www.sarissa-
biomedical.com) Above this concentration range the sensorÕs response was 
not linear but did not plateau at concentrations tested (up to 10 mM). The 
sensorÕs response was found to be linear across the entire concentration range 
when plotted on a logarithmic scale, verifying its exponential nature (Fig. 
4.2.C).
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Figure 4.2 Calibration curve for lactate biosensor. Pipetting lactate onto the 
biosensor in the perfusion chamber gave a does-dependent increase in lactate signal 
from the sensor.  A) Raw trace from calibration experiment; additions are indicated 
by arrows under trace and the lactate concentration (mM) is given by the number 
above the trace. B) Lactate concentration plotted against peak lactate signal from the 
biosensor. C) Data from B plotted on a logarithmic scale for lactate concentration. 
For B and C, data are mean values (n = 3) from one sensor. SDs are too small to be 
visualised on the Þgure (maximum = 4.46 nA).  
4.3.2 Lactate is Produced by the Mouse Optic Nerve
The mouse optic nerve (MON) produces lactate when minimally stimulated 
and supplied with glucose as an external energy substrate. Positioning an 
enzyme-based lactate biosensor in close proximity to the MON revealed that 
lactate was released from the nerve at a stable rate. The lactate sensor reading 
was interpreted as a proxy for extracellular lactate in the nerve (see 
Discussion). The extracellular lactate concentration in the optic nerve was 440 
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± 86.0 !M (n=3) in aCSF containing 10 mM glucose when the supra-maximal 
CAP was evoked every 30 seconds. This value was obtained by calibrating the 
biosensor against a known range of lactate concentrations in the bath at the 
end of the experiment. It was found that the position of the sensor relative to 
the nerve, i.e. how much of the sensor was in contact with the nerve, could 
alter the strength of the signal observed. For this reason the lactate signal in 
further experiments was expressed as a normalised value. This was calculated 
by dividing by the stabilised lactate signal for each nerve in 10 mM glucose. A 
null electrode was not used after it was determined that the background noise 
measured by the null was not great enough to warrant subtraction from the 
signal of the lactate sensor. 
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4.3.3 The Relationship Between Glucose Supply and 
Extracellular Lactate
The effect of ambient glucose upon the lactate concentration was investigated 
by altering the concentration of glucose supplied to the nerve between 0.5 - 30 
mM (Fig 4.3). Fig. 4.3.A shows that the concentration of lactate measured was 
unaffected by glucose concentrations between 5 and 30 mM. The lactate signal 
was not signiÞcantly different to that at 10 mM glucose for 5 and 30 mM (p > 
0.05). At a glucose concentration of 2 mM and below the concentration of 
lactate fell, which prompted measurement of the lactate signal at lower 
glucose concentrations. The lactate signal for nerves incubated in 2 mM 
glucose was 82.6 ± 6.2% of that for 10 mM glucose, this dropped to 63.4 ± 5.6% 
and 32.6 ± 4.2% for 1 and 0.5 mM glucose, respectively (n = 3 for each glucose 
concentration). Each of these readings were signiÞcantly different from control 
conditions at 10 mM glucose (p < 0.05). Nerve activity, as indicated by CAP 
area, was maintained despite falling lactate levels at glucose concentrations of 
1 and 2 mM, but partially fell when the MON was bathed in aCSF containing 
0.5 mM glucose (Fig 4.3.B). The concentration-response of lactate release from 
the MON in different external glucose concentrations is summarised in Fig. 
4.3.C. 
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Figure 4.3 The relationship between external glucose concentration and lactate 
production in the MON. Extracellular lactate was recorded with a biosensor 
positioned against the MON whilst the glucose concentration in the bathing aCSF 
was altered. The lactate signal increased with higher glucose concentrations but 
plateaued at 5 mM glucose. The lactate signal is shown as normalised against the 
stable signal seen with a bathing glucose concentration of 10 mM. A. Lactate signal 
(solid line) and CAP area (open squares) for glucose concentrations between 5 and 
30 mM. Lactate remained stable at all glucose concentrations above 2 mM. B. Lactate 
signal and CAP area for glucose concentrations of 5 mM and below. The lactate signal 
fell in a manner that was glucose-dependent. CAP area was maintained until a glucose 
concentration of 0.5 mM upon which it partially fell.Figure continues on the next 
page. 
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Fig 4.3 (cont.) C. Plot of glucose concentration versus normalised lactate signal (n 
= 3, error bars show S.D.).
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4.3.4 Extracellular Lactate with Fructose as the Sole Energy 
Substrate  
MON function has previously been shown to be partially supported by 
fructose (Allen et al., 2006; Meakin et al., 2007), therefore, the effect of 
substituting glucose with fructose upon the lactate signal was tested. 
Supplying the MON with 10 mM fructose caused a drop in the normalised 
lactate signal to 0.18 ± 0.01. Increasing the fructose concentration to 25 mM led 
to an increase in normalised lactate signal to 0.62 ± 0.02, this still being less 
than the lactate signal in the presence of 10 mM glucose. 
Figure 4.4 The effect of fructose on the lactate signal and CAP area of the MON. 
The experiment commenced in control aCSF (10 mM glucose) which was switched 
to 10 mM, 25 mM or 0 mM fructose (indicated by black bars) in the absence of 
glucose. The lactate signal (solid line, left axis) fell in 10 mM fructose, partially 
recovered in 25 mM fructose and was lost in 0 mM. CAP area (open squares, right 
axis) was maintained in 10 mM and 25 mM fructose but began to fall in 0 mM 
(aglycemia). 
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4.3.5 Lactate Production Requires Glycolytic Metabolism of 
Glucose
Figure 4.5.A shows the effect of a period of aglycemia upon CAP area and 
lactate signal in the MON. Aglycemia was induced by replacing the standard 
aCSF bathing the nerve with an aCSF solution made up lacking glucose.  The 
extracellular lactate concentration fell to zero in a sigmoidal manner reaching 
50% after 10.2 ± 0.2 mins with a latency to CAP failure of 28.4 ± 0.8 mins (n = 
4).
The effect of inhibiting glycolysis upon lactate production and nerve activity 
was investigated by the addition of 1 mM iodoacetate (IA), an irreversible 
inhibitor of the glycolytic enzyme glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (see Chapter 1, Fig. 1.2). Figure 4.5.C shows that 
addition of IA to the aCSF resulted in a rapid decrease of lactate concentration 
in the nerve reaching 50% after 5.5 ± 0.2 mins. This was followed by a 
complete failure of the CAP with a latency to failure of 16.7 ± 1.1 mins (n = 4). 
Both of these falls were signiÞcantly accelerated in comparison to those seen 
after induction of aglycemia by removal of glucose from the aCSF (p < 0.05) 
(see also Fig. 4.8.C-D).
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Figure 4.5 The effect of aglycemia and glycolytic inhibition on the MON CAP and 
lactate release. A. Induction of aglycemia caused a fall in extracellular lactate as 
monitored by a lactate-sensitive biosensor (solid line), which was followed by a 
delayed fall in CAP area (open squares) (n = 4). B. CAP traces during aglycemia, 
rearmost traces are Þrst chronologically with traces commencing at t = -10  min 
from A. The fall in CAP area over time is clearly seen. C. Inhibiting glycolysis using 1 
mM sodium iodoacetate (IA) caused a qualitatively similar effect, but this was 
accelerated for both lactate and CAP area in comparison to aglycemia (n = 4). D. 
CAP traces during exposure to IA. Scale bars for B and D are 1 ms (x-axis) and 1 mV 
(y-axis).
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4.3.6 Inhibition of Oxidative Metabolism in the MON
Oxidative energy metabolism was blocked by using 1 mM NaCN to inhibit the 
electron transport chain (See Chapter 1 Fig. 1.3). The blockade of the electron 
transport chain causes a rapid energy deÞcit and depolarisation of axons in 
rodent optic nerve (Leppanen and Stys, 1997). The disruption of axonal 
function in this manner is seen as a fall in CAP area to 0 after less than 10 
mins. Lactate concentration in the MON initially increased after cyanide 
administration, but gradually fell to below the control concentration. 
Figure 4.6 Inhibiting oxidative metabolism in the MON affects lactate production. 
A. Non-speciÞc inhibition of the electron transport chain by 1 mM NaCN. Cyanide 
caused a very rapid fall in CAP area (open squares, right axis) and an initial rise in 
lactate followed by a slow but incomplete fall (solid line, left axis) (n = 3). B. CAP 
traces during cyanide exposure, rearmost traces are Þrst chronologically with traces 
commencing at time = -10 min from A. C. Disruption of TCA cycle ßux in astrocytes 
by 10 mM sodium ßuoroacetate (FA). Normalised CAP signal is shown on the right y-
axis for clarity (n = 3). D. CAP traces during exposure to FA. Scale bars for B and D 
are 1 ms (x-axis) and 1 mV (y-axis). 
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Selective disruption of astrocyte energy metabolism was investigated by 
applying 10 mM sodium ßuoroacetate (FA) to the nerve. FA is rapidly taken 
up by astrocytes where it exerts toxic effects by inhibiting the TCA cycle 
(Fonnum et al., 1997). FA is Þrst converted to ßuorocitrate which then acts as a 
suicide inhibitor of the enzyme aconitase (Swanson and Graham, 1994). Fig. 
4.6 shows that 10 mM FA had no effect on CAP area but affected the lactate 
concentration. Lactate initially decreased before increasing to a concentration 
above the control value prior to FA exposure, 20 mins after FA exposure the 
normalised lactate signal was 1.23 ± 0.01 relative to baseline.  
4.3.7 Glycogen Metabolism Contributes to Extracellular 
Lactate
The observation that inhibition of glycolysis caused a more rapid loss of 
lactate and CAP area than bathing the nerve in glucose-free aCSF raised the 
possibility that glycogen metabolism may be contributing to the lactate signal. 
Astrocytic glycogen is used to form lactate which fuels axons during 
aglycemia in the mouse optic nerve (Brown et al., 2003; 2005). The glycogen 
phosphorylase inhibitor 1,4-dideoxy-1,4-imino-D-arabinitol (DAB) has been 
successfully used to prevent glycogen metabolism in the optic nerve (Walls et 
al., 2008). DAB was used at a concentration of 1 mM as would achieve the 
greatest inhibition of GP within the concentration range of DAB that Walls et 
al. recommended for experimental use. The effect of DAB on MON lactate 
release was examined and it was found that incubating MONs in aCSF 
containing 1 mM DAB and 10 mM glucose caused the lactate release to fall 
upon addition of DAB. Twenty minutes after introduction of aCSF containing 
DAB the normalised lactate signal was 0.78 ± 0.02, there was, however, no 
effect on CAP area (Fig. 4.7.A). Under control conditions in the MON 
preparation this result shows that 22 ± 2.4 % (n = 3) of extracellular lactate is 
the result of glycogenolysis. 
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The glycogen shunt model of brain energy metabolism (Shulman et al., 2001) 
predicts that under increased energy demands, the contribution of glycogen to 
ATP generation will increase. This theory was examined by stimulating MONs 
at a higher frequency than the control frequency of one CAP every 30 seconds. 
A stimulus frequency of 10 Hz increased the lactate signal by 50 % and led to a 
small increase in CAP area, due to broadening of the CAP area. Applying DAB 
to MONs stimulated at 10 Hz resulted in a decrease in the lactate signal (Fig. 
4.7.B). The relative decline in lactate in the combined presence of DAB and 10 
Hz stimulation was greater than that observed with DAB under control 
conditions. The proportion of lactate derived from glycogen metabolism was 
taken as the relative fall in lactate signal between pre-incubation and 20 mins 
after incubation with 1 mM DAB, which at 10 Hz  was 33.9 ± 2.0 %, whereas at 
0.03 Hz glycogen accounted for 22.2 ± 2.4 %, a signiÞcantly lower contribution 
(p < 0.001) (Fig. 4.7.C).  
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Figure 4.7 The contribution of glycogen metabolism to lactate production and 
release. A. 1 mM DAB caused a decrease in lactate signal in the MON (solid line, left 
axis) without affecting CAP area (open squares, right axis). B. Stimulating the nerve at 
a higher frequency (10 Hz) increased lactate production in the MON, and addition of 
1 mM DAB during the 10 Hz stimulation resulted in a decrease in lactate signal. C. 
The ratio of lactate signal prior to, and after application of 1 mM DAB was calculated 
from A and B.  A greater proportion of lactate was derived from glycogen when the 
nerve was under increased metabolic demand during the high frequency stimulus (n = 
3). 
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The effect of both increasing or decreasing glycogen availability on lactate 
release and CAP area during aglycemia was determined. Glycogen availability 
was increased by pre-incubating nerves for 2 hours in 30 mM glucose (Brown 
et al., 2003), to negate any effects of increased glucose in the extracellular 
space prior to aglycemia the nerve was exposed to 10 mM glucose for 10 
minutes before glucose withdrawal. Based on Fig. 4.1.B, this should be 
sufÞcient time for the complete exchange of solutions. Using pre-incubation in 
30 mM glucose to increase glycogen content resulted in an increase in the 
latency to both the fall of lactate released by the nerve and CAP failure. 
Lactate concentration reached 50 % after 12.2 ± 1.7 mins and the latency to 
CAP failure was 33.2 ± 1.1 mins (Fig 4.8.A). To achieve the opposite effect of 
limiting glycogen availability during aglycemia nerves were exposed to 1 mM 
DAB (a glycogen phosphorylase inhibitor) throughout the experiment. 
Although DAB causes an increase in the glycogen content it is rendered 
inaccessible by the inhibitory effect of DAB on glycogen phosphorylase (Walls 
et al., 2008). DAB caused the lactate concentration to reach 50 % after 7.8 ± 1.0 
mins and CAP failure to occur after 23.3 ± 1.5 mins (Fig 4.8.B). 
Figure 4.9 shows the effect on CAP area and lactate release in the MON of: 
aglycemia, aglycemia with up-regulated glycogen, aglycemia in the presence 
of DAB, and for comparison the effect of inhibition of glycolysis by IA. All 
conditions led to loss of the lactate signal prior to CAP failure which was 
complete in all cases. For comparison the data are presented in Þgure 4.9.C-D, 
and all data points for CAP failure and loss of lactate signal were statistically 
signiÞcant from the control condition, which was aglycemia after 2 hours pre-
incubation in 10 mM glucose (p < 0.05).
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Figure 4.8 Increasing glycogen content and decreasing glycogen availability in the 
MON affects the latency to failure of the CAP and the fall in lactate signal during 
aglycemia. A. Glycogen stores were up-regulated by a pre-incubation of MONs in 30 
mM glucose aCSF for 2 hours prior to aglycemia. In the 10 mins before aglycemia 10 
mM glucose aCSF was introduced to allow glucose concentration in the nerve to 
equilibrate to control levels. Increasing glycogen availability delayed CAP failure (open 
circles) and loss of lactate signal (solid line). B. Glycogenolysis was inhibited by 1 mM 
DAB throughout the experiment which had no effect on the CAP when glucose was 
available but accelerated the decline in CAP area (open triangles and loss of lactate 
signal (solid line) during aglycemia (n = 4). See Þgure 4.9 for comparison. 
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Figure 4.9 (following page) Comparison of the effects of aglycemia on CAP 
area under a range of metabolic conditions. A. Normalised CAP area in the presence 
of glycolytic inhibition with 1 mM IA (◇), 1 mM DAB (֖), aglycemia after pre-
incubation in 10 mM glucose (), and aglycemia after pre-incubation in 30 mM 
glucose (). B. Normalised lactate signal with glycolytic inhibition with 1 mM IA 
(red), aglycemia in the presence of 1 mM DAB (blue), aglycemia after pre-incubation 
in 10 mM glucose (black) and aglycemia after pre-incubation in 30 mM glucose 
(green).  C. Comparison of delay to CAP failure. D. Comparison of lactate falls; n = 4 
for all, * denotes p < 0.05, n.s.: not signiÞcant. 
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4.4 Discussion
There is an ongoing controversy regarding lactate and the role that it plays in 
CNS energy metabolism. One body of evidence that challenges the primacy of 
glucose as the main energy substrate used by neurons and instead suggests 
that lactate is a key source of energy (Pellerin and Magistretti, 1994; Mangia et 
al., 2003; Pellerin, 2004). A counter argument maintains the traditional and 
dogmatic view that the major source of energy for axons is glucose and that 
lactate is not a signiÞcant energy substrate for neurons (Chih and Roberts, 
2003; Leegsma-Vogt et al., 2003). Either way, the Þndings in this Þeld have 
important implications for normal brain physiology, clinical conditions, and 
the principles underlying brain imaging (Bonvento et al., 2005). Research into 
CNS energy metabolism has often focused on grey matter as it has a higher 
metabolic rate than white matter (Dienel, 2009), and is widely accepted as the 
tissue responsible for cognition. However, white matter (which comprises 50 
% of brain volume (Zhang and Sejnowski, 2000) should not be ignored, since it 
connects brain areas, is vulnerable to pathology and associated deÞcits in 
function (Goldberg and Ransom, 2002). Injury to white matter is a major 
source of disability following stroke and it is vulnerable to even short periods 
of ischemia (Pantoni et al., 1996). The experiments described in this chapter 
were carried out to determine whether lactate plays a role in white matter 
energy metabolism, and to shed further light on what is perhaps one of the 
more lively debates in neuroscience. 
4.4.1 Biosensors for Real-Time Measurement of Lactate
The Þrst objective of the experiments described in this chapter was to evaluate 
the use of a commercially-available enzyme-based lactate biosensor in order to 
measure lactate release from the optic nerve in real time. Prior to experimental 
use with tissue the sensor was checked for its speciÞcity and calibrated in the 
perfusion chamber which was used to record electrical activity in the MON. 
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The speciÞcity of the sensorÕs response to lactate was good, and the current 
response of the sensor was linear in a physiological range of lactate 
concentrations. A wide signal to noise ratio allowed for clear recordings to be 
made of changes in extracellular lactate even in the absence of a null sensor, 
which is not the case for many biosensor applications (Dale et al., 2005). 
When biosensors are used to measure the concentrations of substances in the 
extracellular space (ECS) it is important to be aware of what constitutes the 
signal. A stable concentration of lactate in the ECS as measured by the sensor 
is achieved by a balance between cellular lactate release, cellular lactate 
uptake and lactate wash out into the tissue bath. This is shown schematically 
in Figure 4.10. Changes in the lactate concentration or lactate signal in these 
experiments are a summation of the relative contribution of these lactate 
ßuxes. 
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Figure 4.10 Schematic of the factors affecting extracellular lactate in the isolated 
mouse optic nerve preparation. A proxy for extracellular lactate [Lac], the signal 
recorded amperometrically by the biosensor, is a combination of lactate release by 
glia (GR), release from axons (AR), uptake by glia (GU), uptake by axons (AU), and (W) 
the washout from the ECS into the tissue bath across the porous membranes of the 
pia mater and arachnoid (broken line). The exact rates of these lactate ßuxes, with the 
exception of W, cannot be directly determined by biosensors alone. 
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4.4.2 Extracellular Lactate in White Matter
Lactate is present in the extracellular space of the brain. In humans and rats 
the concentration of lactate in the brain ECS is greater than in plasma, 
suggesting signiÞcant lactate production within the limits of the blood brain 
barrier (BBB) (Abi-Saab et al., 2002). Blood lactate concentration is 
independent of lactate levels in the brain (Kuhr et al., 1988) meaning that 
lactate in the brain is produced locally i.e. within the BBB. The results 
presented in this chapter indicate that lactate is produced and released into the 
ECS of the mouse optic nerve (MON). The MON provides a useful model 
system for studying the role of lactate in white matter as it is devoid of 
synapses and neuronal cell bodies and thus is a simple model comprising of 
two cellular compartments (Butt et al., 2004). The MON can also be 
maintained in vitro for many hours while the ability of axons to conduct is 
monitored by recording the stimulus-evoked compound action potential 
(CAP). Using a lactate oxidase-based biosensor it has been shown here that the 
in vitro MON preparation has an extracellular lactate concentration of 0.44 mM 
under resting conditions. This lactate signal and the CAP are stable over a 
period of many hours indicating that lactate production is not associated with 
injured or otherwise compromised tissue. 
The concentration of lactate in the brain ECS has been previously documented 
in a number of experimental systems. Typically under resting conditions a 
lactate concentration between 0.5 - 2 mM has been reported (Kogure et al., 
1974; Medina et al., 1975. QuantiÞcation of lactate in the rat striatum using 
microdialysis revealed a baseline concentration of 0.56 mM (Taylor et al., 
1994). The value obtained here in the optic nerve (0.44 mM) is possibly an 
underestimation due to low metabolic demand of the tissue at rest and the 
positioning of the lactate biosensor. Biosensors were positioned on the surface 
of the optic nerve in order to avoid the traumatic injury to the tissue that 
would occur with insertion of sensor into the nerve. The location of the 
sensing tip in contact with the nerve rather than inside it means that the 
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sensor is reading lactate release, which is a proxy of extracellular lactate (see 
Fig. 4.10). The signal from the sensor is proportional to the surface area that is 
in contact with the lactate containing solution. In comparison to the calibration 
readings there is a concentration gradient that will exist across the sensor 
leading to an under-estimation of lactate within the nerve ECS. It should also 
be noted that in the perfusion chamber system fresh aCSF is constantly 
ßowing across the tissue (2 ml / min) which may enhance lactate clearance 
from the tissue (Fig. 4.10). These factors mean that the values obtained in vitro 
and the precise kinetics of the lactate response may vary considerably.
4.4.3 Glucose Availability and Extracellular Lactate
Blood glucose (unlike lactate) correlates with the concentration of lactate in the 
brain extracellular space: higher blood glucose levels result in increased 
glucose and lactate concentrations in the brain (Harada et al., 1993). The 
concentration of lactate in the MON is also related to the externally supplied 
glucose concentration, below about 5 mM. The value of 0.44 mM lactate was 
obtained at the control glucose concentration of 10 mM. Increasing the glucose 
concentration to 30 mM did not have a signiÞcant effect upon lactate, neither 
did lowering the glucose concentration to 5 mM. However, glucose 
concentrations of 2 mM and below caused a decrease in the lactate 
concentration measured. This relationship suggests that the lactate production 
from the nerve saturates at glucose concentrations of about 5 mM and above. 
This observation along with the stability of CAP conduction at these glucose 
concentrations points towards the nerve receiving an adequate supply of 
energy substrate. At 2 mM glucose the lactate concentration decreased but the 
CAP area remained stable. A reduction in CAP area was only seen at a glucose 
concentration of 0.5 mM indicating that the minimum glucose concentration 
that can support axonal activity is between 0.5 - 1 mM. Previous data from the 
MON shows that at 2 mM glucose and below glycogen-derived lactate 
supplements the glucose supply (Brown et al., 2003). Systemic glucose 
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concentration of 2 - 3 mM are considered to be hypoglycemic (Frier and Fisher 
2007). However, in the isolated MON preparation the blood-borne delivery of 
substrates is circumvented. An aCSF glucose concentration of 2 mM is 
probably accompanied by a ECS glucose concentration of close to 2 mM which 
is close to the value observed in normoglycemic rat brain (Silver and 
Erecinska, 1994). The observation that extracellular lactate falls at glucose 
concentrations of 2 mM and below, whilst the CAP is only affected at a 
glucose concentration of 0.5 mM possibly indicates that increased oxidation of 
lactate is occurring and therefore less lactate is released into the extracellular 
space. Lactate is capable of supporting the MON as the sole energy substrate 
(Brown et al., 2001) so it is plausible that under these conditions oxidative 
metabolism of lactate contributes towards ATP production, and compensates 
for the reduced availability of glucose. 
4.4.4 Fructose Metabolism in the Optic Nerve
When fructose was the sole substrate in the aCSF the lactate release was 
considerably lower than that seen with equimolar glucose (Fig. 4.4). Even at 25 
mM fructose the lactate signal was below that seen with 10 mM glucose. This 
matches observations in cultured astrocytes where the lactate release in the 
presence of fructose was also less than that when the cells were supplied with 
glucose (Bergbauer et al., 1996). Metabolism of fructose in astrocytes is most 
likely limited by the reduced afÞnity of fructose as a substrate for hexokinase 
in comparison to glucose (Sols and Crane, 1954). Since some lactate is 
produced in the presence of fructose, and fructose is converted ultimately to 
fructose-6-phosphate (see Fig. 1.2), this reinforces that glycolysis is the source 
of lactate in the MON. Astrocytes in culture have to rely on hexokinase 
activity to metabolise fructose as they lack fructokinase activity (Bergbauer et 
al., 1996).
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In contrast to these Þndings in cell culture, fructokinase immuno-reactivity is 
visible in optic nerve astrocytes and selected axons (Meakin et al., 2007). The 
role of fructokinase (ketohexokinase) in the brain is not currently known, but 
its presence suggests at least some fructose metabolism does occur in the 
brain. 
4.4.5 Metabolic Inhibition 
Lactate is produced as a possible end product of glycolysis; glucose is 
metabolised by the chain of glycolytic enzymes resulting in the formation of 
pyruvate and the generation of energy in the form of ATP. Pyruvate can then 
be further metabolised oxidatively in mitochondria, or converted to lactate by 
the enzyme lactate dehydrogenase which forms NAD+ from NADH in the 
same reaction. The necessity of glycolysis for lactate formation in the MON 
was demonstrated by applying iodoacetate (IA), an inhibitor of the glycolytic 
enzyme glyceraldehyde 3-phosphate dehydrogenase. IA rapidly halted lactate 
production and resulted in CAP failure, as axonal activity is lost due to the 
dependence of membrane potential upon a steady supply of glucose. IA has 
previously been shown to cause a depolarisation of axonal membranes in the 
optic nerve (Leppanen and Stys, 1997) with the combined effect on all axons 
seen as the failure of the CAP (Fig. 4.5.C, D).
Aerobic glycolysis is a term given to the glycolytic production of lactate in the 
presence of physiologically adequate oxygen. Aerobic glycolysis may play an 
important role generating the energy required for normal neural activity in 
white matter, but it is not sufÞcient on its own to support CAP conduction. 
Figure 4.6 shows that after application of cyanide the CAP fails rapidly. 
Cyanide inhibits cytochrome c oxidase which disrupts the electron transport 
chain halting the aerobic production of ATP. The rapid loss of action potential 
conduction shows that white matter requires aerobic generation of energy to 
function normally. This has previously been reported in the rodent optic nerve 
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(Stys et al., 1992). The initial increase in lactate after application of cyanide 
could be due to either increased glycolytic production of lactate, a reduction in 
oxidation of lactate or a combination of both. 
A subset of MON axons maintain function during anoxia, or in the presence of 
cyanide (Tekkok et al., 2003). This observation was not seen here since cyanide 
caused complete failure of the CAP. This discrepancy may be explained due to 
strain differences between mice used. The CD-1 strain shows the same 
response as the rat optic nerve which is not resistant to anoxia (Waxman et al., 
1994). The age of animals is also a factor as anaerobic function in the mouse 
optic nerve declines with age (Hamner et al., 2011). Animals used for 
experiments in this chapter were chosen from within a weight range rather 
than a speciÞc age, although all animals used were considered adult. The 
mechanism underlying age-dependent resistance to anoxia is not known, thus 
it is difÞcult to explain why no function persisted during chemical anoxia in 
these mice. Optic nerve diameter is not thought to be important, but there may 
be differences in glucose metabolism although this is purely speculative at this 
stage (Hamner et al., 2011). 
An observation that has not been previously described is the effect of blocking 
oxidative metabolism on the lactate concentration in white matter. Cyanide 
caused a transient increase in lactate before it reached a steady concentration 
at a value less that that seen before the onset of chemical anoxia. The need for 
oxidative metabolism to support CAP function may be attributed to the axons 
which have a high oxidative demand. The stable conduction of CAPs in the 
MON may not require astrocytic oxidative metabolism as selectively blocking 
TCA cycle ßux in astrocytes with ßuoroacetate (FA) does not result in CAP 
failure. Fig. 4.6 shows the effect of FA, which is a selective toxin for astrocytes, 
as it is preferentially taken up by these cells where it inhibits the enzyme 
aconitase (Fonnum et al., 1997). However, experiments with astrocytes in 
culture show that FA may not impair ATP production as FA did not cause a 
drop in intracellular ATP  (Swanson and Graham, 1994). 
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4.4.6 Glycogen as a Source of Lactate
Glycogen, the only storage carbohydrate available in the mammalian brain, is 
located exclusively in astrocytes and can act as an energy reserve providing 
fuel for axons in the absence of glucose (Ransom and Fern, 1997). Lactate is a 
product of glycogen metabolism in white matter. Experiments in the optic 
nerve show that it is lactate that is produced from glycogen that fuels axons 
during periods of glucose withdrawal (Brown et al., 2007). The availability of 
glycogen can be inßuenced prior to aglycemia by either up- or down-
regulating glycogen content or pharmacologically blocking glycogen 
metabolism. The effect of these interventions on axonal conduction during 
aglycemia has previously been documented in the MON (Brown et al., 2005). 
The experiments  performed by Brown et al. were repeated, but with the 
addition of monitoring  extracellular lactate (Fig. 4.8 and 4.9). It was observed 
that extracellular lactate persisted longer during aglycemia when glycogen 
stores were elevated, and that the lactate signal was lost sooner when 
glycogen metabolism was blocked. The timing of the fall in extracellular 
lactate is consistent with the fall in glycogen content during aglycemia, as both 
reach their nadir before CAP conduction begins to fail.
Whether the function of astrocytic glycogen in vivo is as a dormant energy 
reserve may be questionable; consciousness is rapidly lost when the brain is 
deprived of glucose although these circumstances are rare. Perhaps a more 
physiologically realistic function of glycogen is as an energy buffer, which 
may act as a source of energy substrate during times of heightened energy 
demand. An example of this is that glycogenolysis supports high frequency 
Þring of axons in the optic nerve (Brown et al., 2005). The degree of the 
increase in demand required to cause mobilisation of glycogen stores need not 
be great. Glycogenolysis occurs in response to normal sensory stimuli 
(Swanson et al., 1992), an observation that links glycogen metabolism to 
normal physiological function. It has been proposed that glycogen may be 
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used to fuel speciÞc cellular functions in astrocytes which are then up-
regulated during neural activity. 
4.4.7 Evidence for a Glycogen Shunt
The glycogen shunt model proposes that a proportion of glucose metabolism 
in the brain is processed via glycogen and that glycosyl residues are constantly 
being added and removed from the glycogen skeleton as part of normal 
energy metabolism (Shulman et al., 2001). A glycogen shunt is believed to 
operate in muscle tissue and evidence shows that the glycogen shunt plays a 
large role in astrocyte energy metabolism (Walls et al., 2009). 
In muscle the glycogen shunt pathway is responsible for the formation of 
lactate during aerobic exercise (Shulman, 2005).  If the glycogen shunt is 
present and active in neural tissue it could be the source, or a contributing 
source, of lactate production in the brain. Blocking glycogenolysis caused a 
fall in extracellular lactate, which reveals that glycogen metabolism 
contributes to  lactate release in the MON under minimally stimulated 
conditions (Fig. 4.7.A). This supports the notion of constant glycogen 
metabolism; if glycogen metabolism was only required during periods of high 
activity or hypoglycemia, then it would not be expected that resting lactate 
would be affected by the availability of glycogen. The contribution of 
glycogen to lactate production increases under conditions of higher metabolic 
demand (Fig 4.7.B,C), an observation that is predicted by the glycogen shunt 
model (Shulman et al., 2001). High-frequency stimulation of the MON was 
used to place a high metabolic demand on the tissue. Stimulation frequencies 
were within the physiological range of the MON (Brown et al., 2005), but the 
stimulus is unlikely to reßect the Þring pattern of the nerve in vivo. In 
astrocytes stimulated by noradrenaline, glycogen shunt activity accounts for 
40 % of glucose metabolism (Walls et al., 2009); it appears that glycogen shunt 
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activity may account for a similar fraction of lactate production in the MON 
during high-frequency stimulation.
Metabolism of glycogen that results in the formation of lactate may seem an 
inefÞcient pathway of energy production when compared to full oxidation of 
glucose, but under certain conditions it makes metabolic sense. Obtaining 
glycosyl residues from glycogen is advantageous due to the speed with which 
glycogen phosphorylase can be activated (Shulman and Rothman, 2001). 
Computer modelling suggests that fuelling the requirements of astrocytes by 
glycogenolysis ensures that glucose supplies are preserved for use by neurons 
(DiNuzzo et al., 2010). The cellular architecture of astrocytes may also be 
responsible for the use of the glycolytic pathway under fully oxygenated 
conditions. Astrocytes have many cytoplasmic processes that are too narrow 
to contain mitochondria, and this could make them at least partly reliant upon 
glycolytic metabolism of glycogen resulting in lactate production. The increase 
in lactate production and the greater proportion of lactate which is derived 
from glycogen during a 10 Hz stimulus can be explained by the rapid rise in 
energy demand that occurs in astrocytes in response to increased neural 
activity being fuelled by this pathway. Astrocytes express the transporters 
necessary for this rapid and high level of lactate trafÞcking across the 
membrane (Hertz and Dienel, 2005). One of the major functions of astrocytes 
that is linked to neural activity is K+ homeostasis via K+ uptake and spatial 
buffering. Ion pumping which is necessary for control of K+ concentrations 
inside and outside the cell is associated with glycolysis, and may be the source 
of lactate production during activation in the optic nerve; this will be explored 
further in Chapter 5. 
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Chapter Five
Activity-dependent 
increases in white matter 
lactate production are 
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5.1 Introduction
Neural tissue is subject to ßuctuating levels of activity, reßected in variations 
in the energy demands of the tissue. The principle that local increases in 
energy demand is coupled to increases in glucose and oxygen consumption 
underpins the rationale behind neuroimaging techniques such as positron-
emission tomography (PET) and functional magnetic resonance imaging 
(fMRI) (Magistretti and Pellerin, 1999). Traditionally it has been assumed that 
the glucose is metabolised oxidatively in both the resting and active brain 
(Sokoloff et al., 1977). As brain imaging became widely adopted as a method 
for studying brain function observations emerged that questioned the 
traditional view. It was found that the increase in glucose uptake was not 
matched by an equivalent level of oxygen consumption (Fox et al., 1988; 
Vaishnavi et al., 2010). The un-coupling between glucose and oxygen 
consumption raised the possibility that a major contributor to energy 
metabolism during neural activity is glycolysis and lactate production. 
5.1.1 Lactate and Increased Neural Activity
The brain is a highly oxidative organ but increased neural activity is 
accompanied by an increase in glycolysis. Indirect evidence for lactate 
production during neuronal activity comes from the increase in glucose 
metabolism that is not matched by an increase in oxygen consumption 
necessary for full oxidative metabolism of this glucose (Fox et al., 1988). This 
effect shows regional variability and is greatest in the pre-frontal cortex and 
medial and lateral parietal cortex (Vaishnavi et al., 2010).
The increase in glycolysis and lactate production have been linked to recycling 
of synaptic glutamate. In the previous chapter the results showed that lactate 
is released from white matter, and that an increase in the rate of action 
potential conduction led to greater lactate release. These results suggest that 
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an increase in glycolysis that out-weighs oxidative phosphorylation may also 
be a response to rising energy demand in white matter. 
5.1.2 Lactate and Pathological Conditions
An increase in lactate production in the CNS has also been associated with 
pathological conditions. Determination of lactate concentration in the blood is 
used as a clinical test, with increases in lactate interpreted as a negative sign 
for a patientÕs outlook (Schurr, 2002). Increases in brain lactate concentration 
occur as part of the ageing process (Ross et al., 2010) and this elevated lactate 
in the brain may be a risk factor for AlzheimerÕs disease (Xiang et al., 2010). 
Lactate is also raised after stoke and traumatic insults and has long been 
considered a marker of Òbrain deathÓ (Paulson et al., 1971). This association of 
raised lactate with poor prognosis has proven difÞcult to overcome despite 
evidence that lactate is an important energy substrate for the brain during 
recovery from hypoxia (Schurr et al., 1997a; 1997b). The energy demands of 
the injured tissue are likely to be greater than normal and lactate accumulation 
at the injury site possibly reßects the tissues enhanced need for energy 
substrate (Chen et al., 2000). 
5.1.3 Aims
There is a lively debate ongoing as to the nature of lactate increases that 
accompany neural activity. The association between raised lactate and 
pathological conditions has resulted in a negative dogma surrounding brain 
lactate even though lactate is produced during normal neural activity. 
Conßicting evidence and opinions mean that the origin, movement and 
disposal of lactate are all as yet unresolved important questions. The aim of 
this series of experiments was to investigate the dynamics of extracellular 
lactate produced during times of high neuronal activity in white matter. The 
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mouse optic nerve (MON) was selected as a model tissue in which to perform 
these experiments. 
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5.2 Methods
The methods used in this chapter are as detailed in Chapter 2 and Chapter 4. 
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5.3 Results
5.3.1 Extracellular Lactate Increases During Axonal Activity
5.3.1.1 Effect of Stimulus Frequency
To observe how extracellular lactate concentration related to tissue metabolic 
demand in the MON, the demand on the tissue was increased by evoking 
CAPs at higher frequencies than the 0.33 Hz used under standard conditions. 
The MON was stimulated for 2 minutes at a range of frequencies up to a 
maximum of 50 Hz while the lactate concentration and CAP were recorded. 
Figure 5.1.A shows an example trace from one experiment where a MON was 
stimulated at a range of frequencies between 2 and 50 Hz, being allowed to 
recover between each stimulus train, with the traces from each stimulus set 
overlaid. The Þgure shows that as the stimulus frequency increases the evoked 
lactate concentration rises and then recovers towards baseline when the 
increased demand is over. The relationship between lactate concentration and 
stimulus frequency can be seen in Þgure 5.1.B, where a stimulation frequency 
of 60 Hz for 2 mins results in a peak normalised lactate signal of 2.12 ± 0.02 
(Fig. 5.1.B). 
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Figure 5.1  The effect of high frequency stimulus on lactate in the MON. A. The 
normalised lactate signal is shown for a single nerve stimulated for 2 mins at 
frequencies of 2, 5, 7.5, 10, 20, 40, 50 or 60 Hz. The period of increased stimulus 
frequency is shown by the bar and bordered by broken lines, at other times a CAP 
was evoked once every 30 s (0.033 Hz). B. The peak normalised lactate signal for 
each frequency is shown, data are mean from 3 nerves. 
5.3.1.2 Effect of Stimulus Duration
The effect of the duration of increased stimulation frequency upon lactate 
concentration was also examined (Fig 5.2). A 50 Hz stimulus was applied to 
generate a deÞned number of CAPs between 100 and 6000 (i.e. a stimulus of 
between 2 and 120 seconds). The peak lactate above baseline rose rapidly for 
stimuli consisting of between 100 and 2000 action potentials but above this 
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number the increase appeared to saturate. The maximum increase in lactate 
signal was seen after a 50 Hz stimulus lasting 120 s (6000 action potentials) 
which was 2.37 ± 0.02 that of baseline lactate (Fig. 5.2.B).
Figure 5.2 The effect of the duration of high frequency stimulus on the lactate signal 
in the optic nerve. A 50 Hz stimulus was applied to the optic nerve for a deÞned 
number of action potentials between 250 (5 s duration) and 6000 (120 s duration). 
A. Lactate response to these stimuli each applied 3 times and averaged for a single 
nerve. Arrow indicates onset of stimuli and horizontal lines show the durations. Each 
increase in duration of the stimulus caused a further increase in the lactate signal. B. 
Peak lactate signal for each stimulus (n = 3). 
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5.3.1.3 Analysis of the Lactate Response
Figure 5.3 shows the mean lactate trace (n = 3 from a single nerve) of a 2 mins 
50 Hz stimulus, with the period of the stimulus indicated as the shaded area. 
This chart shows that in the Þrst few seconds after stimulus onset there was an 
initial slight decrease in lactate followed by a rapid increase. Upon returning 
to stimulating once every 30 s there was a further increase in lactate followed 
by a gradual return to baseline lactate over a period of 8 -10 mins. The initial 
dip in lactate was quite small in comparison to the increases seen, and was not 
always clearly observed at lower stimulation frequencies. The increase in 
lactate seen at the end of a stimulus was also more pronounced at higher 
frequencies. 
Figure 5.3 Detail of the lactate response to a high-frequency stimulus. An averaged 
trace of the lactate response of the MON to a 2 min 50 Hz stimulus (n = 3). Lactate 
dips at start of a period of high frequency stimulation and peaks after the stimulus is 
stopped. 
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5.3.1.4 Effect of Na+ channel block
Figure 5.4 The effect of Na+ channel block on CAP area and lactate signal in the 
MON. A representative experiment is shown where the Na+ channel blocker TTX 
was applied to the MON whilst periodic stimuli at 50 Hz for 2 mins were performed 
(arrows). The concentration of TTX is indicated in nM above the trace, CAP area is 
represented by open squares (right axis) and lactate via the solid line (left axis). 10 
nM TTX had no apparent initial effect so the concentration was increased to 50 nM, 
which caused a decrease in CAP area. At 50 nM TTX also lowered the lactate 
response to a high-frequency stimulus with the peak amplitude of lactate for a 
stimulus decreasing over time. Washout of TTX restored CAP area and partially 
restored the lactate response to a high-frequency stimulus. The Þgure shows a single 
experiment. 
The association between lactate production and axonal activity in the form of 
action potential propagation was further examined by applying the sodium 
channel blocker TTX (tetrodotoxin). Initially a 10 nM concentration of TTX 
was applied to the nerve along with a 2 min 50 Hz stimulus. This stimulus 
produced an increase in lactate that was the same as that seen prior to TTX 
application, however, there was also no effect observed upon the CAP area 
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suggesting that ion movement was not signiÞcantly affected at this 
concentration. The TTX concentration was then increased to 50 nM which 
caused a decline in CAP area and a decrease in the peak lactate response to a 2 
min, 50 Hz stimulus. The lactate response to this stimulus then further 
decreased after subsequent stimuli while there was no change in baseline 
lactate between stimuli. Washing off the TTX saw a partial recovery in CAP 
area and peak lactate response to a high frequency stimulus. This experiment 
with TTX was only carried out once. This must be taken into account when 
making conclusions from it. The clarity of the effect and its reversibility 
suggest that future repeats will conÞrm these results. 
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5.3.2 Extracellular Potassium Stimulates Lactate Production 
5.3.2.1 Effect of Extracellular K+
High amounts of neuronal activity lead to an increase in extracellular 
potassium ([K+]O) in the rodent optic nerve (Ransom et al., 2000; Brown et al., 
2001), therefore, the effect of experimentally-induced changes to [K+]O upon 
the extracellular lactate concentration in the MON was examined by exposing 
nerves to concentrations of K+ above the control of 3 mM from 4.5 - 15 mM. 
Increasing the [K+]O for 10 mins resulted in a dose-dependent increase in the 
lactate concentration (Fig. 5.5). The lactate began to fall after [K+]O was 
returned to 3 mM, but after 20 mins had not returned to baseline levels (Fig. 
5.5.A). The peak lactate signal at varying [K+]O is shown in Fig. 5.5.B. The 
maximum peak relative to the normalised lactate signal was 2.06 ± 0.14 with a 
[K+]O of 15 mM. The relationship was linear between 3 and 15 mM [K+]O unlike 
that seen for high frequency stimulation, where the lactate signal appeared to 
saturate when it reached a normalised value of over 2.0. Higher [K+]O than 15 
mM were not used as these are not seen under physiological conditions 
(Heinemann and Lux, 1977; Ransom et al., 1986). 
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Figure 5.5 The effect of [K+]O on lactate release from the optic nerve. Increasing [K
+]O above the control concentration of 3 mM resulted in an increase in lactate 
production in the MON. A. Normalised lactate signal for a 10 mins exposure to x 
mM K+ (given by number above trace). Traces show the mean signal from different 
experiments overlaid (n = 3). B. Peak normalised lactate signal for each concentration 
of K+ applied to the MON, lactate signal increased with K+ (n = 3).   
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5.3.2.2 Effect of K+ Channel Blockers
The inßuence of K+ was further evaluated by observing whether K+ channel 
blockers had any effect upon lactate concentration in the MON. Barium ions 
(Ba2+) are known to interfere with a number of K+ channel subtypes (Newman, 
1989). In astrocytes Ba2+ has been shown to cause depolarisation by blocking 
the inward rectiÞer K+ channel (Walz et al., 1984). Tetraethylammonium (TEA) 
is another commonly used K+ channel blocker which has been used to study 
K+ conductance in astrocytes  (Perillan and Simard, 1999). 2 mM BaCl2 caused 
a very large increase in lactate, 3.5 fold compared to a normalised signal. 
Similarly, TEA produced an increase in lactate, but not as great as that 
observed for Ba2+ (Fig. 5.6). 
Figure 5.6 The effect of K+ channel blockade on lactate in the MON. A 10 minute 
exposure to 2 mM BaCl2 caused an increase in lactate signal in the MON which 
returned to baseline in control aCSF. A similar effect but with a lower increase in 
signal was seen for 20 mM tetraethylammonium (TEA). The labeled black bars show 
the period of exposure. This Þgure shows the trace from a single experiment.
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5.3.3 Post-aglycemia Recovery
Aglycemia is also known to cause an increase in [K+]O which persists when 
glucose is re-perfused (Brown et al., 2001). The lactate response to aglycemia is 
shown in Chapter 4. The lactate signal from the MON falls during glucose 
withdrawal and CAP failure is seen shortly after the lactate reaches zero. To 
expand upon these Þndings the lactate signal was recorded during MON 
recovery post-aglycemia. The effect of re-perfusion of the MON with 10 mM 
glucose after a 25 minute period of aglycemia is shown in Fig. 5.7. Lactate rose 
rapidly when glucose was reintroduced to the tissue, as the CAP area 
recovered the lactate concentration increased above its pre-aglycemia baseline 
until the CAP area stabilised when the lactate concentration returned to the 
value it was prior to the insult.
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Figure 5.7 The effect of a 25 minute period of aglycemia on MON lactate and CAP 
area. Aglycemia was induced by replacing control aCSF with zero glucose aCSF 
(indicated by the bar). The lactate signal (solid line, left axis) decreased and this was 
followed by a delayed fall in CAP area (open squares, right axis). The CAP area 
reached 0 at 25 mins when 10 mM glucose was restored to the nerve. Reintroducing 
glucose cause a rapid spike in lactate signal followed by a sustained period during 
which the lactate signal deviated above baseline. During this period the CAP 
recovered completely and equilibrated as the lactate level returned to the pre-
aglycemia value (Data are presented as means, n = 3). 
The effect of a longer period of energy deprivation on the CAP and lactate was 
examined by reintroducing glucose after 30 mins to allow for complete CAP 
failure (Fig 5.8). Recovery after this insult was incomplete in the representative 
trace shown in Fig 5.8. CAP area only recovered to 59 % of its pre-aglycemia 
value. In experiments such as this with incomplete CAP recovery the lactate 
signal also did not return to baseline. Lactate remained above the pre-
aglycemia concentration but was gradually falling. A subsequent period of 
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aglycemia was applied to determine what would happen to extracellular 
lactate when axonal injury was too severe to allow CAP recovery. The latter 
portion of Fig. 5.8 shows that after a further 90 mins of aglycemia, there is no 
recovery in CAP area. Reintroducing 10 mM glucose in the second recovery 
phase led to a rapid increase in lactate signal from the nerve to baseline levels 
prior to both aglycemic episodes. 
Figure 5.8 The effect of two periods of aglycemia on MON CAP area and lactate. A 
representative trace is shown for an exposure to 30 mins aglycemia, followed by 60 
mins recovery, a second period of aglycemia lasting 90 mins and a Þnal recovery 
period in 10 mM glucose. During the Þrst period of aglycemia lactate signal and CAP 
area fall to zero. In the Þrst recovery phase a partial recovery of CAP area is seen 
along with an elevated lactate level. The second period of aglycemia again caused 
complete loss of CAP area and lactate signal. A second recovery phase did not reveal 
any restoration of CAP area, but lactate returned towards baseline.   
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5.4 Discussion
5.4.1 The Effect of Axonal Activity on Extracellular Lactate
The concentration of extracellular lactate increases when extra metabolic 
demand is placed upon CNS tissue. In the results presented here this 
increased metabolic demand is triggered by an increase in the frequency of 
action potentials conducted by the axons. Seizures are a pathological increase 
in neural activity which results in increased metabolic demand. Seizure 
activity has been shown to increase lactate concentrations in CSF and blood 
(Brooks and Adams, 1975) and locally within the brain (During et al., 1994; 
Cornford et al., 2002). Increases in lactate can also be generated by 
experimental stimulation of CNS tissue. The effect of increased axonal activity 
in the MON is in agreement with these other results in that substantial 
increases in extracellular lactate are observed upon stimulation of the nerve 
(Fig. 5.1). 
The increase in lactate concentration at higher frequencies appeared to reach a 
plateau at 50-60 Hz when the peak lactate was not signiÞcantly different. The 
plateau of the lactate concentration is likely to be caused by a rate-limiting 
step in its production. Whether this is due to glucose supply or enzyme 
saturation cannot be directly determined from these results, but repeating the 
stimuli at higher glucose concentrations could reveal whether this was the 
limiting factor. Other possibilities are saturation of glycolytic enzymes or 
lactate transport from the cell. High concentrations of lactate can inhibit 
lactate dehydrogenase thus constraining lactate synthesis (Moorhouse et al., 
2010). The maximum increase in lactate brought about by electrical 
stimulation of the tissue was 2 - 3 times baseline, which is approximately 
equivalent to that seen in experiments that have used microdialysis to 
measure brain lactate.
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5.4.2 Time Course of Lactate Production
The temporal characteristics of the transient increase in extracellular lactate 
that accompanies increased neural activity have received much attention in a 
number of studies. Understanding the mechanisms behind the lactate 
response will allow a clearer picture of brain energy metabolism to be formed. 
Microdialysis experiments are capable of revealing the increase in lactate but 
are not best suited to examine the time course of lactate changes. Since 
microdialysis is limited in its temporal resolution, due to constraints on the 
frequency with which quantiÞcation can occur. The use of enzyme-based 
biosensors allows a much greater time resolution of the lactate response to 
stimulus.
The in vivo use of biosensors have shown that a 5 s stimulation of the 
perforant pathway in the rat hippocampus caused an increase of up to 200% in 
lactate, which took 10 - 14 mins to return to baseline levels (Hu and Wilson, 
1997). In the optic nerve a 120 s stimulus at 60 Hz resulted in a similar lactate 
increase which then took 4 - 6 mins to return to baseline post-stimulus (Fig. 
5.3). The lactate response after stimulation is qualitatively similar in both grey 
and white matter. A combination of experimental protocol and tissue 
differences most likely account for the quantitative differences in the lactate 
response. The isolated MON is constantly bathed in fresh aCSF and is 
therefore likely to have a faster clearance of lactate from the tissue than exists 
in vivo. 
The changes in extracellular lactate in response to a stimulus have been 
interpreted as supporting the hypothesis that lactate is taken up and oxidised. 
In the MON upon onset of a period of high-frequency stimulation an initial 
decrease in lactate is observed. When the stimulus is stopped there is a further 
increase in the rate of lactate release (Fig. 5.3). These observations may be due 
to a fraction of the lactate produced by the nerve being taken out of the 
extracellular space during the stimulus, which is consistent with axonal 
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uptake and presumably oxidation of lactate. Hu and Wilson (1997) similarly 
observed a decrease in lactate after initiating a stimulus in the hippocampus 
(their Figure 1a closely resembles Figure 5.3 in this chapter).As the effect is 
seen at the onset and termination of an electrical stimulus use of a null sensor 
would add further conÞdence to this observation. It is possible that electrical 
stimulation caused an artefact on the sensor. This would be detected by a null 
sensor. However, similar decreases in brain lactate content have been observed 
in the human brain upon the onset of neural activity triggered by a visual 
stimulus (Mangia et al., 2003). A coinciding dip in NADH ßuorescence in 
neurons at stimulus onset is also seen which is interpreted as an initial 
response of neuronal oxidation followed by astrocytic glycolysis and 
extracellular lactate acting as an energy buffer (Kasischke et al., 2004). The 
results of in vivo and in vitro experiments are further supported by studies 
carried out which have utilised computer modelling to recreate the lactate 
response (Cloutier et al., 2009).
Further evidence to support the notion that lactate is being taken up and 
oxidised in the MON could be obtained from the use of MCT blockers. MCTs 
are responsible for lactate transport across cell membranes (Halestrap and 
Price, 1999). Neurons express MCT2, a different isoform to the MCT1 and 4 
expressed by astrocytes (Debernardi et al., 2003; RaÞki et al., 2003). Neuronal 
MCT2 can be selectively blocked by using the MCT inhibitor 4-CIN at a 
concentration of 100 !M (Erlichman et al., 2008). A potential pitfall of the use 
of 4-CIN is that it has been reported to block pyruvate entry into the 
mitochondrion (McKenna et al., 2001). However, this effect was observed at 
higher concentrations (0.25 - 1 mM) than those used to inhibit MCT2. 
Preliminary experiments were attempted with this compound but they did 
not generate presentable results. It is predicted that if the theory of lactate 
uptake by neurons is correct then the extracellular lactate signal in the MON 
would increase after the application of 4-CIN. Quercetin is another MCT 
inhibitor but it acts to preferentially block lactate release from astrocytes 
(McKenna et al., 1998). Comparing the effects of these two MCT inhibitors on 
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lactate concentration in the MON would enhance our understanding of lactate 
ßuxes in this tissue. These are important experiments which will take 
precedence in any future work.
The transient lactate response observed after neural activity has been linked to 
glutamate uptake by astrocytes. However, it has been argued that the energy 
cost of glutamate uptake by astrocytes is not sufÞcient to stimulate astrocyte 
lactate production (Fillenz, 2005). The similarity between the lactate transient 
in grey matter (Hu and Wilson, 1997; Simpson et al., 2007) and that observed 
here in white matter also argues against glutamate uptake being the trigger for 
this metabolic switch. A mechanism which is common to both grey and white 
matter is more likely. 
5.4.3 Potassium Homeostasis and Lactate Production
The resting level of [K+]O in the brain is maintained at about 3 mM by a 
number of tightly controlled regulatory processes (Katzman, 1976). However, 
local changes in [K+]O do occur. The need for tight regulation of [K+]O is 
required as [K+]O can inßuence many of the processes vital to normal brain 
function. Release of neurotransmitters is inßuenced by [K+]O as is neuronal 
activity and resting membrane potential. Cerebral blood ßow responds to 
[K+]O and importantly for these experiments concerning energy metabolism, 
both glucose uptake and its subsequent metabolism respond to [K+]O (Salem et 
al., 1975). 
Increased neuronal activity causes in an elevation in extracellular potassium 
([K+]O) in both grey and white matter (Connors et al., 1982; Ransom et al., 
2000). Each individual action potential can lead to a local increase in [K+]O of 
approximately 0.75 mM (Adelman and Fitzhugh, 1975) and the total increase 
is proportional to the intensity of the neuronal activity. Normal physiological 
activity can lead to increases in [K+]O of up to 12 mM measured in the optic 
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nerve (Connors et al., 1982). It is possible for [K+]O to exceed this concentration 
under pathological conditions, such as during spreading depression and 
epileptic activity (Somjen, 2002). 
As intense neural activity results in an increase in lactate and [K+]O, I 
investigated whether a causal link connected increases in [K+]O and lactate 
release in white matter. A concentration-dependent increase in lactate was 
observed at [K+]O above the normal physiological concentration of 3 mM. The 
ability of increases in [K+]O to evoke lactate release suggests that this lactate 
release may be astrocytic in origin. This effect could also be replicated by 
blocking the inward rectiÞer K+ channel with Ba2+ and TEA (Fig. 5.6), an 
intervention which depolarises astrocytes (Walz et al., 1984), providing 
indirect evidence that lactate production and release occurs in astrocytes. A 
full characterisation of MON lactate release in response to Ba2+ and TEA was 
not carried out since the objective of this experiment was merely to show that 
disrupting K+ homeostasis would have an effect on lactate release. In future a 
full concentration-response relationship may provide further mechanistic 
detail.
An explanation for lactate release is that increases in [K+]O or disruptions to 
potassium currents (IK) lead to an increase in energy demand upon the cell as 
energy is required to maintain the resting balance of ion concentrations and 
ion gradients across the membrane. Whether this lactate is then used as a 
metabolic substrate or not further utilised locally remains an open question.  
5.4.4 Ion Pumps and Aerobic Glycolysis
Production and release of lactate at times of high neuronal activity or 
increased [K+]O are likely to be brought about by increased tissue energy 
demand. One of the main requirements for high frequency propagation of 
action potentials is the rapid return to resting membrane potential in axons. 
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Maintaining the resting membrane potential is in part due to the activity of the 
Na+/K+ ATPase (the sodium pump) which restores the ionic gradients 
required for action potentials. This process requires energy which may be 
derived from aerobic glycolysis, i.e. metabolism of glucose via glycolysis that 
produces lactate as its end product in the presence of adequate oxygen. 
Previous measurements of lactate in the brain have shown similar 
concentrations to that observed in vitro in the MON. Therefore, it is unlikely 
that lactate produced in the MON is due to the tissue being in a state of 
hypoxia. The potential of hypoxia affecting in vitro tissue is important to 
consider as the blood is an extremely efÞcient carrier of oxygen. 
A link between aerobic glycolysis and Na+/K+ transport has been 
demonstrated in muscle tissue. In vascular smooth muscle oxidative 
metabolism is generally used to support contractile mechanisms, whereas, 
glycolysis provides the ATP necessary for membrane ion pumps (Paul et al., 
1979). The spatial localisation of the glycolytic enzyme chain in the cell has 
been put forward as the reason behind this. For white matter, a co-localisation 
of ion pumps and the enzymatic machinery responsible for glycolysis may be 
similarly responsible for the production of lactate in response to increased 
[K+]O. 
It is possible that attributing lactate production to the action of the sodium 
pump could provide a common link between lactate release in white matter 
and the lactate production in grey matter that is incorporated into the ANLSH 
model. 
5.4.5 Lactate and Aglycemia
The response of white matter tissue to glucose withdrawal or aglycemia has 
been used as a method to understand energy metabolism in this tissue. 
Understanding the injury mechanisms that underlie aglycemic injury in white 
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matter also has important clinical implications. Glucose deprivation 
commonly occurs in conjunction with hypoxia in conditions such as stroke 
(Siesj, 1988), but can occur independently in diabetic patients (Frier and 
Fisher, 2007). 
As discussed above maintenance of an energy supply is vital for the brain in 
both grey and white matter, otherwise the membrane potentials that are 
required for both glia and neurons to function are dissipated. The question 
that remains is what happens to the tissue during the period of time where 
energy is not available. Considering the role of lactate is important from two 
perspectives: Þrstly, lactate, produced from astrocytic glycogen is thought to 
be shuttled to axons providing them with an energy supply during times of 
energy deprivation; secondly, it has been shown that lactate is an important 
substrate for CNS tissue following a period of hypoxia (Schurr et al., 1997). 
Thus, whether lactate plays a similar role post-aglycemia is a clinically 
relevant question.
Fig. 5.7 shows that when glucose was withdrawn entirely the lactate 
concentration fell to zero prior to axon conduction failure. The delay between 
extracellular lactate reaching its nadir and failure of the CAP could be due to 
the time taken for axons to exhaust the intracellular energy substrates built up 
prior to aglycemia. Alternatively, astrocytes may still be releasing lactate as a 
breakdown production of glycogen, but as the uptake rate of lactate by axons 
is rapid the lactate is not recorded in the extracellular space. 
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5.5 An Integrated Overview of Lactate in 
White Matter 
The results contained in this chapter and Chapter 4 add to our knowledge of 
energy metabolism in white matter, and can be discussed in a broader context 
and integrated into current models of white matter energy metabolism.   
5.5.1 Are astrocytes the Source of White Matter Lactate?
Large increases in extracellular lactate accompany periods of intense axonal 
activity or exposure to high [K+]O in white matter. Models of brain energy 
metabolism propose that astrocytes and neurons have different metabolic 
responses to increased workload and that the increase in lactate may be 
associated with a speciÞc cell type.  A theory that shows strong popularity is 
that astrocytes are the main producers of lactate and that this lactate may then 
be oxidised by neurons. However, these models are generally discussed in the 
context of grey matter Determining the origin and fate (see next section) of 
brain lactate is an important step in producing an accurate model of brain 
energetics. 
Extracellular lactate remains elevated for some time after a period of increased 
neural activity. The prolonged nature of the increase in lactate seen after 
stimulation in the hippocampus has been used as evidence to argue that this 
lactate is not involved in the uptake of synaptic glutamate (Hu and Wilson, 
1997). The energy requirement for glutamate uptake by astrocytes has been 
estimated as 3 % of brain ATP, which is insufÞcient to stimulate astrocyte 
glycolysis and lactate production (Fillenz, 2005). The qualitative similarity 
between the changes in lactate shown here in the optic nerve argues against 
the involvement of synaptic mechanisms as synapses are absent from the optic 
nerve. Instead it is likely that the production of lactate is linked to a process 
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that is common to white and grey matter, namely an increase in extracellular 
potassium ([K+]O) that follows increased neural activity. This is supported by 
the K+-induced, concentration-dependent increase in lactate production 
shown here in white matter (Fig. 5.5).
The observation that lactate production is closely related to [K+]O in the optic 
nerve may be interpreted as hinting towards lactate having an astrocytic 
origin. Astrocytes are exquisitely sensitive to rises in [K+]O and their Na+ 
pump can be activated by a rise in [K+]O of 1 mM. Conversely, the Na+ pump 
on the neuronal membrane is not activated by small changes in [K+]O, or 
activated by increases in intracellular [Na+]. The sensitivity of astrocytes to 
elevated [K+]O is related to their role in K+ regulation. 
It has been shown here that in the MON a proportion of the extracellular 
lactate is derived from glycogen metabolism (Fig. 4.7). This is true even under 
minimally stimulated conditions, and as glycogen is exclusively located in 
astrocytes, the source of this lactate will be astrocytic in origin.
Further evidence that the source of lactate is from astrocytes can be taken from 
Fig. 5.8 which shows that after two 60 minute periods of aglycemia there is no 
recovery of the CAP but the lactate concentration remains similar to that seen 
prior to the insult. Absence of the CAP indicates that axons are non-
functioning and as astrocytes are less vulnerable to aglycemic insults they are 
still viable and able to produce lactate.
Astrocytes and axons exhibit a relationship that is highly interdependent 
which makes determining the source of lactate in the optic nerve difÞcult and 
sometimes reliant on circumstantial evidence. Any manipulation which affects 
one cell type quite often directly affects the other, e.g. both axons and 
astrocytes have TTX-sensitive channels (Nowak et al., 1987), so administration 
of TTX will not simply block action potentials, it will alter the physiology of 
astrocytes too. Even in cases where an intervention is meant to target one cell 
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type there is likely to be a knock-on effect as axons rely on astrocytes to 
maintain the extracellular environment. FA, which is selectively taken up by 
astrocytes, was found to initially reduce lactate production but this was then 
followed by an increase. This pattern could be due to a direct effect on the 
astrocytes reducing their ability to produce lactate, and then a secondary effect 
on the axons as the extracellular environment changes. Confounding factors 
such as this are perhaps why much of the data which has been used to 
produce models of CNS energy metabolism has come from cell culture studies 
on single cell types. Mathematical modelling combined with computer 
simulations may be a fruitful avenue for examining this cellular relationships. 
These in silico experiments allow manipulations, such as speciÞc alterations in 
properties of a single cell type, to be performed which would not be possible 
in vivo or in vitro. The lactate response during neural activity has already been 
modelled and its predictive value demonstrated (Cloutier et al., 2009). 
5.5.2 The Fate of Extracellular Lactate
The quantities of lactate produced by the MON are high even under minimal 
activity which would suggest that lactate metabolism is an important 
component of white matter energetics. The question remains as to the end fate 
of this lactate. If a mechanism like that preposed by the ANLSH exists in white 
matter then the lactate released by astrocytes would be taken up by axons to 
be metabolised oxidatively. The results presented here are equivocal with 
respect to metabolic shuttling of lactate from astrocytes to axons in white 
matter. The lactate increase in response to activity occurs after a delay and 
persists beyond the stimulus which has previously been used to argue against 
the ANLSH. However, Fig. 5.3 shows that when a 2 min period of 50 Hz 
stimulation is applied there is an initial drop in lactate concentration before a 
substantial rise is seen and there is an increase in the gradient of the rising 
lactate concentration upon cessation of the stimulus. This observation may 
imply that there is some degree of lactate uptake occurring during this 
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activity, although it is small in relation to the increase in extracellular lactate 
that is not taken up by axons.
The ability of astrocytes and neurons to take up and release lactate has often 
been used as evidence for and against shuttling of lactate between cell types. 
Monocarboxylate transporters (MCTs) are responsible for lactate transport 
across the cell membrane and are expressed in white matter. There are eight 
subtypes of MCT which have different afÞnities for lactate and show speciÞc 
expression patterns in the brain. The main subtypes of MCT which are of 
relevance to white matter are MCT1 and 2, both are expressed in the MON 
(Tekkok et al., 2005). MCT1 expression has been localised to astrocytes, 
whereas MCT2 is present of the neuronal cell membrane (Koehler-Stec et al., 
1998). It has been suggested that MCT1, which has a lower afÞnity for lactate, 
is more suited to lactate export and MCT2 for lactate uptake. The expression 
pattern in white matter supports the hypothesis of astrocyte lactate release 
and axonal uptake (Tekkok et al., 2005). Pharmacological inhibition of MCTs 
has also been used to explore their possible role in brain energetics, 4-CIN 
accelerates CAP failure during aglycemia and this has been attributed to its 
application blocking entry of lactate into axons by its speciÞc action on MCT2 
(Wender et al., 2000). The use of 4-CIN in intact animals has shown that 
neurons in the rat retrotrapezoid nucleus take up lactate and this has been 
cited in support of the ANLSH model (Erlichman et al., 2008). A criticism of 
the use of MCT blockers such as 4-CIN is that they may also inhibit entry of 
pyruvate into the mitochondrion and have metabolic effects beyond blocking 
lactate uptake. More recently, MCT1 expression has been demonstrated in 
myelin (Rinholm et al., 2011) which implies that the signiÞcance of lactate 
metabolism may not be restricted to the relationship between astrocytes and 
axons. 
The debate surrounding lactate metabolism in the brain has largely focused on 
two main cell types: neurons and astrocytes. There is evidence to suggest that 
a two compartment model is insufÞcient in describing the true picture of 
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lactate as a metabolic substrate in the brain. Oligodendrocytes are responsible 
for covering the axons of neurons in the CNS with myelin and they require 
metabolic substrates in order to synthesise this specialised lipid membrane. 
Experiments with oligodendrocytes in cell culture reveal that these cells 
oxidise lactate at a higher rate than astrocytes or neurons and synthesise lipids 
from lactate to a much greater extent (Sanchez-Abarca et al., 2001). 
Oligodendrocytes are injured during periods of energy deprivation (Salter and 
Fern, 2005) and lactate can be used by oligodendrocytes to support 
myelination under low glucose conditions (Rinholm et al., 2011). These data 
give rise to the possibility that a fraction of the lactate released by astrocytes in 
white matter is taken up by oligodendrocytes rather than axons, although the 
postulated role for MCT1 as a lactate exporter is not in agreement with this. 
The role of oligodendrocytes and myelin in lactate metabolism warrants 
further examination in order to integrate it into white matter energy 
metabolism models. 
The fate of increased extracellular lactate in response to neural activity may 
not be solely restricted to its use as a substrate for oxidative metabolism. The 
release of lactate possibly contributes to neuro-vascular coupling which in 
turn may underpin the principles of neuroimaging (Attwell et al., 2010). 
Imaging the brain has become a widely used technique to study a vast range 
of normal brain processes and pathologies; because of this it is important to 
understand the cellular activity that generates the signal underlying this 
technology. 
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Chapter Six
A Functional Role for 
Peripheral Nerve 
Glycogen
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6.1 Introduction
Recent studies have shown that glycogen, located in astrocytes in the CNS, 
can act as an energy buffer, which may fuel axons during times of increased 
activity or under aglycemic conditions (Wender et al., 2000; Brown et al., 2003). 
Much of what is known about glycogen in the CNS is discussed in previous 
chapters. However, the role of glycogen in the peripheral nervous system has 
not been addressed in great detail. 
There are a number of reasons why the regulation of glycogen may differ in 
the PNS to that of the CNS. Firstly, the cell type which contains glycogen in 
the CNS, the astrocytes, are not present in peripheral nerves. Secondly, energy 
metabolism in peripheral nerves is not restricted to substrates which can cross 
the blood brain barrier which leaves the potential for the nerves to derive their 
energy from different sources and pathways than CNS neurons and glia. 
Thirdly, peripheral nerves have a less reliable supply of energy substrates than 
CNS tissue as they can be susceptible to postural ischemia as a result of 
normal body movements. The capillaries supplying peripheral nerves are also 
of greater diameter than erythrocytes resulting in less efÞcient oxygen 
delivery and a greater tendency for anaerobic metabolism (Low et al., 1997). 
This combination of factors means that the physiology of glycogen 
metabolism in the CNS cannot be simply applied to the PNS, and thus 
warrants investigation. 
6.1.1 Peripheral Nerve Morphology
Peripheral nerve is a noticeably different tissue compared to the CNS. The 
PNS is not constrained spatially in the same way as the CNS, where 
evolutionary pressure dictates that neurons and glia Þt inside the limited 
volume of the skull. The reduced pressure for compaction of the peripheral 
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nervous system can be seen by the much larger extracellular space in 
peripheral nerves, and this greater distance between axons and glia is likely to 
impact upon intercellular communication. Perhaps another hallmark of the 
increased volume in the periphery is the evolution of axons of much greater 
diameter than in the CNS, which allows increased conduction velocity 
necessary for transmitting impulses over the much greater distances that 
axons traverse. These large axons tend to be present in peripheral nerves 
which reach to distal body regions and can either be afferent or efferent. 
Smaller axons are found in autonomic nerves and also grouped in sensory or 
motor nerves, where they are un-myelinated and conduct slow signals 
involved in functions such as nociception. 
6.1.2 Glial Cells in Peripheral Nerves
In the PNS the glial population is composed of Schwann cells and satellite 
glial cells, which do not share the same morphology and physiology as CNS 
glia such as astrocytes and oligodendrocytes. Satellite glial cells are found 
mainly in peripheral ganglia where they envelop neurons, possibly 
performing a role analogous to CNS astrocytes (Hanani, 2010). Schwann cells 
are responsible for myelination in peripheral nerves. Each myelinating 
Schwann cell myelinates only one axon, in contrast to CNS oligodendrocytes, 
which can form myelin sheaths around many axons. There are also Schwann 
cells which support smaller un-myelinated axons forming structures called 
Remak bundles, where one Schwann cell can surround over 20 axons. The 
exact number of axons in a single Remak bundle varies with location. In more 
distal areas the number of axons per bundle tends to be lower (Murrinson and 
GrifÞn, 2004). 
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6.1.3 Energy Metabolism in Peripheral Nerves
Further differences between the CNS and PNS emerge when considering 
energy metabolism in each of these tissues. These differences start with the 
fuels available to the cells. In the CNS, axons and their surrounding glial cells 
are restricted to metabolic substrates that can pass through the blood brain 
barrier (BBB) or are produced within the brain parenchyma. Peripheral nerves 
have access to a wider range of possible substrates, as they are not contained 
within the BBB. Peripheral nerves also differ in their energy demands in 
comparison to CNS tissue. The brain is well known as a large consumer of 
energy but peripheral nerves consume relatively little energy (Low et al., 
1997). 
6.1.4 Glycogen in Peripheral Nerves
Whilst the glycogen content of peripheral nerves has not been functionally 
characterised in the same way as CNS glycogen, it is not a completely 
unexplored subject. The presence of glycogen in peripheral nerves has been 
described in cases of disease and trauma. Glycogen granules have been 
observed in PNS axons at speciÞc stages of Wallerian degeneration (Zelena et 
al., 1980). Glycogen is also known to accumulate in nerves of patients with 
glycogen storage diseases (Komure et al., 1985). A number of studies 
examining nerves of diabetic patients and animal models of the disease have 
revealed the presence of glycogen-like deposits (Mancardi et al., 1985; Weiss 
and Schroder, 1988). These Þndings would suggest that peripheral nerves 
have the enzymatic machinery involved in glycogen metabolism, which raises 
the question as to whether glycogen has a role in non-pathological peripheral 
nerves. The situation may be the same as in the CNS where neurons have the 
ability to synthesise glycogen but when glycogen is synthesised in neurons it 
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causes apoptosis (Magistretti and Allaman, 2007) and hence is associated with 
pathological states.  
The evidence for a physiological role for glycogen in the PNS is less well 
documented, but it has been reported that sympathetic nerves do contain and 
synthesise glycogen in vitro (De Ribaupierre, 1968). The majority of other 
references to glycogen in healthy nerves are restricted to the Þeld of 
embryology, where glycogen is present in the embryonic nerves of a number 
of species (Gage, 1917). The paucity of recent exploration of this subject may 
provoke the assumption that there is little to gain from studying glycogen in 
peripheral nerves. However, demonstrating a role for glycogen in peripheral 
nerve energy metabolism may have clinical implications for conditions such 
as diabetes, where peripheral nerve energy metabolism is thought to play a 
role in the development of peripheral neuropathy (Murakawa et al., 2002; 
Vincent et al., 2010). 
6.1.5 The Sciatic Nerve as a Model
The sciatic nerve is a large nerve in the mammalian body, which has its origin 
in the spinal cord and innervates the lower limbs. The mouse the sciatic nerve 
primarily originates from the third and fourth lumbar nerves (L3 and L4), 
with a small contribution from L5 (Rigaud et al., 2008) It contains myelinated 
motor axons and a mixture of myelinated and un-myelinated sensory and 
sympathetic axons (Schmalbruch, 1986). The mouse sciatic nerve (MSN) was 
chosen as a model peripheral nerve in which to study glycogen metabolism 
due to its size, ease of access, prevalence in the literature and known 
susceptibility to peripheral neuropathy. The MSN can be dissected out of the 
animal and maintained in vitro, which allows experimental protocols based on 
those used to evaluate glycogen and energy metabolism in the CNS (Brown et 
al., 2003; 2005) to achieve similar objectives for the PNS.   
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6.1.6 Aims
The primary aim of this work was to determine whether glycogen was present 
in the mouse sciatic nerve, and whether it could be used to support axon 
conduction during reduced glucose availability. The cellular localisation of 
glycogen in peripheral nerve was also examined. The methods used for this 
study were based on those which determined the location and functional role 
of glycogen in CNS white matter (Brown et al., 2003). 
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6.2 Methods
6.2.1 Electrophysiology
Compound action potentials (CAPs) were recorded from the isolated mouse 
sciatic nerve (MSN) as described in Chapter 2. The MSN CAP has two main 
components: an A Þbre and C Þbre component (See Results). These 
components required different stimulus amplitudes to evoke the supra-
maximal CAP. The stimulus artefact generated when stimulus amplitude was 
large enough to evoke the supra-maximal C Þbre response obscured the fast A 
Þbre response, therefore, they were not monitored simultaneously. 
6.2.2 IdentiÞcation of Glycogen Granules
Glycogen can be visualised in cells by examining electronmicrographs of 
osmium-stained tissue (Foster, 1960). Glycogen appears in the form of roughly 
circular granules of densely stained material. The granules are usually 
between 15 and 40  in diameter (Revel, 1960). In order to locate glycogen in 
the sciatic nerve, electronmicrographs were prepared as described in Chapter 
2. To aid the identiÞcation of glycogen granules, control nerves were 
compared with nerves exposed to aglycemia (i.e. glycogen-depleted). For each 
sample (normal: n = 2 and aglycemia n = 2) 12 Þelds encompassing juxta-
nuclear cell bodies of myelinating Schwann cells were acquired.
6.2.3 Immunohistochemistry
Sciatic nerves were processed as described previously (Black et al., 2004). 10 
!m cross-sectional cryosections of the sciatic nerves were cut and mounted on 
Fisher Superfrost Plus glass slides, and the sections were processed for 
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immunoßuorescent detection of glycogen phosphorylase, S-100 and 
neuroÞlament. Sections were incubated sequentially in: (1) blocking solution 
(3 % cold Þsh skin gelatin (Sigma, St. Louis, MO), 3 % normal donkey serum 
(Sigma), and 0.1 % Triton X-100 (Sigma) in PBS) for 15 min at room 
temperature; (2) primary antibodies (goat anti-glycogen phosphorylase (1:100, 
Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-S-100 (1:200, Abcam, 
Cambridge, MA), and chicken polyclonal NF-H (1:5000, Encor, Alachua, FL)) 
in blocking solution overnight at 4℃; (3) PBS, 6 x 5 min each, (4) secondary 
antibodies (donkey anti-goat-488 (1:500, Jackson ImmunoResearch, West 
Grove, PA), donkey anti-mouse-549 (1:500, Jackson ImmunoResearch), and 
donkey anti-chicken-649 (Jackson ImmunoResearch)) in blocking solution for 
6-8 hours at room temperature, (5) PBS 6 x 5 min each. Sections were mounted 
with Aqua Poly/mount (Polysciences, Warrington, PA) and images were 
acquired with a Nikon C1 confocal microscope
All other methods were carried out as detailed in Chapter 2. 
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6.3 Results
6.3.1 Morphology of the Sciatic Nerve
An electron micrograph of a transverse section of sciatic nerve illustrates the 
heterogeneous morphology of the constituent axons in the sciatic nerve (Fig. 
6.1). The axons fall into two main classes, large myelinated Þbres (A), and 
smaller groups of un-myelinated Þbres (C) which are ensheathed in Schwann 
cell cytoplasm, respectively (Fig. 6.1.B - D).
Figure 6.1 Morphology of the mouse sciatic nerve. A. Transverse EM of sciatic 
nerve illustrating the large myelinated Þbres that contribute to the A-Þbre response, 
and the smaller un-myelinated C-Þbres contributing to the delayed response. B.  A-
Þbre (A) showing myelinated axon surrounded by Schwann cell cytoplasm (Cy) and 
nucleus (N). The C-Þbres encapsulated in Schwann cell cytoplasm are also visible (c). 
C. Higher power image illustrating a myelinated A-Þbre axon associated with a single 
Schwann cell. D. Groups of un-myelinated C-Þbres (c) encapsulated by a single 
Schwann cell. Scale bars:  A 10 μm, B 5 μm, C 2 μm, D 0.5 μm. 
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6.3.2 The stimulus- evoked compound action potential 
(CAP) in sciatic nerve
 The compound action potential (CAP) evoked by a supra-maximal stimulus is 
illustrated in Fig. 6.2.A. A small stimulus artefact precedes a large unipolar 
peak within 1 ms of the stimulus, followed by a smaller bipolar response 
between 5 to 15 ms after the stimulus artefact (inset, Figure 6.2.A). The large 
unipolar peak is contributed to by the large myelinated A-Þbres and is named 
the A-peak, whereas the smaller bipolar peak is contributed to by the un-
myelinated C-Þbres, and is named the C-peak (Ogawa et al., 1984). 
Figure 6.2 Stimulus-evoked CAP. A. Individual recording illustrates the large, rapid 
A-Þbre response immediately after the stimulus artefact (shaded arrowhead), 
followed by the slower and smaller C-Þbre bipolar response approximately 10 ms 
after the stimulus artefact (inset). Scale bars 1 mV and 1 ms: inset scale bars 0.05 mV 
and 1 ms. B and C. Increasing the stimulus current results in increased amplitude of 
the A- and C-Þbre response, respectively. Scale bars are 5 mV and 0.25 ms for B and 
0.25 mV and 1 ms for C. D. Plotting the stimulus intensity versus the normalised 
amplitude of the A- (ഋ) and C- () Þbre CAPs, demonstrates the lower threshold for 
activation of the A Þbres relative to the C-Þbres response (n = 3).
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Stepwise increases in the stimulus current result in increases in the amplitudes 
of both the unipolar A-peak (Fig. 6.2.B) and the C-peak (Fig. 6.2.C; the 
amplitude of the C-peak is measured as the difference between the maximum 
positive peak and the maximum negative peak). The relationship between the 
normalised peak amplitude and the stimulus current is shown in Figure 6.2.D, 
illustrating that the A-peak has a much lower threshold than the C-peak, 
reaching its maximal amplitude at a current stimulus of about 1 mA, a 
stimulus intensity that only evokes about a quarter of the maximal C-peak 
response.
6.3.3 Glycogen content of the sciatic nerve 
Glycogen content of acutely isolated sciatic nerve was 8.61 ± 0.90 pmol 
glycogen (!g protein)-1 (n = 3; blood glucose concentration at sacriÞce was 9.50 
± 1.80 mM, n = 18).  Sciatic nerve glycogen content was signiÞcantly higher 
than in acutely isolated optic nerve (6.82 ± 0.40 pmol glycogen (!g protein)-1; p 
= 0.037) measured using similar methods (Brown et al., 2003).  
Glycogen content was stable for many hours in sciatic nerves incubated in 10 
mM glucose aCSF. In CNS white matter the glycogen content varies with 
ambient glucose concentration (Brown et al., 2003). To test whether the same 
relationship held true for the PNS the effect of bath glucose concentration on 
sciatic nerve glycogen content was determined. Sciatic nerves were incubated 
in aCSF with variable glucose concentrations ranging from 2 mM to 30 mM. A 
pre-incubation period of 60 minutes in 10 mM glucose aCSF preceded each 
experiment to allow nerves to equilibrate under identical conditions. Nerves 
were subsequently incubated in the desired glucose concentration by 
switching the glucose content of the aCSF to the appropriate value for two 
hours. Nerves were preserved in ice cold 85% ethanol / 15% 30 mM HCl prior 
to assay to prevent glycogen breakdown. In nerves bathed in 2 mM, 4 mM, 7 
mM, 10 mM or 30 mM glucose for two hours, respectively, the glycogen 
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content was 2.35 ± 0.07 pmol glycogen (!g protein)-1 (n = 3), 7.16 ± 0.53 pmol 
glycogen (!g protein)-1 (n = 3), 9.68 ± 1.08 pmol glycogen (!g protein)-1 (n = 3), 
10.98 ± 1.00 pmol glycogen (!g protein)-1 (n = 3) or 15.21 ± 0.98  (n = 3) pmol 
glycogen (!g protein)-1 (n = 3), respectively (Fig. 6.3). In addition, the glycogen 
content of sciatic nerves immediately upon removal from the mouse was 8.61 
± 0.90 pmol glycogen (!g protein)-1 (n = 3). These data illustrate an asymptotic 
relationship between ambient glucose concentration and glycogen content 
(Fig. 6.3), similar to that seen in mouse optic nerve (Brown et al., 2003). 
Figure 6.3 Glycogen content of the mouse sciatic nerve. Nerves bathed for 2 hours 
in 2, 4, 7, 10 or 30 mM glucose showed increasing concentrations of glycogen (open 
squares: left axis scale pmol glycogen (μg protein)-1). Sciatic nerves removed from 
mice, with a mean blood glucose concentration of 9.5 ± 1.8 mM at the time of death, 
and immediately frozen for glycogen assay, had a glycogen content of 8.61 ± 0.90 
pmol glycogen (μg protein)-1 (grey square). Inset shows [glucose] (mM) plotted on a 
logarithmic scale demonstrating the exponential relation between glycogen content 
and ambient [glucose]. Left axis as main Þgure.
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The presence of labile glycogen in peripheral nerve prompted two questions: 
(1) can the glycogen provide a utilisable energy substrate to sustain axonal 
excitability in the absence of glucose, and (2) where is the glycogen located? To 
investigate the Þrst question the temporal correlation between glycogen 
content and the ability of the nerve to conduct action potentials during 
glucose deprivation was studied. The cellular location of glycogen was 
investigated using electron microscopic techniques as this technique has 
previously proved successful in identifying glycogen in the optic nerve.  
6.3.4 Effects of glycogen content on the CAP during 
aglycemia
Glycogen stored in astrocytes is used to support axon conduction in white 
matter during aglycemia (Wender et al., 2000; Brown et al., 2003). In order to 
test whether the glycogen content of the MSN had a similar functional role the 
effects of aglycemia on the A-Þbre and C-Þbre CAP peaks were investigated. 
Sciatic nerves were removed from the mouse and immediately placed in the 
interface chamber and perfused with glucose-free aCSF. The A peak was 
maintained for 1.55 ± 0.52 hours before it failed (n = 6), whereas the C-Þbre 
peak lasted only 0.81 ± 0.45 hours (n = 5) before failure (Fig. 6.4.A). In separate 
experiments the glycogen content was systematically manipulated by 
incubating sciatic nerves in aCSF containing glucose concentrations ranging 
from 2 to 30 mM before exposing nerves to aglycemia. The C peak had a 
latency to failure of 0.35 ± 0.29 hours (n = 6), 0.57 ± 0.10 hours (n = 4) and 0.75 
± 0.09 hours (n = 4), respectively, when pre-incubated in 2 mM, 10 mM or 30 
mM glucose aCSF, respectively (Figure 6.4.C), whereas the A-Þbre peak had a 
latency to failure of 0.28 ± 0.30 hours (n = 4), 2.10 ± 0.34 hours (n = 4) and 2.92 
± 0.42 hours (n = 5), respectively, following incubation in 2 mM, 10 mM or 30 
mM glucose aCSF, respectively (Figure 6.4.B). Plotting latency to CAP failure 
for the A- and C-Þbre peaks relative to the glycogen content in the nerve pre-
incubated in 2 mM (n = 3), 10 mM (n = 3) or 30 mM glucose (n = 3) revealed a 
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saturating response, where increasing glucose concentration led to increases in 
latency to failure (Figure 6.5.A). The relationship between the glycogen 
content of the tissue prior to aglycemia and the latency to CAP failure after 
onset of aglycemia was linear for both the A and C-Þbre CAPs, although the 
slope for the A-Þbres was steeper than for the C-Þbres (Figure 6.5.C). The 
values obtained for nerves subjected to aglycemia directly after sacriÞce (Fig. 
6..5.B) were also plotted on these graphs for comparison.
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Figure 6.4 Normalised CAP area during aglycemia. A. CAPs recorded from sciatic 
nerves immediately after removal from mouse. Normalised CAP amplitude of the A-
() and C- () Þbre peak plotted against time relative to introduction of zero 
glucose aCSF at 0 hrs. B. A-Þbre peak in nerves pre-incubated in 2 mM, 10 mM or 30 
mM glucose for 2 hours prior to onset of aglycemia at 0 hrs. The peak amplitude was 
normalised to the value at aglycemia onset. The response was maintained longest in 
nerves pre-incubated in 30 mM glucose (), followed by pre-incubation in 10 mM 
() then 2 mM () glucose. C. The C-Þbre peak showed qualitatively the same 
pattern of failure as the A-Þbre response, although the latencies were shorter. 
Symbols for B also apply. n = 5 in all cases.   
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Figure 6.5 Latency to CAP failure during aglycemia for the sciatic nerve. A. 
Relationship between latency to reduction to 95% of baseline value of the A-Þbre () 
and C-Þbre () peak amplitude versus pre-aglycemia bathing glucose concentration. 
B. Latency to CAP failure for nerves in which recordings were carried out 
immediately on removal from the animal. Directly after sacriÞce the blood glucose 
average was 9.5 mM (n = 18) and glycogen content was 8.6 pmol glycogen (μg 
protein)-1; these data points are represented on A and C by Þlled grey symbols. C. 
Relationship between latency to 95% CAP failure and glycogen content at the onset 
of aglycemia of the A () and C () peaks, demonstrating a linear relationship for 
both responses.  n = 3 unless stated. 
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6.3.5 Effects of aglycemia on glycogen content and 
relationship to CAP failure
The effect of removing glucose from the perfusing aCSF (aglycemia) on the A- 
and C-Þbre CAP responses was investigated. At the onset of aglycemia the 
CAPs were stable. The A-peak initially remained stable and only began to fail 
2.10 ± 0.34 hours after the onset of aglycemia. The CAP had almost entirely 
disappeared by 4.5-hour post onset of aglycemia (n = 4). The C-peak failed 
more rapidly, it began to fall after 0.42 ± 0.11 hours and was completely absent 
by about 2.5 hours (n = 4). The glycogen content at the onset of aglycemia was 
10.98 ± 1.00 pmol glycogen (!g protein)-1 (n = 3). Glycogen fell to 7.28 ± 0.71 
pmol glycogen (!g protein)-1 (n = 3) after 1 hour of aglycemia, 2.99 ± 0.56 pmol 
glycogen (!g protein)-1 (n = 3) after 2 hours of aglycemia and 2.31 ± 0.13 pmol 
glycogen (!g protein)-1 (n = 3) after 4 hours of aglycemia (Fig. 6.6).  The 
continuing presence of glycogen was tightly correlated with the ability of A-
Þbres to conduct CAPs, although, some glycogen remains even in the absence 
of glucose (Wender et al., 2000).  The excitability of C-Þbres, however, was not 
well correlated with glycogen loss; these Þbres failed well in advance of 
glycogen loss suggesting that their excitability was not supported, or only 
partially supported, by glycogen breakdown.
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Figure 6.6 Aglycemia and glycogen content of sciatic nerve. Aglycemia resulted in 
onset of delayed failure of the A-peak after about 2 hours, and total failure after about 
4.5 hours (open squares), whereas the C-peak response failed after about 0.5 hours 
and disappeared by 3 hours. Glycogen content (open columns; right y-axis) decreased 
during aglycemia, reaching a nadir after about 2 hours which was coincident with the 
onset of A-peak failure.   
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6.3.6 Effect of inhibiting glycogen phosphorylase on the 
CAP
The compound DAB inhibits glycogen phosphorylase (Walls et al., 2008) 
which prevents glycogen metabolism and accelerates the failure of axonal 
conduction during aglycemia. The ability of DAB to reduce the latency to 
CAP failure in the MSN was tested by pre-incubating nerves for 2 hours in 
aCSF containing either 10 mM glucose, or 10 mM glucose plus 1 mM DAB. 
Aglycemia was then induced by removing glucose from the aCSF. In the 
control nerves the A-Þbre CAP latency to failure was 2.10 ± 0.34 hours, 
whereas in the nerves incubated with 1 mM DAB the latency to failure was 
signiÞcantly shorter at 0.64 ± 0.12 hours (p < 0.0009 n = 4; Fig. 6.7.A and 6.8). 
The C-Þbre latency to failure was 0.58 ± 0.06 hours (n = 4) in control conditions 
and 0.50 ± 0.04 hours (n = 4) in the presence of DAB (p = 0.13, Fig. 6.7.B and 
6.8). As DAB did not have a signiÞcant effect on the latency to failure of the C-
Þbre peak the experiment was repeated but with a pre-incubation in 30 mM 
glucose to increase glycogen stores. In nerves pre-incubated in 30 mM glucose, 
or 30 mM glucose plus DAB, the C-Þbre latency to failure was 0.75 ± 0.10 
hours and 0.71 ± 0.09 hours, respectively; this was again not signiÞcantly 
different between control and DAB-treated (p = 0.17, n = 3, Fig 6.7.C and 6.8). 
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Figure 6.7 Effect of inhibiting glycogen phosphorylase on latency to CAP failure and 
glycogen content. A. Introduction of the glycogen phosphorylase inhibitor DAB 
resulted in accelerated failure of the A-Þbre peak () relative to control, untreated 
nerves (). B. DAB had no effect on latency to CAP failure of C-Þbres incubated in 
10 mM glucose. C. In nerves pre-incubated in 30 mM glucose DAB did not accelerate 
CAP failure. 
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Figure 6.8  Inhibition of glycogen phosphorylase affects A-Þbre but not C-Þbre 
survival during aglycemia. DAB signiÞcantly accelerated CAP failure after onset of 
aglycemia in A-, but not C-Þbres incubated in 10 mM glucose or 30 mM glucose, 
although, C-Þbre failure was slightly delayed by pre-incubation in 30 mM glucose 
possibly due to increased extracellular glucose at the start of aglycemia. 
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To show that DAB was indeed preventing glycogen breakdown during 
aglycemia the glycogen content was measured. Sciatic nerves were incubated 
for 2 hours in aCSF containing 10 mM glucose in the presence or absence of 1 
mM DAB, then exposed to aglycemia for 2 hours. In control nerves the 
glycogen content fell from 10.98 ± 1.00 pmol glycogen (!g protein)-1 to 2.99 ± 
0.56 pmol glycogen (!g protein)-1 (p = 0.001, Fig. 6.9) after 2 hour aglycemia, 
whereas in the DAB-treated nerves the fall in glycogen was attenuated from 
14.17 ± 2.37 pmol glycogen (!g protein)-1 to 12.25 ± 1.50 pmol glycogen (!g 
protein)-1 and not signiÞcantly lower after 2 hours of aglycemia (p = 0.3, Fig. 
6.9).
Figure 6.9 Effect of inhibiting glycogen phosphorylase on sciatic nerve glycogen 
content pre- and post- aglycemia. Glycogen content is shown for nerves incubated in 
10 mM glucose for two hours (shaded columns) and after a 2 hour period of 
aglycemia (open columns). This is shown for control nerves and those maintained in 
the presence of 1 mM DAB. After 2 hours of aglycemia the glycogen content had 
signiÞcantly fallen in control nerves (* p < 0.05, n = 3) whereas in nerves incubated in 
1 mM DAB throughout the glycogen content had not fallen signiÞcantly during 
aglycemia (n.s. p > 0.05, n = 3).
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6.3.7 Ultrastructural identiÞcation of glycogen in sciatic 
nerve
Electron microscopic studies were carried out on immersion Þxed sciatic 
nerves to identify glycogen. Glycogen was visualised as small densely stained 
spheres of up to 40 nm diameter and was prominently located in Schwann cell 
cytoplasm (Fig. 6.10). In nerves exposed to zero glucose aCSF for 2 hours, 
conditions known to deplete glycogen (see above), the density of glycogen 
granules decreased (Fig 6.10.D) compared to control nerves (Fig 6.10.C). We 
made no attempt to quantify glycogen based on the EM images but our strong 
impression was that the majority of glycogen granules were located in 
Schwann cell cytoplasm. (A small number of glycogen granules may have 
been present in some axons.) 
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Figure 6.10 (next two pages). Location of glycogen in the sciatic nerve 
determined by electron microscopy. A. Glycogen granules (g) are present in Schwann 
cell cytoplasm of  A-Þbres, glycogen is visualised as dark spherical granules located 
throughout the cytoplasm. B. Ribosomes attached to endoplasmic reticulum are also 
present (ER). D. Nerves incubated in aglycemic conditions showed a decreased 
density of glycogen granules compared to control (C). Scale bar 500 nm.
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6.3.8 Expression of glycogen phosphorylase
At present, robust antibodies to immunocytochemically detect glycogen 
within Þxed tissues are unavailable, and, therefore, as a surrogate, 
immunohistochemical labelling was performed to determine the presence of 
the brain isoform (BB) of glycogen phosphorylase, a key enzyme in glycogen 
metabolism. In the CNS, this enzyme appears to be selectively localised to 
astrocytes (Pfeiffer et al., 1990), the only cell in the adult brain that contains 
glycogen (Cataldo and Broadwell, 1986). Staining longitudinal sections of 
sciatic nerve using the H and E method revealed Schwann cell bodies (purple) 
interposed between axons (Fig. 6.11.A, pink). Higher power images allowed 
clear resolution of individual axons with the occasional Schwann cell body 
(Fig. 6.11.B). Triple labelling studies were carried out using S-100 or 
neuroÞlament to localise the glycogen phosphorylase to either Schwann cells 
or axons, respectively. Glycogen phosphorylase immunolabeling was detected 
in both axons and Schwann cells, as evidenced by the co-localisation of the 
glycogen phosphorylase antibodies with markers for axons (neuroÞlament) or 
Schwann cells (S-100) (Fig. 6.11.C Ð F). 
Chapter 6
171
Figure 6.11 Expression of glycogen phosphorylase in sciatic nerve. A. H & E 
staining of longitudinal sections of sciatic nerve revealed Schwann cell bodies as 
purple oblongs diffusely arranged between axons. B. Higher power images revealed 
individual axons in longitudinal section. C-F.  Immunohistochemical studies revealed 
the presence of glycogen phosphorylase (green), whose cellular location was 
identiÞed using speciÞc cellular markers for Schwann cells (S-100; red) and axons 
(neuroÞlament; blue). F. Merged images demonstrate that glycogen phosphorylase is 
detected in both Schwann cell cytoplasm (yellow) and axons (cyan). Scale bar 10 μm. 
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6.3.9 Role of lactate
Given the cellular location of glycogen and the ability of glycogen to support 
axon conduction during aglycemia, a transportable conduit must be produced 
for intercellular transport between the Schwann cell and the axon. The most 
likely candidate is lactate for the following reasons. Perfusing the sciatic nerve 
for 4 hours in the presence of 10 mM glucose results in a stable A-Þbre CAP. 
Introduction of aglycemia resulted in a slow, delayed loss of conduction (Fig. 
6.12.A) as previously described (n = 4). However if aCSF containing 10 mM 
glucose was reintroduced at 2.5 hrs, when the A-Þbre CAP had fallen to 
approximately 50% of its baseline value, the CAP was fully restored to 
baseline values (n = 4). In a similar manner the A-Þbre CAP was fully 
supported with 20 mM lactate as sole exogenously applied energy substrate (n 
= 4). The A-Þbre peak was also fully rescued by introduction of 20 mM lactate 
aCSF at 2.5 hrs, after partial loss induced by a period of aglycemia from 0 to 
2.5 hrs (n = 4, Fig. 6.12.B). The C-Þbre peak was supported by 10 mM glucose 
for 4 hours and was rescued by 10 mM glucose (Fig. 6.12.C, n = 4) after 
aglycemia reduced the peak to about half baseline value. In the presence of 20 
mM lactate the C Þbre CAP was supported although it decreased to below 
baseline after 4 hours. The C-Þbre peak was only partially restored by 20 mM 
lactate after a period of aglycemia (Fig. 6.12.D, n = 4).
Lactate release from the sciatic nerve was measured using an enzyme-based 
lactate biosensor in the same manner as recordings were made from the optic 
nerve in Chapters 4 and 5. Fig. 6.13.A shows that the lactate signal remained 
stable in 10 mM glucose and when aglycemia was induced fell to 50 % of its 
initial value after 18.2 ± 1.6 mins (n = 3). The concentration of lactate released 
from the sciatic nerve was calculated as 0.18 ± 0.01 mM during exposure to 10 
mM glucose (Fig. 6.13.B). This value is lower than that obtained for the optic 
nerve in Chapter 4. 
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Figure 6.12 Ability of glucose and lactate to sustain and rescue the CAP. A. The A-
Þbre peak was supported for many hours with aCSF containing 10 mM glucose (), 
but introduction of aglycemia at 0 hrs led to delayed failure of the CAP (). 
Reintroduction of aCSF containing 10 mM glucose after 2.5 hrs of aglycemia, during 
which the CAP had fallen to about 50% of baseline value, fully rescued the peak (). 
B. A similar experiment showed that lactate could support function when present in 
the aCSF (), and also that lactate could rescue function () after a 2.5 hr period of 
aglycemia. C. Pre-incubating nerves in 10 mM glucose supported the C-peak 
conduction, but the CAP was only partially rescued by reintroduction of 10 mM 
glucose after a period of aglycemia. D. In nerves pre-incubated in 20 mM lactate the 
C-Þbre CAP was maintained for several hours but rescuing the CAP after a brief 
period of aglycemia resulted in incomplete CAP recovery.
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Figure 6.13 Lactate is present in the mouse sciatic nerve and its concentration falls 
during aglycemia. A. A lactate biosensor was positioned in contact with the nerve 
prior to, and during aglycemia. A lactate signal was present when the nerve was 
bathed in 10 mM glucose aCSF, but this signal was reduced and was lost during a 
period of aglycemia (n = 3). B. The lactate concentration in optic and sciatic nerves 
was determined by measuring the lactate signal in individual nerves and comparing 
this to a standard curve of known lactate concentrations. Extracellular lactate was 
lower in the sciatic nerve than the optic nerve (n = 4). 
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6.4 Discussion
In the experiments described here the mouse sciatic nerve (MSN) was used as 
a model peripheral nerve to examine the content, cellular location and 
function of glycogen within the PNS. This study drew inßuence from those 
which characterised the glycogen in the CNS using the mouse optic nerve 
(MON) as a model (Brown et al., 2003; 2005). Many of the Þndings are, 
therefore, discussed in direct comparison and contrast with the CNS where a 
model of glycogen metabolism is well established. 
6.4.1 Sciatic Nerve Morphology
The sciatic nerve is one of the largest and longest peripheral nerves in the 
body and contains a diverse array of axons. An initial step was to examine the 
morphology of the sciatic nerve and how it related to the observed CAP. Like 
many peripheral nerves, the sciatic nerve contains both motor and sensory 
Þbres, which conduct action potentials both from and to the CNS, respectively. 
The directionality of axonal conduction in vivo is somewhat irrelevant when 
the nerves are isolated from the animal with the cell bodies excised, as there is 
no visible difference between afferent and efferent axons in the TEM images 
presented here. When recording the CAP all axons are stimulated at the same 
end of isolated nerve, which will mean that some axons are conducting anti-
dromically. However, this should not matter as isolated axons are equally 
capable of conducting action potentials in either direction. The possibility that 
afferent or efferent axons could have different metabolic properties should not 
be dismissed, but it is beyond the scope of the methods used here to explore 
this question.
The experiments in this chapter replicate some of those previously conducted 
in the optic nerve (e.g. Brown et al., 2003; 2005). It is, therefore, useful to make 
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an initial comparison between the structure of the optic nerve and the MSN. 
Axons in the sciatic nerve exhibit a much greater range of diameters than the 
optic nerve. In the adult MON all axons are myelinated, but this is not the case 
in the adult MSN which contains groups of small un-myelinated Þbres.
6.4.2 The Sciatic Nerve Compound Action Potential
The morphological differences between sciatic nerve and optic nerve axons 
manifest in a markedly different CAP proÞle. The three-peaked CAP of the 
adult MON is not seen in the MSN. Instead there is an initial peak, which 
generally occurs in isolation and displays a faster conduction velocity than the 
Þrst peak of the MON CAP. This is followed by a slow biphasic peak that is of 
much smaller amplitude than the Þrst peak. The CAP evoked from the MSN 
was qualitatively and quantitatively similar to that previously recorded by 
other groups using suction electrode and sucrose gap methods (Kriz et al., 
2000; Matsuka and Spigelman, 2004; Thakor et al., 2009). The large myelinated 
axons contribute to the fast large amplitude peak and small, un-myelinated 
axons contribute to the slow, low-amplitude biphasic peak. In myelinated 
axons the potassium efßux is shielded from the extracellular ßuid by the 
myelin surrounding the axon, but in un-myelinated Þbres the extracellular 
ßuid is in contact with the recording electrode (Kocsis and Waxman, 1980), 
hence the monopolar proÞle of myelinated axons and the bipolar proÞle of un-
myelinated axons. The biphasic proÞle of the CAP evoked from un-
myelinated axons has also been observed in other peripheral nerves (Vega et 
al., 2003), in the immature rodent optic nerve (Foster et al., 1982; Fern et al., 
1998) and in myelin-deÞcient rats (Waxman et al., 1990).
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6.4.3 The Presence and Location of Glycogen in the Sciatic 
Nerve
 
QuantiÞcation of sciatic nerve glycogen by biochemical assay showed that the 
MSN does contain glycogen and that this glycogen content can be up or 
down-regulated by exposing nerves to glucose concentrations above and 
below the animalsÕ normal blood glucose concentration (approximately 10 
mM). The glycogen content of the nerve was found to be greater than that 
measured in the MON using the same technique. A 2 hour incubation in 30 
mM glucose for the optic nerve resulted in a measured glycogen content of 
just under 10 pmol glycogen (!g protein)-1 (Brown et al., 2003), considerably 
less than the value of 15.2 pmol glycogen (!g protein)-1 measured in the MSN 
under identical conditions. The glycogen content of the sciatic nerve incubated 
in 10 mM glucose was also greater than that in the optic nerve incubated in 30 
mM glucose. As these values are corrected for tissue protein content it is clear 
that the sciatic nerve contains proportionally more glycogen when incubated 
the same concentration of glucose for 2 hours in vitro.
Whilst an assay can detect the presence of glycogen and indeed quantify it, 
information about its cellular location cannot be determined. It is possible to 
measure the glycogen content of cultures of individual cell types such as 
astrocytes and neurons, but this information is not necessarily reßective of the 
situation in vivo. An attempt to locate glycogen granules and determine which 
cell type(s) they were contained in was made using TEM. Previous 
experiments using TEM have shown that in the CNS glycogen is almost 
exclusively located in astrocytes (Brown and Ransom, 2007). The MSN as a 
peripheral nerve does not contain astrocytes, therefore, clearly glycogen 
cannot share the same cellular location. Examination of transverse sections of 
MSN revealed glycogen-like granules located within the cytoplasm of 
myelinating Schwann cells. Exposing nerves to aglycemia and hence depleting 
their glycogen content reduced the apparent density of these granules 
suggesting they are indeed glycogen (Fig. 6.10). No structures similar to 
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glycogen granules were identiÞed in the axoplasm of myelinated or un-
myelinated axons. It should be noted that identiÞcation and localisation of 
glycogen granules within a peripheral nerve warrants a study of its own. It 
cannot be ruled out that glycogen granules may be found in areas not 
examined e.g. the axon at the nodes of Ranvier. 
The results of immunolabelling  of glycogen phosphorylase (GP) in the sciatic 
nerve provide more incentive for a future in-depth examination of glycogen 
granules in peripheral nerve as they show that GP is strongly expressed in 
large axons (Fig. 6.11). A proÞle of GP expression in rat nervous tissue showed 
that GP was expressed in neurons of the afferent somatosensory system 
(Pfeiffer-Guglielmi et al., 2003) and in peripheral axons (Pfeiffer-Guglielmi et 
al., 2007) as seen in Fig. 6.11. In the MSN GP was also expressed in Schwann 
cells, which is consistent with the localisation of glycogen just described but in 
disagreement with previous studies in rat peripheral nerve (Pfeiffer-Guglielmi 
et al., 2007). A possible explanation for these contrasting observations may be 
the relative intensity of GP staining between axons and Schwann cells. Fig. 
6.11 shows that the GP staining in axons is much more intense and close 
inspection of the Þgures presented by Pfeiffer-Guglielmi et al. (2007) hint at 
possible GP expression outside of the axons. Clearly, the expression of GP in 
Schwann cells demands further investigation. Irrespective of GP expression in 
Schwann cells the presence of GP in axons without any detectable glycogen is 
perplexing. One reason why GP is expressed in peripheral axons may be to 
prevent glycogen accumulation, as glycogen deposits are pathological for 
neurons (Magistretti and Allaman, 2007). However, in the CNS, GP is not 
expressed in axons (Pfeiffer et al., 1990) which would mean that this function 
of GP would be restricted to peripheral nerves. 
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6.4.4 Nerve Conduction During Aglycemia
The two main components of the MSN CAP fall in amplitude during 
aglycemia, indicating that axons become incapable of conducting action 
potentials. The reason for conduction failure during aglycemia is the same as 
in the optic nerve (see Chapters 3, 4 and 5). Brießy, withdrawal of energy 
substrates means that the ion gradients required for propagation of action 
potentials cannot be maintained. In the MSN the loss of function of 
myelinated and un-myelinated Þbres does not occur at the same time. It was 
observed that the A-Þbre component of the CAP was maintained for a longer 
duration than the C-Þbre component during aglycemia. The only exception to 
this being after 2 hours incubation in 2 mM glucose prior to aglycemia, it 
appears that under these conditions both CAP components begin to fail prior 
to aglycemia, indicating that 2 mM glucose is insufÞcient to support nerve 
function as previously described (Brown et al., 2003).  The reason why the C-
Þbre component of the CAP falls before the A-Þbre is most likely due to the 
increased energy demands of C-Þbres. Un-myelinated axons require more 
energy to generate action potentials as the energy required is proportional to 
membrane capacitance  per unit length (Crotty et al., 2006) which is greater in 
un-myelinated axons (Wang et al., 2008). The difference between  A- and C-
Þbre survival during aglycemia could also be attributed to differences in these 
axonÕs access to glycogen if this glycogen has a functional role as an energy 
store. 
6.4.5 A Functional Role for Peripheral Nerve Glycogen
The ability of the MSN CAP to persist during an extended period of aglycemia 
would seem to suggest that there exists an internal store of energy substrate 
which can be metabolised to support nerve function. Without an energy 
supply axons cannot maintain their membrane potentials and therefore cannot 
propagate action potentials, as these are both energy-dependent processes. It 
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is proposed here that the glycogen content of the sciatic nerve can be used as 
an energy store to maintain axonal function in the absence of exogenously 
supplied glucose. This role for glycogen is analogous to that demonstrated in 
the rodent optic nerve during glucose deprivation (Ransom and Fern, 1997; 
Brown et al., 2003). This conclusion is in part drawn from the observation of 
the correlation between MSN glycogen content prior to aglycemia, and the 
latency to failure of CAP conduction after glucose is withdrawn. Measurement 
of nerve glycogen content shows that at the point where function begins to 
fail, indicated by a steady fall in CAP amplitude, the glycogen content of the 
nerve has been almost entirely exhausted. The link between CAP failure and 
glycogen content reaching its nadir has been previously observed in the optic 
nerve (Brown et al., 2003). Further conÞrmation of glycogen as the energy 
store that allows axon function to persist in the absence of glucose comes from 
inhibiting glycogenolysis. Glycogen phosphorlyase is inhibited by DAB, 
which has been shown the accelerate CAP failure during aglycemia in the 
optic nerve (Walls et al., 2008). The same observation has now been repeated 
in the sciatic nerve, where the use of DAB indicates that without glycogen 
CAP function cannot be maintained during aglycemia. 
6.4.6 Glycogen Metabolism Supports only Myelinated 
Fibres during Aglycemia
Examining the relationship between the glycogen content prior to aglycemia 
and the latency to CAP failure shows that up or down-regulating the nerveÕs 
glycogen content by altering the external glucose concentration determines the 
length of time conduction persists during aglycemia. This observation is more 
robust for the A-Þbre peak compared to the C-Þbre peak. A-Þbre latency to 
failure during aglycemia was well correlated with nerve glycogen content. 
The A-Þbre CAP fell when glycogen stores were depleted, and up-regulating 
glycogen content had a beneÞcial effect on the maintenance of conduction 
during aglycemia. On the other hand, C-Þbre amplitude fell before glycogen 
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was exhausted and there was little effect on CAP failure in the presence of 
DAB. A small increase in C-Þbre latency to failure during aglycemia was seen 
when nerves were pre-incubated in 30 mM glucose, but it is possible this is 
due to an increase in extracellular glucose rather than glycogen stores as DAB 
did not decrease this latency (Fig. 6.7.C and 6.8). 
There a few possible explanations as to why the beneÞcial effects of glycogen 
during aglycemia are restricted to myelinated Þbres. It is possible that C-Þbres 
have no access to glycogen. Glycogen granules were not identiÞed in Remak 
Schwann cells surrounding C-Þbre axons. However, this could also be 
explained if the amount of glycogen available to un-myelinated Þbres is small 
and therefore diffusely located in the cytoplasm. Un-myelinated C-Þbres have 
a higher metabolic demand than myelinated axons (Nave, 2010), and if they 
do have access to small quantities of glycogen their high metabolic demand 
would likely see these stores exhausted rapidly during aglycemia. 
Unfortunately, the glycogen assay cannot identify where the glycogen is 
located in the nerve, it can only determine gross content. If un-myelinated 
axons do have access to glycogen then it is likely to be a separate pool to that 
available to myelinated axons. When C-Þbre conduction fails there is still over 
50 % of the glycogen content of the nerve remaining (Fig. 6.6) suggesting that 
this is glycogen that C-Þbres do not have access to.
The behaviour of myelinated A-Þbres appears similar to that observed in the 
axons of rodent optic nerves (also myelinated) exposed to similar conditions 
(Brown et al., 2003). The conclusion reached in the case of the optic nerve is 
that glycogen content is under dynamic control, and can act to provide energy 
substrate to support axons. The data presented in this chapter point towards a 
similar situation in myelinated axons in the PNS. Glycogen content is labile 
and can be catabolised to provide an energy substrate for A-Þbre axons in the 
sciatic nerve. 
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6.4.7 Glycogen in the PNS vs CNS
The majority of the data described here has also been gathered in equivalent 
experiments in the optic nerve and comparisons have been discussed. The 
sciatic nerve shares similarities with the optic nerve in terms of the functional 
role of glycogen. However, a striking difference is the observation that 
glycogen in the sciatic nerve can support CAP conduction for a much longer 
duration than under comparable conditions in the optic nerve. A 2 hour pre-
incubation prior to aglycemia with 30 mM glucose will support optic nerve 
CAPs for around 30 minutes (Brown et al., 2003) whereas, in the sciatic nerve 
the same incubation will result in CAP failure after 230 minutes, over 7 times 
longer. This large difference in survival time during aglycemia is most likely 
due to the greater glycogen content of the nerve combined with the low 
energy requirements of peripheral nerve (Low et al., 1997). The direct 
comparison should be approached with caution as the optic nerve CAP is 
typically measured by its area rather than amplitude due to its more complex 
proÞle. Despite this there is a clear difference between the two nervesÕ abilities 
to continue to conduct action potentials when external energy substrates are 
removed. 
6.4.8 A Model of Peripheral Nerve Glycogen Metabolism
This study demonstrates that glycogen can act as a source of energy substrate 
during aglycemia in the sciatic nerve. What remains to be shown is the exact 
pathway through which this energy substrate is supplied. In the CNS lactate is 
the product of glycogen breakdown which is then shuttled from glia to the 
axons Ð this may also be the case in the PNS. It appears as though lactate has a 
role in the PNS as lactate is produced by the MSN (Fig. 6.13) as it is by other 
peripheral nerves (Vega et al., 1998). Under resting conditions lactate is 
released into the tissue bath where it can be detected with a lactate biosensor 
which is similar to the CNS (Chapter 4 and 5). Lactate is also capable of 
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maintaining and restoring axonal conduction in the absence of glucose (Fig. 
6.12), a further property shared with the CNS. 
The model of PNS glycogen metabolism will depend upon the exact location 
of the glycogen discussed above but evidence suggests that Schwann cells take 
up around 75% of the glucose available to peripheral nerves, and that they 
transfer a metabolic substrate to axons which is thought to be lactate (Vega et 
al., 2003). Other studies have shown that the MCT1 transporter is expressed 
on the perineurium (Takebe et al., 2008) which is in fact consistent with either 
a ßux of lactate out of the nerve into the blood, or transfer of plasma lactate to 
nerve Þbres and Schwann cells. MCT transporters are bi-directional and 
therefore their expression pattern alone is not sufÞcient to determine direction 
of lactate transport. Based upon experiments which show staining for GP in 
the axons of rat vagus nerve by Pfeiffer-Guglielmi et al. (2007) suggest that the 
lactate transferred from glia to axons may be entered into the gluconeogenesis 
pathway and in turn used to produce glycogen. This would be in contrast to 
the situation in the optic nerve where lactate passed from glia to axons is a 
product of stored glycogen which is then used as an energy substrate (Brown 
et al., 2004). Future experiments are required to address this issue in further 
detail. However, preliminary localisation of glycogen to the Schwann cells 
would suggest that a model closer to that in the optic nerve rather than the 
one proposed by Pfeiffer-Guglielmi et al. (2007) would hold true for the mouse 
sciatic nerve. Another factor to consider is that experiments by Pfeiffer-
Guglielmi et al. (2003; 2007) were performed in rat rather than mouse where 
the nerves are larger and diffusion distances increased, which may create a 
requirement for an energy source to be stored in axons rather than Schwann 
cells.
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6.4.9 Summary 
In conclusion, sciatic nerve glycogen content correlates with ability of sciatic 
nerve to maintain CAP conduction in myelinated axons during substrate 
withdrawal and once this glycogen is exhausted CAP function begins to fail. 
The glycogen appears to be located in the Schwann cells, which would suggest 
a similar model to that of CNS tissue where a substrate is shuttled to the axons 
from glial cells when required. The candidate molecule for this intercellular 
exchange is likely to be lactate which is present in the sciatic nerve. However, 
further investigation is needed in order to conÞrm the exclusive localisation of 
glycogen and the role of lactate in peripheral nerves. 
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Chapter Seven
Summary
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This thesis demonstrates novel contributions to our knowledge of energy 
metabolism in central white matter and peripheral nerves. The summary that 
follows gives a brief overview of these contributions and also suggests some 
future directions for further experimentation. 
7.1 Central white matter
In this thesis I have demonstrated that the neuroprotective role of glycogen in 
the MON augments that achieved by clinically utilised degrees of 
hypothermia. Depletion of nerve glycogen prior to aglycemia results in as 
severe irreversible damage as that induced by moderate hyperthermia. These 
Þndings demonstrate a possible future role for glycogen up-regulation as a 
therapeutic intervention. However, this comes with the caveat that clinical 
means of manipulating brain glycogen must be developed. This is unlikely to 
be simple. 
Glycogen metabolism in the MON was also demonstrated under non--
pathological conditions. I found that glycogen turnover contributes to the 
concentration of extracellular lactate observed in the MON. The contribution 
of glycogen to the lactate signal increases with metabolic demand. This is a 
feature compatible with the glycogen shunt model (Shulman et al., 2001). 
Clearly glycogen is not a quiescent energy store in CNS white matter. It is a 
contributor to the energy metabolism of the MON even under conditions of 
low metabolic demand. 
I went on to further explore the relationship between axonal Þring frequency 
and extracellular lactate. Stimulating the MON at higher frequencies caused 
the concentration of extracellular lactate to rise. Lactate production is 
triggered by extracellular K+ as MON lactate concentration was found to rise 
with increases in [K+]O. It was concluded that increases in lactate production 
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in the MON may be related to the operation of the Na+ / K+ ATPase. This ion 
pump has been shown to use energy derived from glycolysis in muscle tissue 
(James et al., 1999). A similar association has been put forward for brain tissue 
and is consistent with the observations presented here. This relationship could 
be further explored in future by pharmacological inhibition of the Na+ / K+ 
ATPase by the drug ouabain. It would also be interesting to determine 
whether the proportion of lactate release attributed to glycogen is associated 
with increased demand on the  Na+ / K+ ATPase. These experiments could be 
extended by the use of MCT blockers as discussed in chapter 5. When carried 
out they may be able to determine whether an ANLSH-like model can be 
applied to the optic nerve. 
7.2 Peripheral Nerves 
The role of glycogen in the brain has received an increasing amount of 
attention in the past decade (Brown, 2004). The same cannot be said of 
glycogen within peripheral nerves. Although, a role in the supply of energy to 
axons has been suggested (Pfeiffer-Guglielmi et al., 2007). This conclusion was 
based upon the presence of the enzyme glycogen phosphorylase within 
peripheral nerves. An energy store in the form of glycogen might be expected 
in peripheral nerves due to their structural properties. Large internode 
distances in myelinated peripheral axons restrict the axoplasm from free 
access to substrates contained in the extracellular ßuid. This has led to the idea 
that glial cells surrounding the axon could supply nutrients to the internodal 
areas of the axon (Nave, 2010). Calculations in central axons with shorter 
internodes suggest that adequate glucose can be taken up by the axon at the 
node (Harris and Attwell, 2012). However, the authors note that for peripheral 
axons the node length is such that this might not be the case and the theory 
put forward by Nave (2010) may hold true. 
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The results presented in this thesis support the hypothesis that peripheral glia 
are able to supply energy substrates to axons. Glycogen contained in the 
Schwann cells surrounding peripheral myelinated axons fulÞls this role. It is 
able to support the activity of myelinated axons in the absence of glucose. In 
the CNS lactate is released by glycogen-containing astrocytes and taken up by 
axons. It is presumed that the mechanism with which Schwann cells provide 
PNS axons with an energy substrate is the same. In this thesis I have shown 
that lactate is present in the extracellular space of the MSN. In order to 
conÞrm that glycogen-derived lactate is the substrate sustaining the activity of 
myelinated axons during aglycemia it will be necessary to attempt to block 
lactate uptake with inhibitors of MCTs such as 4-CIN. This experimental 
method was used to conÞrm likewise in the MON (Wender et al., 2000). An 
interesting observation is that un-myelinated PNS axons appear to receive no 
beneÞt from glycogen reserves. Whether this property plays a role in 
conditions such as small Þbre neuropathy is an intriguing question. 
Experiments presented in this thesis were all conducted in vitro. Certain 
aspects do not reßect the conditions as they are in vivo. An example of this is 
the stimulation of the nerve and the CAPs recorded. The stimulus used to 
evoke the supra-maximal CAP is not reßective of nerve Þring in vivo. A 
frequent criticism of experiments that have looked at nervous system energy 
metabolism is that results have often not been replicated in vivo (Chih and 
Roberts, 2003). A future direction worth exploring would be transitioning 
these experiments to an in vivo model. This would enable the use of 
physiological stimuli such as a tail pinch, or a visual stimulus. ConÞrming the 
results presented here in such a way would validate the use of in vitro models 
and strengthen the conclusions being made. 
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